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Abstract 
Non-invasive ventilation (NIV) is an evidenced based treatment of alveolar hypoventilation 
in patients with hypercapnic respiratory failure (HRF). Volume assured pressure support 
(VAPS) is a new mode of NIV that aims to maintain alveolar ventilation (VA) by autotitration 
of the pressure support (PS) delivered to a patient in response to changes in respiratory 
physiology.  The overall aim of this thesis was to investigate the use of VAPS ventilation in 
patients with chronic HRF during wakefulness and sleep, specifically in the detection and 
treatment of acute exacerbations.  
Specific aims were to:  
a) determine if VA was maintained during VAPS ventilation in patients, with obstructive 
and restrictive pathologies, specifically during during exacerbations, and sleep 
(Chapters 3 and 4). 
b) determine the mechanism(s) of presumed maintenance of VA (Chapters 3 and 4).  
c) determine whether changes in the ventilator-measured respiratory parameters can 
be used to identify or predict exacerbations (Chapter 3).  
d) determine if VAPS can be used clinically to treat ventilatory failure as effectively as 
standard PS NIV in acute hypercapnic exacerbations of chronic respiratory disease, 
and in patients naive to NIV therapy (Chapters 5 and 6). 
I have concluded that VAPS ventilation provides an alternative ventilatory mode to standard 
PS ventilation, and can effectively maintain VA during sleep, and during exacerbations, when 
lung characteristics are changing. The mechanism of VA maintenance is likely to be the 
integration of complex patient-ventilator interactions, with large variability between 
patients, independent of diagnosis. Further studies of patient-ventilator interaction and its 
impact on the target ventilation may be aided by measuring respiratory drive or diaphragm 
work. 
 Changes in ventilator-measured parameters were not predictive of impending 
exacerbation. Clustering may help to understand the physiological characteristics of 
 8 
exacerbations and individual ventilatory responses, and also to determine whether an 
autotitrating iVAPS improves outcomes of exacerbations, including survival.  
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1.1 General introduction to thesis: overview of chapter 1 
The overall aim of this thesis was to investigate the use of autotitrating volume assured 
pressure support (VAPS) ventilation in patients with chronic hypercapnic respiratory 
failure (HRF) during wakefulness and sleep, specifically in the detection and treatment of 
acute exacerbations.  
In this introduction I have outlined the mechanisms of HRF and the therapeutic role of NIV. 
The barriers and challenges to effective therapy are discussed, specifically the clinician 
expertise required to balance optimal therapeutic outcome with patient tolerance of the 
therapy.   
The methods of delivering NIV have evolved over recent years, culminating in ventilators 
with new hybrid autotitrating servoventilation modes: including volume assured pressure 
support (VAPS) and other ‘intelligent’ technological developments (eg: ‘artificial intelligence’ 
for automated selection of NIV settings). These technologies are reviewed with a focus on 
the role of intelligent volume assured pressure support (iVAPS; ResMed, Australia). This 
ventilator mode aims to guarantee alveolar ventilation regardless of clinical and 
physiological variations over time. The studies in this thesis have investigated this mode of 
ventilation, with two clinical themes; acute exacerbations of chronic respiratory failure and 
automation of NIV initiation and titration. The role of iVAPS in sleep is also covered. 
1.2 Hypercapnic respiratory failure  
Respiratory failure occurs as a result of inadequate gas exchange, either oxygenation or 
ventilation, and can be defined as either hypoxic (type I; PO2 < 8kPa, 60mmHg) or 
hypercapnic (type II; PCO2 > 6kPa, 45mmHg) or a combination of both. Respiratory failure is 
caused by failure of one or more components of the respiratory system (see Figure 1-1): the 
chest wall (including pleura and diaphragm), airways, alveolar-capillary units, pulmonary 
circulation, nerves and the central nervous system or brainstem. Respiratory failure may be 
acute, chronic or acute on chronic.  
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Figure 1-1: Aetiologies of respiratory failure; adapted from (Keenan and Mehta 2009) 
CNS = central nervous system, COPD = chronic obstructive pulmonary disease, MV = minute ventilation 
 
Hypoxaemic respiratory failure: is a failure of oxygen (O2) exchange, predominantly due to ventilation/perfusion (V/Q) 
mismatching. Hypercapnic respiratory failure: is a failure to exchange or remove carbon dioxide (CO2), predominantly due 
to decreased alveolar ventilation (VA). This reduction in VA can be either due to decreased total minute ventilation (MV) or 
an increase in dead space ventilation (VD). 
In this thesis, I have studied HRF in adults, divided into two groups:  
Obstructive conditions, primarily affecting the airways, include diseases such as chronic 
obstructive pulmonary disease (COPD), bronchiectasis, and chronic asthma. 
Restrictive conditions include both disorders of extrapulmonary restriction, including chest 
wall disorders (CWD) such as kyphoscoliosis and obesity hypoventilation syndrome (OHS), 
and also neuromuscular disorders (NMD) such as motor neuron disease (MND), muscular 
dystrophies. 
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These two groups not only differ in their pathophysiology, but also their response to NIV 
and pose specific issues for an autotitrating system. 
1.2.1 Pathophysiology of hypercapnic respiratory failure  
As shown in Figure 1-1, HCRF results from decreased capacity, increased load or decreased 
drive of the respiratory system, which can occur both acutely and chronically. 
 Acute hypercapnic respiratory failure (AHRF) is the acute evolution of ventilatory failure, 
resulting primarily from either a progression of underlying disease or, more commonly, from 
a superimposed insult to an already stressed ventilatory system functioning close to 
capacity.  Chronic disease progression is punctuated by exacerbations which are defined as 
‘periods of acute, sustained worsening of the underlying condition from the stable state and 
beyond normal day to day variability which may require a change in treatment’ (Rodriguez-
Roisin 2000; Bilton, Canny et al. 2011). Additional burdens are typically respiratory 
infections (bacterial or viral) or other causes of airway inflammation.  Another common 
cause is a worsening of co-existing heart failure, particularly in obese patients. All of these 
are potentially reversible with appropriate treatment. 
Chronic hypercapnic respiratory failure (CHRF) is due to the progression of the underlying 
disease with or without the sleep-related changes in physiology contributing to nocturnal 
hypoventilation, which may progress to chronic daytime hypoventilation.  
The pathology that leads to acute and chronic respiratory failure varies between underlying 
diagnoses. Understanding the impact of the changes in physiology is vital for early detection 
and successful NIV treatment. The following section reviews 4 common causes of 
respiratory failure: COPD, NMD, CWD and OHS. 
 COPD: is characterised by expiratory flow limitation and its resultant physiological 
ventilatory dysfunction (Vestbo, Hurd et al. 2013). Chronic airway inflammation causes 
irreversible structural bronchial airway remodelling (bronchitis) and also the loss of elastic 
tissue support for small airways (emphysema). These pathological changes, combined with 
increased mucosal secretions and bronchospasm, increase airway resistance and produce 
expiratory flow limitation. This in turn leads to incomplete expiration causing hyperinflation. 
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The hyperinflation is exacerbated during periods of increased minute ventilation (MV) 
demand, such as exercise, and is defined as dynamic hyperinflation (DHI) (Rodriguez-Roisin 
R 1998; Parker, Voduc et al. 2005; Stevenson, Walker et al. 2005; O'Donnell and Parker 
2006). DHI causes an intrinsic positive end expiratory pressure (PEEPi) which increases the 
inspiratory threshold, as well as forcing ventilation to occur higher on the pressure-volume 
curve; thereby further increasing work of breathing (WOB). Respiratory muscle fatigue may 
result (O’Donnell and Parker 2006), however this is still debated. Inspiratory muscles, 
particularly the diaphragm, are affected in several ways: hyperinflation of the lungs leads to 
reduced load-tension capacity of mechanically disadvantaged respiratory muscles. Muscles 
are also affected chronically through malnutrition, steroid use, chronic hypoxaemia and 
hypoxia. Despite these burdens, fatigue of the diaphragm has not been observed in relation 
to CHRF, even by induced hyperventilation (Polkey, Kyroussis et al. 1995).  
In acute exacerbations of COPD, MV demand increases with increased stimulation of the 
respiratory centres, but WOB is high.  Patients’ respiratory pattern changes to prevent 
respiratory muscle fatigue (Tobin, Laghi et al. 2009). The protective strategy of rapid shallow 
breathing, reduces the WOB and therefore inspiratory muscle oxygen consumption.  
However, this pattern of breathing leads to an increased deadspace ventilation (VD) and is 
deleterious to gas exchange. This can result in acute hypercapnia and hypoxia, plus 
worsening hypoxia attributable to a worsening V/Q mismatch due to an increased VD 
(Calverley 2003). 
NMD: In NMD, muscle weakness is the key factor in the pathophysiology of HRF.  Weakness 
occurs in 3 main muscle groups; inspiratory, expiratory and upper airway muscles with 
resultant deficits in ventilation, airway protection and airway clearance (Rezania, 
Goldenberg et al. 2012). This not only leads to a progression towards HRF, but also places 
patients at high risk of aspiration and recurrent infections. Respiratory infections lead to 
bronchial mucous plugging and further muscle weakening of up to 25% resulting in  
reductions of VC of >10% (Mier-Jedrzejowicz, Brophy et al. 1988; Poponick, Jacobs et al. 
1997). This increased load is on a system already working near capacity and is often 
associated with muscle fatigue, hypoventilation and thereby acute HRF. The 
pathophysiology of NMD is in contrast with acute exacerbations in patients with COPD, 
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where muscles may not fatigue. Chronic HRF in NMD occurs by chronic inspiratory muscle 
weakness and decreased respiratory drive as a result of reduced chemosensitivity (see 
Section 1.2.2).  
Chest restriction:  
CWD: Primary deformities of the chest, such as kyphoscoliosis, or in the presence of 
thoracoplasty, can cause altered respiratory mechanics that may lead to respiratory 
insufficiency. The reduced compliance of the respiratory system produces ventilation higher 
on the pressure volume curve, even at rest. This increased thoracic impedance, contributes 
to greater loading of muscles, which are mechanically disadvantaged and chronically 
weakened. Muscle fatigue may ensue, due to an inadequate force production (Goldstein 
1992).  
OHS: is the association between obesity (BMI > 30kg/m2) and chronic daytime alveolar 
hypoventilation (daytime hypercapnia PCO2 > 6kPa) (Piper 2011). Obesity impairs 
respiratory mechanics and increases WOB. Patients breathe at low lung volumes with 
reduced lung compliance, as in CWD (Behazin, Jones et al. 2009).  Airway resistance at low 
volumes is also high, leading to potential expiratory flow limitation and PEEPi, as in COPD, 
also with increased inspiratory thresholds (Pankow, Podszus et al. 1998; Steier, Jolley et al. 
2009). V/Q mismatch occurs as peripheral lung units collapse, worsened by the supine 
position. Additionally, in OHS, sleep disordered breathing is common, particularly 
obstructive sleep apnoea (OSA) and frank hypoventilation (Berger, Ayappa et al. 2001). 
Respiratory drive is affected by reduced chemosensitivity associated with hormones of 
obesity (leptin) (Shimura, Tatsumi et al. 2005) as well as nocturnal hypoventilation (see 
Section 1.2.2). 
1.2.2 The impact of sleep on ventilation of patients with chronic respiratory disease 
Sleep and wakefulness are distinct states of consciousness, as defined by changes in the 
neural activity of the brain, measured by changes in frequency of electroencephalogram 
(EEG).  Sleep is divided into non rapid eye movement (NREM) and rapid eye movement 
(REM), with cyclical transitions of approximately 90 minute durations throughout the night. 
 30 
NREM sleep is divided into 4 stages; stages 1 and 2 which are unsteady transitional stages 
and stages 3 and 4 which are deep sleep, termed slow wave sleep (SWS).  
Respiratory physiology changes from wakefulness to sleep, and across sleep stages. 
Nocturnal ventilation is progressively reduced during sleep due to changes to all 3 
components of the load-drive-capacity balance, which can precipitate or worsen existing 
respiratory failure. In healthy people, minute ventilation (MV) is decreased by 
approximately 10%. A reduced hypercapnic ventilatory response (HCVR) decreases 
ventilatory drive in the presence of raised CO2 (Douglas, White et al. 1982; Douglas, White 
et al. 1982; Skatrud and Dempsey 1983). Respiratory muscle contraction is also reduced, 
and a reduction in upper airway tone increases airflow resistance.  Overall, the decrease in 
MV, predominantly due to reduced tidal volumes (Vt) (Douglas, White et al. 1982; Stradling, 
Chadwick et al. 1985), results in a rise in CO2 (up to 1kPa) and slight decrease in oxygen (1-
2%). 
In health these changes are not deleterious, however in chronic respiratory disease they 
may lead to nocturnal respiratory insufficiency and blood gas derangement.  During REM 
sleep, when accessory muscle activity is markedly reduced, MV is reliant on diaphragm 
efficiency which may be reduced due to differing mechanisms; weakness (as in NMD), 
mechanical disadvantage (as in COPD), or due to excessive load (as in OHS) (Simonds 2013). 
In COPD, a decreased functional residual capacity (FRC) worsens V/Q relationships and 
therefore gas exchange, particularly oxygenation. Additionally, the supine position is 
independently detrimental leading to decreased tidal volumes, especially during REM sleep. 
Such effects have also been observed in diaphragm weakness, OHS (Steier, Jolley et al. 
2009) and in patients with kyphoscoliosis. Sleep disordered breathing may further 
compound nocturnal ventilatory failure (Resta, Foschino-Barbaro et al. 2000).  
In patients with chronic nocturnal hypoventilation, daytime gas exchange can be influenced 
through resetting of chemosensitivity associated with renal bicarbonate retention (Piper 
and Sullivan 1994). Symptoms of nocturnal hypoventilation include sleep disruption, 
daytime hypersomnolence, morning headache, dyspnoea and fatigue.  
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Sleep can be further affected in patients; high CO2 levels can cause frequent arousals and 
sleep fragmentation, and disruption to normal sleep architecture. Daytime hypoxia is also 
independently associated with impaired sleep efficiency (McSharry, Ryan et al. 2012).  
Primary disease symptoms including cough, sputum, wheeze and breathlessness may also 
add to sleep disruption in patients (Klink and Quan 1987). 
1.2.3 The treatment of respiratory failure with NIV 
Non-invasive ventilation (NIV) is a means of treating HRF without the need for endotracheal 
intubation (ETI).  Pressure support is applied via a face mask, or other non-invasive 
interface, to augment spontaneous breathing effort. NIV is a well-established, evidence 
based treatment of acute, acute-on-chronic and chronic HRF. However, rationale and 
mechanisms of actions differ between aetiology of ventilatory failure. 
The use of NIV in acute HRF has evolved over the last 2 decades. In COPD patients with 
acute hypercapnic exacerbations, NIV is the recommended first line treatment (BTS 2002). 
Compared to standard medical therapy alone, the addition of NIV produces a more rapid 
resolution of blood gas derangement and symptoms, and has been shown  to decrease the 
rate of ETI (Brochard, Mancebo et al. 1995; Plant, Owen et al. 2000), length of hospital stay 
(Brochard, Mancebo et al. 1995) and mortality (Bott, Keilty et al. 1993; Brochard, Mancebo 
et al. 1995; Plant, Owen et al. 2000). In patients with heterogeneous acute HRF, treatment 
with NIV leads to similar reductions in ETI and associated complications, length of stays and 
mortality (Ambrosino, Foglio et al. 1995; Wysocki, Tric et al. 1995; Celikel, Sungur et al. 
1998; Carlucci, Richard et al. 2001).  Indeed, NIV has been used in acute ventilatory failure 
associated with OHS with similar efficacy to in COPD but better outcomes were observed 
with lower hospital mortality and improved one year survival (Carrillo, Ferrer et al. 2012). 
In the acute setting, NIV is used to correct rapid shallow breathing, and augment alveolar 
ventilation to maintain gas exchange, increasing MV (increased Vt) whilst unloading the 
inspiratory muscles (Diaz, Iglesia et al. 1997). This therefore reduces RR, WOB and dyspnoea 
(Bott, Keilty et al. 1993; Diaz, Iglesia et al. 1997; Tobin, Jubran et al. 2001).   Additionally, in 
patients with acute exacerbations of COPD, the intrinsic PEEP can be counteracted by 
externally applied PEEP, reducing the inspiratory threshold and WOB. In these ways, NIV 
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provides support during the medical treatment of the underlying cause of the acute 
ventilatory insufficiency, thus allowing patients recover and return to spontaneous, 
unassisted breathing. 
Domiciliary NIV is used to treat chronic HRF and nocturnal hypoventilation. The main aim is 
to augment nocturnal alveolar ventilation resulting in improved overnight gas exchange, 
leading to improved daytime blood gases and alleviation of the symptoms of 
hypoventilation. Evidence exists for increased survival and quality of life for patients with 
NMD and chest wall disorders when treated with NIV (Leger, Bedicam et al. 1994; Simonds 
and Elliott 1995). In patients with COPD, benefits in sleep, nocturnal oxygen saturations, 
diurnal and nocturnal PCO2 have been observed following NIV. However, there is continued 
debate regarding the survival and cost benefits of long-term NIV in COPD (Wijkstra, Lacasse 
et al. 2003; Kolodziej, Jensen et al. 2007; McEvoy, Pierce et al. 2009). New evidence has 
shown that NIV targeted to greatly reduce hypercapnia (aiming for  a PCO2 <6.5kPa or a 
decrease in baseline PCO2 of 20%) has a survival benefit at one year, when compared to 
optimal standard treatment in COPD GOLD IV patients (Kohnlein, Windisch et al. 2014). 
Despite these uncertainties, nocturnal NIV is widely used in the treatment of patients with 
COPD. NIV use is also increasing in patients with OHS who do not respond to CPAP 
(Janssens, Derivaz et al. 2003; Lloyd-Owen, Donaldson et al. 2005) with the treatment of 
OHS now the most common reason for chronic NIV therapy initiation (Janssens, Derivaz et 
al. 2003). 
1.2.4 Mechanism of action of NIV in differing pathologies of hypercapnic respiratory 
failure 
In chronic hypoventilation and ventilatory failure, several mechanisms of action of NIV 
action have been investigated, in particular the effect of nocturnal NIV therapy on daytime 
blood gas improvement. Three major mechanisms suggested include resting of the 
respiratory muscles, changes in pulmonary mechanics and resetting of chemosensitivity and 
neural drive. A fourth mechanism may be the normalisation of sleep architecture and 
reduction in sleep fragmentation. The mechanisms also vary with underlying disease and 
cause of ventilatory failure (Ozsancak, D'Ambrosio et al. 2008) (See Figure 1-2). 
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Figure 1-2: Pathophysiology of chronic ventilatory failure and mechanisms of action of non-
invasive ventilation (NIV), specifically in chronic obstructive pulmonary disease (COPD), 
obesity, and restrictive ventilatory disorders (neuromuscular disease (NMD) and chest wall 
disease (CWD)) (Ozsancak, D'Ambrosio et al. 2008)  
In patients with NMD and CWD, the mechanism of NIV appears to be a change in 
chemosensitivity through reduced renal bicarbonate retention and increased daytime 
responsiveness to PCO2 and pH (Nickol, Hart et al. 2005). Reductions measured in PCO2 after 
NIV initiation correlate with increased ventilatory response to CO2 (Annane, Quera-Salva et 
al. 1999). 
In patients with COPD, the primary mechanism is less clear. Changes to pulmonary 
mechanics appear to play a role in load reduction. Hyperinflation and gas trapping are 
reduced in COPD patients treated with NIV (Elliott, Mulvey et al. 1991; Nickol, Hart et al. 
2008). Improvements in respiratory muscle strength are not common (Schonhofer, Polkey et 
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al. 2006) but have been observed in a small sample in CF patients after one 1 month of NIV 
(Piper, Parker et al. 1992). Resetting of chemosensitivity appears to be less prominent in 
COPD compared to restrictive disorders (Nickol, Hart et al. 2008).  
In patients with OHS, benefits in daytime gas exchange and symptoms, have been observed 
in both CPAP and NIV treatment (Piper, Wang et al. 2008), however in those patients non-
responsive to PEEP alone, NIV is the therapy of choice (Report 1999). An improved 
chemosensitivity with NIV can also lead to daytime normocapnia, as in other restrictive 
pathologies. In these patients, residual sleep disordered breathing, particularly airflow 
limitation, can be consequently managed with CPAP (Piper, Wang et al. 2008).  
1.3 Advances in modes of non-invasive ventilation (NIV) 
From the beginnings of NIV in the 1980s, positive pressure delivery was initially volumetric, 
with pressure-preset ventilators appearing in the early 1990s.  Historically, both pressure- 
and volume-preset modes of breath delivery, have been used with success. However, there 
has been a distinct shift from volume-preset to pressure-preset ventilators as seen in a 7 
year prospective study in the Geneva Lake area (Janssens, Derivaz et al. 2003), particularly in 
long-term NIV where patient comfort is paramount to therapy tolerance and adherence 
(Figure 1-3). 
 
Figure 1-3: Changing patterns of ventilation in a 7 year prospective study in the Geneva Lake 
area; from (Janssens, Derivaz et al. 2003) 
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The amount of ventilatory assistance provided to the patient can be further modified by the 
provision of a preset RR which may be either mandatory (T: Timed ventilation) or back-up 
(S/T: spontaneous-timed). The inspiratory time (Ti) may also be set for both mandatory and 
spontaneous breaths, depending on the ventilator and mode of ventilation, thus maximising 
opportunity for gas exchange to occur. 
Further advances in pressure-preset modes have included options in pressurisation (range, 
leak compensation), size, noise, improvement of patient-ventilator synchrony by adjustable 
triggering and cycling sensitivities, and built in software for monitoring NIV efficacy (Rabec, 
Rodenstein et al. 2010). More recently, hybrid modes that attempt to combine the benefits, 
and reduce the limitations, of both pressure and volume preset breaths have been 
developed.  Intelligent servoventilation algorithms have also been developed to increase 
patient comfort, whilst attempting to personalise ventilatory assistance. They are based on 
algorithms that respond constantly to patients’ spontaneous ventilatory requirements, 
including changes in lung physiology, sleep, patient effort and even changes in position or 
activity.  
1.3.1 Pressure v volume preset ventilation 
In current practice, NIV is most commonly delivered by bi-level pressure support. This 
provides an inspiratory pressure to augment tidal volume (Vt) and maintains a lower level of 
pressure during expiration to splint the upper airway and recruit alveoli. Comparable 
outcomes have been observed with both pressure or volume preset modes of ventilation in 
both acute HRF (Meecham Jones, Paul et al. 1994; Girault, Leroy et al. 1997; Kirakli, Cerci et 
al. 2008) and chronic HRF (Schonhofer, Sonneborn et al. 1997; Tuggey and Elliott 2005; 
Windisch, Hendrik Storre et al. 2005).  
Volume-preset ventilation provides greater stability of the potential volume delivered to 
the lungs in the face of varied patient effort, chest wall compliance or airway resistance 
(Schonhofer, Sonneborn et al. 1997). However the presence of unintentional leak can 
reduce the intended Vt by up to 50% (Smith and Shneerson 1996; Mehta, McCool et al. 
2001).  Also, the fixed inspiratory flow rate can be insufficient for the dyspnoeic patient 
causing an increased WOB (Marini, Rodriguez et al. 1986). If inspiratory flow rate is 
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manually increased to better match patient demand, alongside a guaranteed Vt, 
barotraumas can result. This is a particular risk during acute lung changes, such as sputum 
plugging, bronchospasm and collapse (Haake, Schlichtig et al. 1987).  There is also the risk of 
over-ventilation, particularly during sleep when ventilatory demands may decrease, leading 
to hypocapnia-induced vocal cord closure (Jounieaux, Aubert et al. 1995; Jounieaux, Aubert 
et al. 1995; Parreira, Jounieaux et al. 1997).  
Pressure-preset ventilation compensates for unintentional leak, but tidal volumes delivered 
to the lungs are reduced if the maximum inspiratory pressure is reached early due to 
increased airways resistance or decreased lung compliance. It is, however, more 
comfortable and better tolerated due to an inspiratory flow rate that is able to match the 
patient’s demand (MacIntyre 1986) and less variation of peak inspiratory pressure 
(Windisch, Hendrik Storre et al. 2005). 
A summary of volume preset versus pressure preset ventilation is shown in Table 1-1. 
Table 1-1: Summary of features of volume- and pressure- preset ventilation modes 
R= lung resistance, C= lung compliance 
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1.3.2 Volume assured pressure support (VAPS) ventilation  
Volume assured pressure support (VAPS) ventilation is a hybrid form of servoventilation that 
may combine the benefits of both pressure- and volume- preset NIV, whilst reducing the 
separate limitations of both types of ventilation. PS, and also RR, are constantly and  
automatically adjusted to achieve and maintain a constant target alveolar ventilation in the 
face of changing ventilatory requirements (see Figure 1-4), i.e. with changes in lung 
mechanics (lung resistance and compliance), patient effort, and in the presence of leak. 
Other ventilatory parameters are similar to standard ventilatory modes; including 
inspiratory fraction (Ti/Ttot), trigger threshold flow, cycling flow (as proportion of peak 
flow), rise time (inspiratory pressure) and fall time (expiratory pressure).  
 
 
Figure 1-4: A trace from an iVAPS ventilator over approximately 2 minutes. (ResMed 
Product Guide) 
Maximum and minimum pressure support (PS) boundaries (dashed lines) are preset by the clinician. The current patient 
alveolar ventilation is constantly compared to the pre-set target alveolar ventilation. The instantaneous PS is then 
adjusted accordingly; as the delivered ventilation falls below the target, the PS is increased until the target ventilation is 
achieved.  Likewise, the PS is again decreased if the achieved ventilation exceeds the target. 
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Mechanism of Action: The iVAPS algorithm is based on the relationship between airflow and 
pressure. The patients’ RR and flow are constantly monitored, from which actual alveolar 
ventilation is derived. These values are compared with pre-set targets. Figure 1-5 shows the 
set-up of the ventilator. 
 
Figure 1-5: Pneumatic flow path from the entrainment of atmospheric air into the ventilator 
and the ‘on-board’ ventilator measurement of airflow and pressures. Adapted from US 
States Patent, Berthon-Jones et al. (Patent No: US 8544467B2; Oct 2013) 
iVAPS servoventilation algorithm: iVAPS is an algorithm for the automatic adjustment of PS 
within pre-set boundaries, in order to achieve a target VA. Target VA (l/min) is the non-
anatomical-deadspace ventilation. During therapy, actual VA, passed through a low pass 
filter is compared to the target VA. PS is then adjusted to produce ventilatory changes 
equivocal to the magnitude and direction of the difference over the following 2-3 breaths. A 
maximum and a minimum PS (IPAP minus EPAP) are set in accordance with patient 
tolerance and underlying respiratory disease. 
NIV nomenclature and algorithms of VAPS modes vary slightly between ventilator 
manufacturers.  iVAPS (ResMed Ltd; Australia) is the ventilation mode being investigated in 
this thesis and is distinct from other VAPS algorithms in: 
• Targeting alveolar ventilation, accounting for anatomical dead space 
• Providing an intelligent back up respiratory rate for maximum patient-ventilator 
synchrony 
• Providing a ‘learn period’ where the ventilator automatically selects therapy settings 
based on a patient’s own breathing pattern during an awake breathing trial 
• Sophisticated data monitoring capabilities; summary and high resolution breath-by-
breath data 
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The above technological developments are discussed in more detail in the general methods 
(see Chapter 2 Section 3). iVAPS and AVAPS (average volume assured pressure support) 
(Phillips Respironics; USA) are the  two most commonly encountered VAPS modes in the 
literature. Other manufacturers and their ventilators that support similar VAPS modes 
include the VIVO 40 (Breas Medical) and Legendair (Airox); Ventimotion (Weinmann). 
1.4 Evidence for the efficacy of iVAPS and benefits compared to other modes of 
ventilation 
Algorithms for automated adjustment of PS have been successfully used in invasive 
ventilation to provide guaranteed volumes (Dojat, Harf et al. 2000) with decreased muscle 
workload and improved patient-ventilator synchrony (Amato, Barbas et al. 1992). In 
addition, autotitration has since become integral in other pressure support therapy delivery, 
such as  continuous positive airways pressure (CPAP) (Littner, Hirshkowitz et al. 2002).  
Bench testing has been performed in each of the VAPS ventilators, evaluating the ability to 
maintain a minimum tidal volume (Vt) during different conditions associated with alveolar 
hypoventilation; namely increased airways resistance, decreased lung compliance and 
unintentional leak. Ventilators were able to maintain VA in altered resistance and 
compliance simulations even when Vt was initially reduced by up to a third, but not during 
leak (Fauroux, Leroux et al. 2010). Reponse to an acute increase in Raw was typically an 
increase of IPAP by 3-10cmH2O over 1-14 breathing cycles, sometimes with associated 
increases in Ti (dependent on the ventilator and manufacturer). Decreases in lung 
compliance produced smaller IPAP increases (1.6 - 3.3cmH2O). Leak, however was more 
challenging, and asynchronies were frequent. Of specific interest to this thesis are studies 
that tested the iVAPS algorithm. These tests have  confirmed the capacity of the iVAPS 
ventilator to approximate a preset target ventilation at a variety of simulated lung 
compliance and resistance levels, with minimal effect of an added leak (Oscroft and Smith 
2010). ResMed ventilators supporting VAPS modes, (not Stellar 150) are successful in VA 
maintenance, with quick responses (within 1 breathing cycle) to both Raw and lung 
compliance changes. During leak, however, extended periods of patient dyssnchrony, 
namely auto-triggering,  were observed alongside the increased PS and  Ti  (Fauroux, Leroux 
et al. 2010).   
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In the acute setting iVAPS feasibility was initially investigated by a short term, non-
randomised application of the device in an intensive care (ICU) setting (Battisti, Tassaux et 
al. 2007). This study showed acute resolution of hypercapnia and acidosis, comparable to 
standard PS ventilation with similar levels of PS delivered. In a study comparing AVAPS with 
standard PS NIV therapy in ICU patients admitted with acute exacerbation of COPD and 
hypercapnic encephalopathy, quicker recovery of consciousness and resolution of PCO2 was 
observed with AVAPS (Briones Claudett, Briones Claudett et al. 2013). In a case report of a 
patient with acute exacerbation COPD and concomitant SDB, AVAPS was used successfully 
to provide greater ventilatory support at night than was required, or tolerated, during the 
day (Okuda, Kashio et al. 2012). This might suggest a benefit in patients with overlap 
pathologies, particularly during exacerbations of chronic ventilatory failure. 
In the chronic setting, VAPS as a ventilator mode (inclusive of iVAPS and AVAPS) has been 
further investigated. Equivalence between VAPS and standard PS in controlling nocturnal 
hypoventilation has been observed in chronic ventilatory failure in COPD (Oscroft, Ali et al.; 
Rodriguez-Roisin R 1998; Crisafulli, Manni et al. 2009), OHS (Murphy, Davidson et al. 2012) 
and mixed diagnoses (Ambrogio, Lowman et al. 2009).  Significantly, greater reductions in 
CO2 by VAPS compared to standard PS ventilation have been observed in OHS (Storre, 
Seuthe et al. 2006; Janssens, Metzger et al. 2009). However, this was at the expense of sleep 
quality and comfort (Janssens, Metzger et al. 2009) with higher pressures and volumes used. 
Additionally, the increased efficiency of CO2 reduction observed did not produce any further 
immediate clinical benefit as measured by the severe respiratory insufficiency (SRI) 
questionnaire (Storre, Seuthe et al. 2006). Moreover, the benefit in superior CO2 reduction 
was lost at 3 months when long-term diurnal CO2 reduction was equivalent  to that achieved 
by standard PS ventilation (Murphy, Davidson et al. 2012). Similarly in patients with stable 
hypercapnic COPD, the reduction in overnight PCO2 was greater with iVAPS than with 
standard PS, however there was no difference in daytime CO2 after 8 weeks of therapy 
(Rodriguez-Roisin R 1998).  
The NIV treatment of COPD often requires high levels of PS, particularly if aiming for 
normocapnia, which has given rise to a ‘high-intensity’ treatment option. High levels 
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compared to lower levels of PS have shown increased improvements in blood gases, lung 
function, exercise-induced dyspnoea and HRQoL (Dreher, Storre et al. 2010; Dreher, 
Ekkernkamp et al. 2011) and more recently survival (Kohnlein, Windisch et al. 2014). In a 
recent study comparing AVAPS with high-intensity PS ventilation, both ventilation options 
provided equivalent result, including an increase in MV by an average of 26%, during a short 
period of supported ventilation during wakefulness (Ekkernkamp, Kabitz et al. 2014).  
The only trial which reported a small but significant under-ventilation using the iVAPS was 
published by my own group in stable NMD patients experienced in NIV use (Jaye, Chatwin et 
al. 2009).  The correction of nocturnal hypercapnia was less during iVAPS but may have 
occurred as a result of increased deep sleep in iVAPS ventilation compared to standard PS 
ventilation. In response to this, the algorithm was adjusted to target 100% of daytime VA 
and I have shown in the data contained in this thesis that the hypoventilation control and 
CO2 elimination is now comparable to standard PS ventilation (Kelly, Jaye et al. 2014) (See 
Chapter 5 Section 3.3). I have also shown an increased adherence of over an hour during 
iVAPS therapy compared to standard PS in patients who were previously naive to NIV (See 
Chapter 5 Section 3.4). 
Lower pressures have clinical benefit in reducing the risk of physiological hyperinflation and 
increased WOB, especially in obstructive diseases, and also unwanted side effects of mask 
leak, aerophagia and general intolerance. In recent studies, reduced levels of PS when 
combined with increased RR during nocturnal ventilation in COPD, have also shown to 
decrease patient ventilator asynchrony, without detriment to nocturnal gas exchange 
(Adler, Perrig et al. 2011). Despite similar MV achieved in both NIV modes, higher PS levels 
during VAPS ventilation than during standard PS were observed in 3 studies; 2 in OHS as 
previously discussed (Storre, Seuthe et al. 2006; Janssens, Metzger et al. 2009) and a third in 
a mixed population of chronic respiratory insufficiency (Ambrogio, Lowman et al. 2009). 
High pressures may be explained by low lung compliance in OHS, however an alternative 
explanation could be that in 2 of these studies, the pre-set minimum PS values did not 
maximise variation ((Ambrogio, Lowman et al. 2009; Janssens, Metzger et al. 2009).  PS  was 
set only 3 or 5cm below the patients’ normal IPAP level, thus inhibiting low levels of PS 
during times of adequate patient effort, thereby potentially reducing other beneficial 
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comfort effects. This clearly displays the importance of the choice of PS boundaries by the 
clinician.  
In sleep, there have been two studies reporting a better subjective sleep experience with 
VAPS. Patients with stable COPD and who were naïve to NIV perceived improved sleep 
efficiency over 5 days with VAPS compared to standard PS (Crisafulli, Manni et al. 2009). 
There was no further clinical benefit observed. In the longer term, Ekkernkamp et al. 
(Ekkernkamp, Storre et al. 2014) reported that patients experience a more restful sleep 
when using VAPS compared to high intensity PS ventilation at home. This was in conjunction 
with improved nocturnal CO2 control. Reported objective sleep efficiency has been 
comparable across all VAPS trials, ranging from 68-86% (Storre, Seuthe et al. 2006; 
Ambrogio, Lowman et al. 2009; Jaye, Chatwin et al. 2009). The previously discussed 
improvements in sleep architecture with more time spent in deeper sleep with iVAPS as 
compared to PS, was however at the detriment of PCO2 control (Jaye, Chatwin et al. 2009). 
It has been previously suggested that the constant alterations in PS might cause sleep 
disturbance, and while this has not been reported in the published trials, a case study in an 
overweight patient with cerebellar atrophy and spinal cord disease reported on persistent 
shallow desaturations (ODI 53.3), sleep fragmentation and diurnal somnolence in VAPS 
therapy. The repetitive arousals were associated with abrupt increases of inspiratory 
pressure of 10cmH2O in a single breath (Carlucci, Fanfulla et al. 2012). Variations in 
manufacturers’ algorithms, particularly in the timing of PS adjustment might account for 
differences observed.  
In NMD, an inability to generate the inspiratory pressure or flow required to trigger the 
ventilator often leads to unrewarded efforts, at cost to patients’ WOB. A study investigating 
the effects of VAPS as compared with both standard PS and pressure controlled modes of 
ventilation revealed similar efficacy on breathing pattern and ABG, however there was 
greater asynchrony in VAPS ventilation with more ineffective efforts and leak (Crescimanno, 
Marrone et al. 2011). Dysnchrony has not been reported on in other VAPS trials. 
Main barriers to the utilisation of NIV: include inadequate equipment and lack of physician 
knowledge and staff training (Maheshwari, Paioli et al. 2006). An intelligent ‘learn’ feature 
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has been incorporated into the ventilator technology, for the automated selection of 
ventilator settings based on the patient’s wake breathing pattern. Consequently patients 
receive the minimum PS required to maintain VA at a RR matched to their own. This may 
offer increased comfort and potentially improve NIV uptake and adherence, while aiding 
NIV initiation in centres with less experienced staff. Ventilators without the ‘learn function’ 
intelligence are reliant on clinician experience or ventilator manufacturers’ 
recommendations. In VAPS studies using clinician-set volumes, Vt was the most frequently 
targeted volume with values ranging from 6-10ml/kg of body weight or 7-12ml/kg of ideal 
body weight (IBW). In the study by Janssens et al (Janssens, Metzger et al. 2009), OHS 
patients were ventilated with the highest target  Vt (8-12ml/kg IBW) resulting in decreased 
comfort as compared to standard PS ventilation, high mean inspiratory pressure (24cmH20), 
the perception of ‘too much air’ and increased leakage. The authors went on to recommend 
a lower target of 8ml/kg IBW.  
During NIV initiation, the intelligent learn function has been used in several studies with 
equivalent success to initiation by a skilled healthcare professional (Jaye, Chatwin et al. 
2009; Oscroft, Ali et al. 2010; Kelly, Jaye et al. 2014). The ventilator automatically set target 
ventilation to a percentage of the patient’s own wake breathing ventilation, typically 100%. 
However, the greatest correction of PCO2 was observed in studies where the MV target was 
an ‘overshoot’ of patients’ spontaneous volumes with a Vt target set to 110% of a learned 
Vt (Ambrogio, Lowman et al. 2009). In contrast, my group previously observed a mild under-
ventilation when a target of 90% was used (Jaye, Chatwin et al. 2009). The algorithm has 
since been modified to target 100% with successful control of overnight gas exchange. This 
suggests that patients require nocturnal ventilation that is at least equivalent to their 
daytime ventilation to prevent overnight blood gas disturbance. 
Summary: VAPS has been demonstrated to show equivalence to other modes of NIV, 
specifically standard PS ventilation in COPD and OHS. Other measures of comfort, health 
related quality of life (HRQoL), respiratory muscle function, lung function measures have 
also been equivalent to measures made with patients receiving standard PS ventilation 
therapy. Other observed benefits of VAPS, but not consistent throughout the literature, 
have included increased subjective comfort and sleep efficiency as well as increased 
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adherence to therapy. There may also be increased benefit in certain pathologies including 
OHS and overlap syndromes. Longer term follow-up studies are required to assess the 
ability of autotitration to maintain ventilation targets during disease progression and also 
the effect on service provision requirements; training, expertise and titration/ follow-up. 
The intelligent learn function of iVAPS has been shown to produce equivalent outcomes to 
manually selected ventilator settings, however a level of expertise is required to make 
appropriate adjustments during administration. The sophisticated data monitoring of the 
iVAPS ventilator may also aid therapy titration and troubleshooting.  
Limitations have been observed in patient ventilator interactions, specifically regarding 
ventilator triggering in NMD and pathophysiological hyperinflation in COPD, and also in the 
presence of unintentional leak. Moreover, excessive autotitrating PS responses have been 
observed to cause disruption to sleep. There is potential for a cheyne stoke pattern of 
ventilation overshoot- undershoot with constant adaptation of the PS delivered. 
Algorithms may still require further refinement. Targeted nocturnal ventilation volumes as a 
percentage of daytime ventilation, particularly in daytime hypercapnic patients may need to 
be increased, particularly to account for increased ventilatory demands as may occur during 
exacerbations. 
1.5 Novel use of iVAPS in exacerbation detection and prediction                                                                                                                                                                                          
Exacerbations of chronic respiratory disease are a great burden – to patients and to 
healthcare systems.  Acute exacerbations are one of the most common causes for hospital 
admission, with associated annual costs totalling over £800 million in the UK (BTS 2006). In 
COPD, in particular, frequent exacerbations are associated with more rapid decline in lung 
function (Kanner, Anthonisen et al. 2001; Donaldson, Seemungal et al. 2002), a reduced QoL 
(Seemungal, Donaldson et al. 1998), and increased risk of morbidity and mortality (Soler-
Cataluna, Martinez-Garcia et al. 2005). 
Identifying exacerbations in a timely manner affords early treatment, a vital part of COPD 
(and other respiratory disease) management, with more favourable outcomes (Wilkinson, 
Donaldson et al. 2004). In asthma, a clear plan exists to monitor, detect and treat 
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exacerbations based on PEF (Reddel, Taylor et al. 2009). In COPD, however, no such 
certainty exists. Indeed, there is no consensus on a standard definition of an acute 
exacerbation of COPD, nor a reliable method of detection or prediction. This is despite much 
research in the field, investigating methods of detection including symptom-reporting, daily 
measurement of physiological parameters (PEF, spirometry, HR, RR, SaO2), medication 
changes (use of antibiotics and steroids) and healthcare utilization (GP and healthcare 
worker visits, emergency room visits, hospital admissions) (Stockley and Burnett 1979; 
Anthonisen, Manfreda et al. 1987, Seemungal, Donaldson et al. 2000; Donaldson, 
Seemungal et al. 2002; Parker, Voduc et al. 2005; Stevenson, Walker et al. 2005; Cazzola, 
MacNee et al. 2008; Vijayasaratha and Stockley 2008; Leidy, Wilcox et al. 2010). However, 
many exacerbations remain unreported and/or untreated leading to a further reduction in 
QoL (Seemungal, Donaldson et al. 1998; Langsetmo, Platt et al. 2008) and increased risk of 
hospitalisation (Wilkinson, Donaldson et al. 2004). 
Recently, interest has turned to prediction of exacerbations, particularly by using data from 
therapies that are already in use (eg: LTOT and NIV) and that do not require patient input or 
additional monitoring. Specifically, the use of domicillary NIV in longitudinal monitoring of 
patients’ condition is a new concept. Day-to-day variability in patients’ respiratory 
physiology, their respiratory pattern and ventilator requirements may be detectable by 
monitoring ventilator parameters, particularly in the context of an exacerbation. The 
patient’s RR rises in response to an acute exacerbation (Murphy, Kumar et al. 2011) and this 
has been successfully detected by nasal cannulae used in LTOT delivery in the prodrome 
period of an exacerbation (Yanez, Guerrero et al. 2012).  Furthermore, a recent study, 
performed since the start of the studies presented in this thesis, has investigated the use of 
ventilator-measured parameters to predict the risk of exacerbation in COPD patients using 
standard PS NIV (Borel, Pelletier et al. 2015). The authors have suggested that daily 
variations in RR and the percentage of respiratory cycles triggered by the patient (% patient 
triggered) can be used to predict an exacerbation in the 2-3 days prior to exacerbation 
onset. Sensitivity, however, of using these ventilator-measured parameters was low; RR 
(46%) and % patient triggered breaths (54%).  
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In clinical practice, our group has observed such changes in ventilator parameters during a 
severe exacerbation requiring hospital admission and subsequently resulting in patient 
death (See Figure 1-6). Original data is from a standard PS ventilator, prior to and during the 
exacerbation (date of onset unknown, patient hospitalised on 6th Feb). The preset fixed PS in 
standard PS therapy, remained stable despite the increasing MV. MV initially rose due to an 
increased Vt, probably indicative of increased patient effort (as PS could not increase). Later 
median RR increased, along with the % of spontaneously triggered breaths, and was 
accompanied by a resultant fall in the Vt. The usage of the NIV decreased, perhaps due to a 
lack of symptomatic relief of WOB or due to synchronisation issues as the patient’s 
breathing pattern changed. 
Exploratoration of this data, with respect to identification of signals that might be of use in 
predicting exacerbations, highlights several key issues. The timing of the exacerbation onset 
is difficult to determine in relation to the patient response (first by increasing Vt and later 
increasing RR). The decreased use of NIV at a time of greatest need may mean that the 
ventilator was not able to adapt to changing patient requirements and as a result the 
patient could no longer tolerate the machine. 
An increased respiratory rate might be an expected outcome in a fixed pressure device in 
order to meet increased respiratory demands during exacerbation, however in iVAPS 
ventilation, an increase in ventilator demand may be met by other mechanisms, ie. an 
increase in PS. This thesis aimed to measure and monitor ventilator parameters over time to 
determine whether changes in any parameters could be used to identify or predict 
exacerbations. Real time adaptations by the iVAPS algorithm allow compensation for both 
transient and more progressive changes in patients’ requirements. Worsening of values may 
indicate a transient change as during an exacerbation or, a progression of the disease 
process. Improvements may also be observed in response to therapies.  
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Figure 1-6: Original data (January 11th – February 26th) from a single patient receiving 
domicillary standard PS NIV therapy. Patient admitted to hospital on 6th February with an 
acute exacerbation and subsequently died. Summary graphs showing daily median, 95th percentile and 
maximum values of selected measured ventilatory parameters (pressure support, tidal volume, minute ventilation, 
respiratory rate) and the percentage of spontaneous triggered breaths and daily hours of use. 
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1.6 Summary of the main themes and overall aims of this thesis 
Non-invasive ventilation (NIV) is an evidenced based treatment of alveolar hypoventilation 
in HRF, the main aim of which is to augment a patient’s own spontaneous ventilation. 
Volume assured pressure support (VAPS) is a new mode of NIV that aims to maintain 
alveolar ventilation by constant autotitration of the pressure support (PS) delivered to a 
patient in response to changes in respiratory physiology.  
The overall aim of this thesis was to investigate the use of autotitrating iVAPS NIV in 
patients with chronic ventilatory failure during wakefulness and sleep, specifically in the 
detection and treatment of acute exacerbations. 
Specific aims were to: 
a) determine if VA was maintained during VAPS ventilation in patients, with both 
obstructive and restrictive pathologies, specifically during physiological challenges ie. 
during exacerbations, and sleep (Chapters 3 and 4). 
b) determine the mechanism(s) of presumed maintenance of VA, and compare 
mechanisms between pathologies (Chapters 3 and 4).  
c) determine whether changes in the ventilator-measured respiratory parameters can 
be used to identify or predict exacerbations (Chapter 3).  
d) determine if autotitrating VAPS can be used clinically to treat ventilatory failure as 
effectively as standard PS NIV in acute hypercapnic exacerbations of chronic 
respiratory disease, and patients naive to NIV therapy (Chapters 5 and 6). 
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2 GENERAL METHODS 
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2.1 Participants and Laboratory information 
Participants in the studies described in this thesis were patients of the Royal Brompton 
Hospital (RBH) and recruited during the period of May 2011 to January 2014.  Studies were 
performed in the Clinical and Academic Unit of Sleep and Breathing, NIHR Respiratory 
Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust and NHLI, 
Imperial College London, UK.    
Adult patients had a variety of diagnoses, leading to hypercapnic ventilatory failure, either 
acute or chronic, necessitating the use of NIV. Patients with both obstructive and restrictive 
ventilatory pathologies were included; COPD, chronic asthma, OHS, CWD and NMD. A 
heterogenous patient group permitted me to compare the ventilator algorithm at work in 
different physiological conditions; both with respect to initial lung function deficits and to 
day-to-day variability and disease progression. Exacerbation pathophysiology, time course 
and recovery also differ between diseases allowing further inter-disease comparisons. Brief 
patient selection criteria are given below. Further specific inclusion and exclusion criteria 
are addressed separately within each of the study chapters following.  
In the longitudinal observational study of iVAPS (Chapter 3), patients were experienced 
users of domiciliary NIV (>3 months) for chronic ventilatory failure and compliant with 
therapy (>4 hours/night for >80% of nights). Recruitment of frequent exacerbators (≥2 
exacerbations/ year) gave an increased pool of exacerbation data to analyse. The same 
patients’ data was analysed in the study of iVAPS in sleep (Chapter 4). 
There were 2 interventional studies of iVAPS ventilation (Chapters 5 and 6); in patients with 
newly diagnosed ventilatory failure and in patients with acute hypercapnic acidotic 
exacerbations. In Chapter 5, patients were newly diagnosed with nocturnal hypoventilation 
(confirmed by daytime PaCO2>6.0 kPa, or overnight sleep study with mean transcutaneous 
CO2 (tcPCO2)>6.0 kPa or peaks of tcPCO2>6.5kPa), and naive to domiciliary nocturnal NIV. 
Patients with an acute exacerbation were excluded. In Chapter 6, patients with acute 
exacerbations of their chronic respiratory disease were hypercapnic (PCO2>6kPa) with mild 
to moderate acidosis (pH=7.25-7.35). Patients with severe acidosis (pH <7.25) were 
excluded. 
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Studies were approved by research ethics committees (REC): London-Chelsea REC (Chapter 
3: REC No: 11/LO/1777); Brompton, Harefield and NHLI REC (Chapter 5; REC No: 
08/H0708/16); South East London REC 3 (Chapter 6: REC No: 10/H0808/56). All patients 
gave informed consent prior to their participation. All studies were registered with 
ClinicalTrials.gov. Copies of patient information sheets and consent forms are included in 
Appendices 1-6. 
2.2 Measurement of respiratory function  
2.2.1 Anthropometrics 
 The same procedures were used in all studies to ensure globally consistent measures. 
Height: was measured by a stadiometer in meters (m) while standing with shoes removed. 
Recordings were made to the nearest cm. If the patient was unable to stand or had a 
scoliosis, the span of two outstretched arms (or distance from the finger tip of one arm to 
the spine, doubled) was used. 
Weight: was measured in kilograms (kg). This was performed with shoes and heavy outdoor 
clothing removed. Recordings were made to the nearest 0.1kg. 
BMI: was calculated by: BMI = weight (kg) ÷ height2 (m). A BMI > 30kg/m2 was considered 
obese, as defined by the World Health Organisation.  
2.2.2 Airway Resistance and respiratory function testing 
Airway Resistance (Raw): is the primary cause of airway obstruction and airflow limitation, 
particularly expiratory flow which is usually due to elastic recoil of the lungs (Snow 1997). 
Changes in airflow as measured by FEV1) and peak expiratory flow (PEF) reflect changes in 
Raw. Decreases are predominantly due to airway occlusion, bronchoconstriction, (secondary 
to mucosal build up (bronchitis) bronchospasm or inflammatory processes (asthma/ COPD)) 
or airway collapse (secondary to increased compliance, occlusion combined with 
compression (emphysema/ cystic fibrosis)). 
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It is most effective to measure Raw directly, for example by body plethsmography, however 
this requires specialist equipment and staff.  In the studies in this thesis, Raw was measured 
indirectly by surrogate measures of airflow (Snow 1997); FEV1 and PEF at baseline and 
follow up visits. Daily measures of PEF were also made by the patients in their home by a 
portable PEF meter (Mini-Wright standard EU scale peak flow meter; Clement Clarke 
International Ltd., UK). Other measures of respiratory function including lung volumes and 
flow rates were measured by portable, handheld spirometry (Microlab; Carefusion, UK) 
(Miller, Hankinson et al. 2005) and global respiratory muscle strength was assessed 
noninvasively by sniff nasal inspiratory pressure (SNIP), and maximal inspiratory and 
expiratory mouth pressures (MIP and MEP) (Micro RPM; Carefusion, UK) (ATS/ERS 2002) 
These are discussed in further detail in section 2.2.5. 
Variability: Normal variability of respiratory function must be established prior to 
understanding clinically significant variations (Rodriguez-Roisin 2000).  Normal variation can 
be described by several methods including multiples of standard deviation (SD) or 
coefficient of variation (CV).  CV is a normalised measure of the dispertion of the 
distribution of measures around the mean (SD/ Mean). Expressed as a percentage, the 
‘extent of variability’ allows comparison between data sets with different values. CV is a 
better descriptor in heteroscedastic scatter (values of greater magnitude have greater 
variation; eg: intrasubject spirometery day-to-day variability in normal subjects); while SD is 
more appropriate in homoscedastic scatter (variation independent of magnitude of variable, 
eg: intrasubject spirometry variability in COPD) (Hutchinson 1981, in Rozas 1982). To 
standardise the measure of variability across diseases with differing lung function deficits, 
the CV was used in this thesis. 
Lung function varies within populations by approximately 20% (Pennock, Rogers et al. 1981). 
Intra subject variations occur both within day, and day-to-day. In health, FEV1 and FVC have 
a diurnal variation, around a mean, of 30% due to variation in airways resistance which is 
highest in the morning and evenings and lowest at noon (Hruby and Butler 1975). Thus, 
serial measurements are most reliable in detecting day-to-day change when measured at 
the same time each day (Pellegrino, Viegi et al. 2005). In Chapter 3, patients were 
encouraged to measure their PEF in the morning after their usual medications. 
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 Changes that falls outside the ‘normal variation’ for a given parameter may be considered 
significant. Values that exceed the conventionally accepted measure of normal variability, 
(ie. 1.96xSD or CV +/- mean), would be expected to occur less than 5% of the time. These 
changes can be reported as an absolute value or as a percentage (Rozas and Goldman 
1982).  Clinically significant day-to-day variability in lung function parameters have been 
reported in the order of 5% in healthy people, however both diurnal, and day-to-day 
variability, are greater in respiratory conditions. Thus the threshold for clinically significant 
variability is also greater; approximately 15-20% in patients with obstructive disease 
(Pennock, Rogers et al. 1981; Rozas and Goldman 1982). This rises further, up to 50% in 
asthmatic patients (Hetzel and Clark 1980).   
2.2.3 Spirometry 
Spirometry was measured (Microlab; Carefusion, UK) in accordance with the ATS/ ERS 
standardised guidlelines (Miller, Hankinson et al. 2005). The Microlab spirometer uses a 
digital volume turbine transducer. It contains a bi-directional turbine, capable of measuring 
flow in two directions, expiratory and inspiratory, however only expiratory flows were 
measured for this thesis. The turbine head contains a rotating vane and LED’s which 
produce infra-red beams which are interrupted by the vane twice per rotation which is then 
sensed by the phototransistors. As the patient blows air through the transducer, the 
number of rotations is proportional to the volume of air passed through the transducer and 
the frequency of rotation is proportional to the flow rate. It has a volume range 0.1-8L and a 
flow range 0.2 to 15L/sec with accuracy of +/-3% which is in line with ATS recommendations 
(ATS 1995). 
The spirometer measures expired air directly at B.T.P.S (Body Temperature and Pressure 
with Saturated water vapour) thus avoiding the inaccuracies of temperature corrections and 
the need for individual calibration of temperature and barometric air pressure prior to 
performing tests. Therefore only a calibration of volume was performed prior to 
measurements with a 3L syringe.  
A forced vital capacity expiratory manoeuvre was used to measure FVC and FEV1. The 
patient wore a noseclip and was instructed to breathe in as fully as possible, and 
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encouraged to blow out as hard and fast as possible until no further air could be exhaled. 
Values were expressed in litres at BTPS and were compared to normative values to also give 
a percentage of predicted values (% predicted). 
FVC is the maximal volume of air exhaled with maximally forced effort from a maximal 
inspiration, i.e. vital capacity performed with a maximally forced expiratory effort. FEV1 is 
the maximal volume of air exhaled in the first second of a forced expiration from a position 
of full inspiration. Acceptable measures had readings of FEV1 that were within 5% or 100ml 
of each other. The largest values of FEV1 and FVC from at least 3 acceptable forced 
expiratory curves, was recorded, even if the 2 values were obtained from different curves.  
Interpretation: Obstructive airways disease: was defined by a reduced FEV1/FVC ratio 
(<70%) and an FEV1 <80% predicted. Further classification of the severity of obstruction, was 
assessed by FEV1 as % of predicted value, as per the Global Initiative of Chronic Obstructive 
Lung Disease (GOLD) classifications (Global Initiative for Chronic Obstructive Lung 2009). 
(See Table 2-1). 
Table 2-1: Global initiative of chronic obstructive lung disease (GOLD) COPD, classifications 
used to describe the severity of the obstruction or airflow limitation. (adapted from (Vestbo, 
Hurd et al. 2013) 
Stage I Mild COPD FEV1/FVC<0.70 FEV1≥ 80% normal 
Stage II Moderate COPD FEV1/FVC<0.70 FEV1 50-79% normal 
Stage III Severe COPD FEV1/FVC<0.70 FEV1 30-49% normal 
Stage IV Very Severe COPD FEV1/FVC<0.70 FEV1 <30% normal, or <50% 
normal with chronic 
respiratory failure present* 
COPD= chronic obstructive pulmonary disease, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity 
Restrictive airways disease: was defined by a proportionately reduced FEV1 and FVC (<80% 
predicted) with a normal or even elevated FEV1/FVC ratio. 
Combined airways diseases: Diseases that affected both the airways and the lungs were 
noted, but a primary spirometry interpretation (obstructive or restrictive) based solely on 
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the flow –volume loop was determined by a respiratory physician blinded to the patients’ 
clinical diagnosis. 
Advantage and Limitations:  FEV1 is the most repeatable lung function parameter in both 
restrictive and obstructive pathologies and FEV1% predicted is often used to describe 
severity of disease. It is therefore appropriate for serial measurement to track change. 
Changes of 12% or 0.2L are considered both statistically and clinically important (Miller, 
Hankinson et al. 2005). However, FEV1 might not detect change in all diseases eg: upper 
airways disease or severe disease. It has also shown poor correlation with symptoms and 
may not, by itself, accurately predict clinical severity or prognosis for individual patients 
(Seemungal, Donaldson et al. 2000). Other parameters including vital capacity (VC), 
inspiratory capacity and total lung capacity might be more informative in tracking changes in 
respiratory status. In COPD, where hyperinflation is a feature, VC and FVC may increase 
despite no change in FEV1. Indeed, studies of lung mechanics during exacerbations, have 
identified deficits on the day of onset that persist until exacerbation resolution (Parker, 
Voduc et al. 2005; Stevenson, Walker et al. 2005). However, Stevenson et al. (2005) 
concluded that improvement in operating lung volumes, specifically inspiratory capacity, 
was the principal change in resolving acute exacerbations of COPD, while resistance, 
FEV1/FVC, and EFL were unchanged. Additionally, the risk of false positive indication of 
change increases with the measurement of more variables. 
Maximum forced manoeuvres ensure maximum, repeatable results. However these 
manoeuvres are complex and dynamic and involve not only true airway measures, but also 
patient effort, muscle strength, lung compliance and elastic recoil. Additionally, in forced 
manoeuvres measuring Raw, patients may generate driving pressures that exceed the 
pressures required to create maximum airflow. Thus increases in Raw may be missed. 
2.2.4 Peak expiratory flow rate 
Peak expiratory flow (PEF) is the highest flow achieved from a maximum forced expiratory 
manoeuvre from maximum lung inflation, and is measured in L/min. Measures were 
performed in accordance with ATS/ERS standardised lung function testing (Miller, 
Hankinson et al. 2005). PEF is dependent on effort and lung volume, thus patients were 
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encouraged to perform a maximum inhalation, obtain a good seal on the mouthpiece, then 
exhale as vigorously as possible without delay in order to obtain their maximum expiratory 
flow (Quanjer, Lebowitz et al. 1997). Patients were monitored for test-induced 
bronchospasm, and instructed not to continue if this was noted. 
Baseline and follow–up visits: At baseline or follow-up in hospital visits, patients performed 
daily PEF measures, on a portable PEF meter provided for the purpose of the study (Mini-
Wright standard EU scale peak flow meter; Clement Clarke International Ltd., Harlow, UK). 
They were taught the technique at baseline, which was reviewed at 1 month follow-up with 
corrections made if required.   
Daily self-administered serial measures: At home, patients were instructed to perform their 
PEF at the same time each day, usually in the morning after their medication, and in the 
same position, usually seated with their neck in neutral. They performed at least 3 
manouvres, and up to 5, and recorded the maximum value.  
Repeatability and test selection: Within the laboratory, between-manouvre repeatability is 
usually accepted within 40L/min (Pedersen, Rasmussen et al. 1996). The patient performed 
a minimum of 3 manouvres, and the largest of 3 acceptable blows was recorded. 
Advantages and Limitations: In asthma, PEF used as a serial day-to-day measurement, forms 
part of the asthma-management programme (Higgins and Douglas 2003). A drop of 25-50% 
from best or predicted PEF values signifies a moderate asthma exacerbation with a 50-67% 
drop being severe and >67% drop life threatening. However, day-to-day variability in PEF is 
less useful in COPD (Stevenson, Walker et al. 2005). In COPD, PEF may underestimate 
airflow obstruction as it is predominantly a measure for the large airways. However in these 
studies it was not used for diagnostic purposes, but for monitoring trends. The EU scale for 
PEF was required to increase sensitivity to change in a patient population with chronically 
reduced lung function, particularly in restrictive patients where baseline PEF was low.  
PEF is less reproducible than spirometry, however the patients taking part in the studies 
presented in this thesis were all CRF patients who were well practiced in performing lung 
function manoeuvres.  A learning effect does occur, however the one month run-in period 
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during Chapter 3 gave patients the opportunity to develop a reliable technique, with review 
and correction by myself prior to the 3 month data monitoring period. Hesitation or flexion 
(causing a relaxation of tracheal visco-elastic properties) can decrease PEF by up to 10%. 
Coughing, tonguing may cause increases. For these reasons, instruction of technique, 
monitoring and correction was essential for accurate results. 
2.2.5 Respiratory muscle strength  
Respiratory muscle strength was tested by volitional, non–invasive maximal inspiratory and 
expiratory manouvres via a hand-held portable respiratory pressure meter (MicroRPM; 
Carefusion, UK) Measures were made according to the ERS/ ATS statement on respiratory 
muscle testing (ATS/ERS 2002). 
Sniff nasal inspiratory pressure (SNIP) and maximal inspiratory (MIP) are measures of 
overall inspiratory muscle strength, whilst maximal expiratory pressure (MEP) measures 
global expiratory muscle strength. They are measured in cmH2O. For normal ranges, see 
Table 2-2. 
Table 2-2: Normal ranges for volitional non-invasive respiratory muscle tests (adapted from 
(ATS/ERS 2002). 
 Male Female 
Sniff Pdi (cmH2O) 148 (24) 122 (25) 
SNIP (cmH2O) 105 (25) 94 (21) 
MIP (FC) (cmH2O) 106 (22) 87 (21) 
MIP (RV) (cmH2O) 106 (22) 88 (18) 
MEP (cmH2O) 125 90 
 Mean (SD) in cmH2O. FRC = functional residual capacity; MIP =maximal inspiratory manoeuvre; MEP = maximal 
expiratoy pressue; SNIP= sniff maximal inspiratory pressure; Sniff Pdi = transdiaphragmatic sniff pressure; RV = residual 
volume 
MIP and MEP measures were made via a mouthpiece. By definition, SNIP/MIP and MEP 
should measure zero at TLC and RV respectively. As such, these should be performed 
starting from the opposite volume (ie RV and TLC respectively). However in this thesis 
SNIP/MIP measures were performed from functional residual capacity (FRC).  MIP has 
previously been performed from RV, but this is difficult for patients, particularly those in 
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an acute exacerbation, and studies have shown that peak pressure from FRC 
approximates (Bruschi, Cerveri et al. 1992). MEP was performed as a maximal forced 
expiration from total lung capacity (TLC).  
SNIP was performed using a nasal bung of appropriate size to form a seal/ occlusion in 
one nostril. Patients were instructed to give a short, sharp sniff. SNIP measures have 
previously been correlated to invasive measures of oesophageal pressure during sniff 
manoeuvres, but only in patients without severe airway obstruction. 
Manoeuvres are effort and lung volume dependent and so tests were repeated at least 3 
times (up to 10 if patient was improving) with at least 30 seconds between, and the 
maximum value was recorded.  
Advantages and Limitations: MIP and MEP measures are non-invasive and easy to perform 
with little equipment. The values assess global strength but are unable to differentiate 
between specific muscle weakness, particularly muscles other than the diaphragm which 
might be more prone to fatigue or recovery from fatigue with NIV. However, in some 
diseases (eg DMD) a decline in MIP precedes that in VC (Smith, Calverley et al. 1987) and 
therefore is a more timely indicator of respiratory function decline. Additionally, SNIP is 
particularly helpful in the prediction of the need for NIV in patients with NMD (Morgan, 
McNally et al. 2005). 
Volitional MIP and MEP measures have a wide normal range. Low values may not be 
representative of weakness, but can be indicative of suboptimal technique or effort. This is 
of particular importance during acute exacerbations when patients may experience severe 
dyspnoea. Also, in NMD, patients may be too weak to inspire all the way to TLC, thus 
limiting maximum MEP potential. MIP values may fail to detect an inability to cope with 
increased ventilatory demand during acute exacerbations; a measure of muscle endurance 
may be more appropriate than a measure of strength.  
2.2.6 Blood gas analysis: arterial, capillary and transcutaneous 
Blood gas analysis was used to determine the acidity of the blood (pH), the partial 
pressure of carbon dioxide (PCO2) and oxygen (PO2), and the bicarbonate level.  
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Arterial PCO2 is the gold standard measure of adequacy of alveolar ventilation. Along with 
oxygen saturation (SaO2) it used to determine the efficacy of NIV therapy, thereby guiding 
ventilation titration. In the presence of hypoventilation, the amount of PCO2 dissolved in 
blood increases (as carbonic acid (H2 CO3)), therefore affecting the blood acidity level via the 
equation: 
CO2 + H2O ↔ H2 CO3 ↔ H
+ + HCO3
-.   (where PCO2 is the partial pressure of CO2 , HCO3
- is 
the concentration of bicarbonate and H+ is the hydrogen iron concentration). 
Respiratory acidosis (pH < 7.35) may result. However, respiratory (fast) and renal (slow) 
pathways exist to maintain homeostasis. The respiratory system increases ventilation within 
hours, typically by tachypnoea. Metabolic buffering of raised H+ levels is by renal secretion 
of H+ or reabsorption of HCO3
- , however this process takes days. 
The typical reference ranges for blood gas homeostasis are given in Table 2-3. 
Table 2-3: Typical reference ranges for ABG analysis 
Analyte Range 
pH 7.34 -7.44 
H+ 35 – 45 nmol/L 
PCO2 4.7 -6.0 kPa (35-45 mmHg) 
PO2 11-13 kPa (75 – 100mmHg) 
HCO3- 22-26mEq/L 
H+ = hydrogen ions, PCO2 = arterial partial pressure of carbon dioxide, PO2 = arterial partial pressure of oxygen; HCO3- = 
bicarbonate, mmHg  = millimetres of mercury, nmol= nanomol, L = litre, mEq = milliequivalent, kPa = kilopascal. 
Changes in pH (blood acidity) are related to PCO2 by the Henderson-Hasselbach equation (ie 
change in pH is proportional to the logarithm of the change in PCO2)  
 
As a guideline, a 1mmHg (0.13kPa) change in PCO2 above or below 40mmHg results in 0.008 
unit change in pH in the opposite direction.  
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Resting blood gas tensions of O2 and CO2 were measured in each study of this thesis 
(Radiometer ABL 30 ; Radiometer, Denmark).  In the studies investigating iVAPS vs standard 
PS NIV (Chapters 5 and 6), arterial blood gas tensions (ABGs) while awake were recorded at 
baseline.  Additional measures were made in the acute acidotic exacerbation trial at +1, +4, 
and +24 hours post initiation of each NIV mode (Chapter 6).   
Patients were offered the choice between radial artery puncture or earlobe capillary 
sampling.   All other measures of SaO2 and CO2 were made non-invasively by transcutaneous 
measurement (tcPCO2), especially to monitor continuous trends overnight, over 24 hours 
(TOSCA 500; Linde Medical Sensors AG, Switzerland). 
Arterial puncture: The gold standard measure of pulmonary gas exchange is by direct 
arterial catheterisation of the radial artery. However this can be painful and limited in it use 
due to it being primarily a physician-performed measure (Pitkin, Roberts et al. 1994).  
Alternative non-invasive measures in use include oximetry and arterialised capillary blood 
sampling. 
Capillary blood sampling:  Arterialised capillary sampling blood sampling can be a reliable 
substitute to arterial puncture (Zavorsky, Cao et al. 2007). Most commonly performed at the 
earlobe or the fingertip, the area is first vasodilated by the application of either a 
vasodilatory topical substance or by heating. Thus arterial and venous PO2 should converge 
and the arterialised sample should reflect arterial blood. Earlobe blood sampling consists of 
obtaining several drops of blood from the earlobe. 
Advantages and Limitations: Capillary sampling is less invasive (Fajac, Texereau et al. 1998) 
and less painful than radial puncture (Spiro and Dowdeswell 1976) and can be performed by 
allied health team members other than physicians (Hughes 1996), thus reducing cost. It is, 
however, reliant on adequate vasodilation achieved by local vasodilatory substance or heat.  
When sampled from the fingertip, it is less accurate in detection of pH and PO2 as discussed 
below. 
 Arterial versus arterialised capillary blood sampling: There have been conflicting data on 
the accuracy of capillary blood to reflect arterial blood.  A  meta-analysis of 29 studies 
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compared paired blood samples; arterial vs earlobe (n=664) and arterial vs fingertip (n=222) 
(Zavorsky, Cao et al. 2007). The authors found that capillary samples accurately reflect 
arterial PCO2 and pH across all values from both sites. Earlobe was more accurate than 
fingertip sampling in CO2 prediction (mean bias of arterial vs earlobe and fingertip 
respectively: 1.9mmHg v 2.2mmHg; p<0.05).  However, PO2 was less accurate (r
2 =0.88, 
mean bias = 3.8mmHg) when measured from the earlobe capillary sample and worse from 
the fingertip (r2=0.48, mean bias = 11.5mmHg). Also to note, lower PO2 levels were more 
accurately represented by capillary samples.  
Transcutaneous measures: Transcutaneous CO2 (tcPCO2), oxygen saturation (SaO2) and 
heart rate (HR) were measured in a variety of settings. Transient daytime measurements 
were made at baseline and followup visits in Chapter 3. Continuous measures were made 
during NIV set-up and titration, overnight during sleep studies (Chapters 3, 4 and 5), and for 
24 monitoring during the study in acute exacerbations (Chapter 6).  Measures were made 
non-invasively using a tcPCO2 monitor (TOSCA 500; Linde Medical Sensors AG, Switzerland) 
via an earlobe sensor; Stow-Severinghaus type PCO2 sensor combined with pulse oximeter. 
See Figure 2-1. 
 
Figure 2-1: The earlobe sensor combining the Stow-Severinghaus pH electrode with pulse 
oximeter seen here attached to the earlobe. (from TOSCA Operating Manual, Radiometer, 
Basel) 
Principles of measurement: The Stow-Sveringhaus electrode contains 2 miniature 
electrodes; a glass pH electrode and a silver/silver chloride (Ag/ AgCl) reference electrode.  
The electrode is heated to 40-44°C to increase local hyperaemia and arterialisation. 
Increased perfusion also augments pulse oximetric signal strength. CO2 gas diffuses from the 
capillaries through tissue to the skin, where it is dissolved in an electrolyte:                          
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CO2 + H2O  H2 CO3 H
+ + HCO3
-.  Hydrogen ions (H+) modify the pH in solution which is 
sampled by the pH electrode. The resultant signal produced is the potential difference 
between the electrodes. 
 The TOSCA has automatic calibration of the sensor with a known gas composition prior to 
each measurement: 12.0% O2, 7.0% CO2, balance N2. 
Corrections: tcPCO2 (analysed as PCO2 of arterialised skin tissue) has a high correlation with 
arterial PCO2, however due to the elevated sensor temperature, tcPCO2 is higher.  A 
correction is applied to account for both the increased temperature (increases tcPCO2 by 
4.5%/ °C = anaerobic factor) and metabolism of epidermal cells (increases tcPCO2 by 
~0.5mmHg (0.07kPa)) (Hazinski and Severinghaus 1982). 
Advantages: The TOSCA is a reliable, robust non-invasive measure of blood PCO2 (Janssens, 
Perrin et al. 2001; Senn, Clarenbach et al. 2005). It provides continuous, instantaneous 
qualitative assessment of the effect of the therapy. Trends can be monitored for  >8 hours 
without local discomfort or significant signal drift, giving a more complete picture of 
nocturnal ventilation than the snapshot pictures that serial ABG ansalysis affords. 
Transcutaneous monitoring also allows a more rapid detection of hypoxemic events and of 
critically high or low levels of CO2 tension. This can be done without sleep disruption and has 
been used with success in monitoring nocturnal NIV therapy efficacy, detecting variations in 
avleolar ventilation, with median ranges of 11.5 (11.0-13.0)mmHg (Storre, Magnet et al. 
2011).  It has also been used during NIV initiaion in OHS  (Senn, Clarenbach et al. 2005; 
Storre, Steurer et al. 2007).  
Limitations: The CO2 values displayed by the TOSCA have a lag time of approximately 
2minutes which is not useful in analysis of short respiratory events ; apnoeas, hypopnoeas 
or brief leak (Storre, Magnet et al.; Janssens, Howarth-Frey et al. 1998). There is also a 
tcPCO2 technical calibration drift overnight of -0.5mmHg/hr (Storre, Magnet et al. 2011). 
This can be compensated for by linear interpolation, but requires 2 arterial PCO2 measures, 
at beginning and end of tcPCO2 recording. 
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The mean reported bias (limits of agreement) of the TOSCA during overnight NIV monitoring 
is reported as 0.8 (-6.8 – 8.3mmHg). There is an increase of bias (arterial > transcutaneous) 
at high PCO2 values and occasional unexplained errant values can occur. There is also limited 
or no correlation between transcutaneous and arterial PCO2 in conditions that affect the 
arterialisation of the earlobe, including profound peripheral vasoconstriction, circulatory 
shock, hypothermia, use of vasoactive drugs. Other skin anomalies and oedema may also 
limit tcPCO2 measurement. Additionally, there can be large individual variances reported, 
especially in critically ill and intubated patients (Rodriguez, Lellouche et al. 2006; Bolliger, 
Steiner et al. 2007), and during acute exacerbations of COPD management. 
The TOSCA requires recalibration and changes of membrance to ensure sufficient precision 
of measures, approximately every 14 days which can make this a relatively expensive 
measurement option. 
2.2.7 Arterial oxygenation: SaO2 and SpO2 
Measurement of the arterial oxyhaemoglobin saturation in the blood was made both 
invasively (ABG analysis) and non-invasively (pulse oximetry).  
Arterial oxygen saturation (SaO2) : was measured invasively by arterial or capillary blood 
gas analysis; as described for arterial CO2 (PCO2) (section 2.2.6). 
Pulse oxygen saturation (SpO2): was measured non-invasively by pulse oximetry; either 
combined with the tcPCO2 sensor in the TOSCA sensor, by portable pulse oximeter, or by the 
Somno oximeter integrated into PSG monitoring (SOMNOmedics GmbH and Co., Germany). 
Principles of measurement: Oxygenation is measured by a sensor, most commonly attached 
to the patient’s finger or ear, and follows 2 main principles:  
1) Oxyhemoglobin (oxygenated blood) and deoxyhemoglobin (non-oxygenated blood) 
differ in their absorption of red and infrared light (spectrophotometry) 
2) The amount of arterial blood in tissue changes with the pulse 
(photoplethysography). 
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Light emitting electrodes (LEDs) that send 2-wavelengths; The TOSCA 500 sensor uses red 
(658nm wavelength) and infrared (880 nm wavelength). Somno-oximeter uses light 
wavelenths of red (660nm) and infrared (910nm @ 3mW Nominal). 
The light is passed through a capillary bed, typically the finger or the earlobe, and detected 
by a photodiode (photodetector). The amount of light absorbed differs between the varying 
quantities of oxygenated and deoxygenated blood, as well as with pulsatile blood volumes. 
The photodetector receives the light and converts it into an electronic signal that is sent to a 
monitor for calculation. The ratio of the absorbance by the 2 waves is then converted into a 
percent corresponding to SpO2. Constant background absorption (DC component) by non-
pulsatile tissues, bone, fluids and venous blood is distinguished from pulsatile changes in 
absorption (AC component). 
The TOSCA monitor uses Masimo SET signal extraction technology to calculate functional 
oxygen saturation (compared to fractional saturation) and pulse rate. 
 
Functional saturation: the amount of oxygenated haemoglobin expressed as a percentage of 
the haemoglobin that can transport oxygen. Fractional saturation: oxygenated haemoglobin 
expressed as a percentage of all measured haemoglobin, including measured dysfunctional 
haemoglobin such as carboxyhaemoglobin or methaemoglobin.  
Advantages and Limitations: Pulse oximetry is a non-invasive, continuous method of 
measurement of blood oxygentation. Pulse oximetry, assessing arterial oxyhaemoglobin 
saturation, is a good measure of oxygen delivery but not of pulmonary gas exchange. Its  
disadvantages include a poor correlation with PaO2 (Pitkin, Roberts et al. 1994). 
Measurement on the finger provides an accuracy (mean absolute difference) of -0.5 to 2.5% 
and precision (SD of differences) of ± 3 to 7.3%; there is improved accuracy and precision 
when measured on the forehead. 
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The shape of the oxyhaemoglobin curve affects the accuracy of the SaO2 measurement. Due 
to the sigmoidal shape, there are limitations in quantification of the degree of hyper and 
hypo-oxaemia as the curve becomes flatter, where small changes in the measured SpO2 
represent large changed in PO2. As such, measures worsen when SaO2 is less than 85%. The 
shape of the oxyhemoglobin dissociation curve can also differ from patient to patient.  
Signal validity relies on the stability of the SpO2 readings over time, which in turn is affected 
by the averaging mode being used. Longer averaging times give greater stability due to a 
dampened response with averages taken over longer periods. However, longer average 
times delay the response of the oximeter and reduce reported variations. 
Similar to tcPCO2 measurement, pulse oximetry relies on the existence of intact transport 
mechanisms of arterial blood to the measurement site. Whenever such transport is 
impaired to the extent that a sufficiently large pulse signal cannot be detected, SpO2 
monitoring is no longer feasible; circulatory centralization (shock), peripheral 
vasoconstriction, venous congestion or generally at low local tissue perfusion. 
Pulse rate: TOSCA reported pulse rate may differ slightly from the HR displayed on the ECG 
monitor due to the differences in averaging times. There may also be a discrepancy 
between cardiac electrical activity and peripheral arterial pulsation. Significant differences 
may indicate a problem with the signal quality due to physiological changes in the patient or 
one of the instruments or application of the sensor.  
2.3 Non-invasive ventilation 
2.3.1 Ventilators 
Ventilators used in the studies in this thesis were provided by ResMed (Australia). All were 
bilevel positive pressure ventilators with an inspiratory positive airway pressure (IPAP) to 
augment ventilation, and an expiratory positive airway pressure (EPAP) to eliminate exhaled 
air, maintain patent upper airway, and improve small airway recruitment. Alternation 
between pressures is in response to either patient flow or a preset fixed inspiratory time. 
Two modes of ventilation were used; standard PS and iVAPS. Ventilators providing the 
standard PS  (ST mode) were the VPAP III ST-A. Ventilators supporting the iVAPS algorithm 
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were the AutoVPAP (a research ventilator without CE marking) and the Stellar 150 (CE 
marked) (see Figure 2-2) The AutoVPAP was the initial iVAPS prototype ventilator for 
research purposes only. The iVAPS algorithm has since been CE marked and the mode is 
now available in several commercially available ResMed ventilators, including the Stellar 
150.  
VPAP III ST-A  AutoVPAP    
(research device only) 
Stellar 150 
Used in Studies 5 & 6 Used in Studies 5 & 6 Used in Studies 3 & 4 
   
Figure 2-2:  The three ventilators used in this thesis, provided by ResMed; the VPAP II ST-A 
provided the standard pressure support therapy set in spontaneous-timed (ST) mode, the 
AutoVPAP and the Stellar 150 provided the intelligent volume assured pressure support 
(iVAPS) mode.  
2.3.2 Standard pressure support mode (PS) 
PS (Pressure Support) or ST (Spontaneous/Timed) mode: The ST mode is an assist/control 
mode. A fixed PS level (IPAP minus EPAP) is preset. The RR and the respiratory pattern are 
determined by the patient, but the ventilator will also supply additional breaths should the 
patient breath rate fall below the clinician's set ’backup’ breath rate. The ventilator detects 
the spontaneous patient-initiated breath and triggers PS to assist ventilation.  It then cycles 
into EPAP at the end of inspiration. Changes in patient flow determine the triggering and 
cycling of the assisted breath, and the sensitivities can be adjusted to be more or less 
responsive to patient effort.  
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Advantages and limitations of assist-control: Most patients find the assist/control or S/T 
mode more comfortable than a controlled mode where the ventilator determines the 
frequency and flow rates regardless of patient effort (MacIntyre 1986). The backup RR 
provides the advantage of ensuring adequate ventilation during sleep when the patient may 
have an unreliable respiratory effort, variable ventilatory mechanics, apnoeas and/or 
hypopnoeas. 
It may be appropriate to use a controlled mode in those patients in whom CO2 levels cannot 
be adequately controlled, despite high pressures or large tidal volumes, or in those with a 
central ventilatory drive disorder. Controlled modes of ventilation are also advocated to 
more adequately rest the respiratory muscles and to optimise CO2 control, however most 
patients find it difficult to tolerate and patient-ventilator dyssynchrony can be problematic 
(Girault, Leroy et al. 1997; Betensley, Khalid et al. 2008). There is also a risk of over-
ventilation and hypocapnia, particularly in NMD patients. In some patients, active glottic 
closure occurs as a protective mechanism under these circumstances, producing stridor 
(Jounieaux, Aubert et al. 1995; Parreira, Jounieaux et al. 1996). 
Advantages and limitations of pressure- vs volume- preset ventilation: have been discussed 
previously (Chapter 1, section 3.1), but in summary: 
1) pressure preset is more comfortable, but delivered volumes are variable  with 
changing physiology and adequate ventilation is not guaranteed. There is 
however, compensation for leak. 
2) volume preset provides guaranteed volumes but at the cost of variable peak 
inspiratory pressures which can be high, leading to side effects such as 
aerophagia and mask leak which is not compensated for. Combined with a fixed 
rise time, the patient cannot dictate the inspiratory flow rate to match their 
demand, thereby reducing comfort. 
2.3.3 Intelligent volume assured pressure support (iVAPS) servoventilation 
Intelligent volume assured pressure support ventilation (iVAPS) is a servoventilation 
algorithm for the automatic adjustment of PS within pre-set boundaries, in order to achieve 
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a target VA. Target VA (l/min) is the non-anatomical-deadspace ventilation. During therapy, 
actual VA passed through a low pass filter is compared to the target VA. PS is then adjusted 
to produce ventilatory changes equivocal to the magnitude and direction of the difference 
over the following 2-3 breaths. A maximum and minimum PS are set in accordance with 
patient tolerance and underlying respiratory disease. 
During the completion of the studies presented in this thesis, there have been modifications 
to the algorithm and the flow driver capabilities of the iVAPS ventilator. The maximum IPAP 
has increased from 30 to 35cmH2O.  Automatic calculation of the Target VA was initially 
based on 90% of patients’ daytime ventilation. This was deemed appropriate for nocturnal 
ventilatory support, due to the nocturnal reduction in metabolic rate. However, a slight but 
significant increase in overnight mean tcPCO2 was observed when compared with standard 
PS ventilation in our group’s first interventional study using iVAPS. The algorithm has since 
been modified to target 100% of daytime VA, with successful control of nocturnal 
hypoventilation. 
A summary of the technical specifications of the ventilators used in this thesis is presented 
in Table 2-4. 
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Table 2-4: Comparison of the ventilators used in the studies presented in this thesis, specifically those supporting the iVAPS algorithm and the 
developments to the algorithm 
 VPAP III ST-A  AutoVPAP (research device only) Stellar 150 
Mode ST 
(standard PS) 
iVAPS 
(volume assured PS servoventilation) 
iVAPS 
(volume assured PS servoventilation) 
Settings: 
    -PS 
 
    -Back-up RR 
 
Clinician set fixed PS value 
 
Clinician set fixed back-up RR 
 
Min-max boundaries: 4 – 25cmH20 
 
Variable intelligent back-up RR (iBR) 
 
Min- max boundaries: 0 - 30cmH2O 
 
Variable intelligent back-up RR (iBR) 
Calculation of Targets 
(VA and RR) 
n/a -clinician set or automated ‘intelligent learn 
period’  
-clinician set or automated ‘intelligent learn 
period’ 
   -if clinician set n/a VA set to achieve appropriate ml/kg 
RR set to just below spontaneous patient RR 
VA set to achieve appropriate ml/kg 
RR set to just below spontaneous patient RR 
   -if intelligent ‘learn        
period’ targets are 
learnt in these ways 
(as per manufacturer 
recommendations) 
n/a Daytime, wake spontaneous breathing ≥1 hour 
(use median values  of entire period) 
Spontaenous mode with an EPAP ≥4cmH2O and 
the lowest PS tolerated (0-3cmH2O) 
Daytime, wake spontaneous breathing ≥1 hour 
(use median values of a steady 5 min window) 
No specified mode with an EPAP ≥4cmH2O + PS 
PS= 4cmH2O if patient is daytime normocapnic 
PS= 6cmH2O if patient is daytime hypercapnic 
Calculation of 
intelligent target VA 
(MV minus VD) 
n/a -initally targeted 90% of learnt  daytime VA, 
increased to target 100%  
- target 100% of learnt daytime VA 
  
Calculation of VA = 
MV minus VD  
n/a 
 
VD = 100x(h/1.7)
3 
(h is height (m)) 
-entered by clinician approximated to 
manufacturers recommendations 
 
VD = 120x(h/175)
2.363 
(h is height (cm)) 
-automatically calculated by ventilator software 
ST = spontaneous-timed, PS= pressure support, RR= respiratory rate, VA = alveolar ventilation, EPAP= expiratory positive airway pressure, MV = minute ventilation, VD=dead space 
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Mechanism of Action: The iVAPS algorithm, based on flow and pressure, constantly 
monitors a patient’s achieved VA and actual RR and compares these to the pre-set targets.  
The servo control response of rate or PS change is designed to be fast enough to avoid 
blood-gas derangement, but gentle enough to avoid sleep disruption. This schema is 
represented in Figure 2-3. 
 
Figure 2-3: Servoventilator apparatus; adapted from US States Patent, Berthon-Jones et al 
(Patent No: US 8544467B2; Oct 2013)  
The iVAPS algorithm constantly monitors a patient’s achieved alveolar ventilation and actual RR and compares these to the 
pre-set targets. Measurement and titration of pressure support is represented by the orange pathway.  The flow is 
measured by the components marked in blue, which is digitally processed to provide values of delivered volumes. This is 
then compared to the target volume and pressure support is adjusted appropriately by the servo controller to attempt to 
meet the target. 
The ventilator (flow generator) features two sensors: pressure and flow. The sensors 
measure pressure at the flow generator and total flow, respectively. Thus, total flow is the 
sum of patient flow, mask vent flow (intentional leak) and leak (unintentional leak). Mask 
vent flow can be predicted from the specifics of the airpath including the mask, and the 
current flow generator pressure and total flow. Leak is estimated based on low pass filtering 
the total flow minus the mask vent flow. Patient flow is then the result of subtracting the 
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mask vent flow and leak from the total flow. Additionally there is a leak compensation 
system (Vsync) that compares learnt flows with actual flow to estimate patient flow in the 
presence of leak. 
iVAPS v other VAPS algorithms: As previously stated, iVAPS ventilation is distinct from other 
manufacturers’ VAPS algorithms in several ways, which are each discussed in more detail in 
the following sections. 
2.3.4 Targeting alveolar ventilation, accounting for anatomical dead space 
MV is the product of volume and rate. The interaction between Vt and RR will determine 
what proportion of ventilation is reaching the alveoli to partake in gas exchange. iVAPS 
targets VA, that which reaches the alveoli. VA is defined as total ventilation minus the 
ventilation ‘wasted’ in the anatomical deaspace ventilation (VD), ie the conducting airways 
(VA = MV – VD). Its contribution is proportional to RR. By using alveolar ventilation as a 
servo-ventilation target, as opposed to tidal volume or total ventilation, the effect of RR 
change on effective ventilation is negated. 
VD, calculated by the ventilator software, equates to (120x(h/175)
2.363) where h is the 
patient’s height in (cm). This formula has been used by ResMed and calculated from work 
published by Hart et al. (Hart, Orzalesi et al. 1963). 
2.3.5 Providing an intelligent back up respiratory rate for maximum patient-ventilator 
synchrony 
Instead of a fixed, mandatory back up rate, iVAPS uses a new intelligent backup rate (iBR) 
which shifts automatically between two limits (timed  and triggered), according to the 
context (see Figure 2-4). The backup RR is variable to maintain optimal patient effort, whilst 
allowing the patient maximal opportunity to trigger the ventilator spontaneously. The 
instantaneous backup rate alternates between a ‘target timed backup rate’,(median of a 
previously learnt RR or preset by clinician) and a ‘triggered rate’ (2/3 of the ‘timed rate’). In 
the event of apnoea (ie. no patient-triggered breaths), there is a progressive increase from 
the triggered rate towards the timed with the aim of correcting the deficit in ventilation. It 
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will adjust quickest typically (within 4-5 breaths) when ventilation is below the target 
ventilation. 
 
Figure 2-4 The intelligent back up respiratory rate (iBR) is not fixed, but alternates between 
two limits (target timed RR and triggered RR).  The ventilator monitors the patient effort and 
spontaneous rate, compares this to the target RR and makes appropriate adjustments over 
4-5 breaths (From ResMed Product Guide). 
2.3.6 Automated set up 
The ventilation targets may be set either manually (by the clinician) or by an automated 
learn function, which learns the patients’ VA during a period of daytime, wake, spontaneous 
breathing and sets targets accordingly. The ventilator learns the patients RR and VA and 
automatically sets these as targets for assisted ventilation (See Figure 2-5). Once targets 
have been learnt and automatically set, NIV therapy can commence.  Patients’ achieved 
level of VA, including RR are then constantly compared to the targets and adjustments are 
made accordingly. 
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Figure 2-5:  iVAPS ‘learn period’ where the ventilator automatically selects therapy 
settings based on a patient’s own breathing pattern during an awake breathing trial; 
shown is a 12 minute period of such breathing, with a moveable 5 min ‘window’ by which 
the clinician selects a stable 5 minute period, from which the median patient alveolar 
ventilation (VA) and respiratory rate (RR) are calculated and thus set as therapy targets 
(From ResMed Product Guide). 
2.3.7 Sophisticated data monitoring capabilities; summary and high resolution breath-
by-breath data 
iVAPS ventilators also have complex data monitoring and storage systems, both real-time 
and downloadable, plus exportable data for remote or delayed analysis. Detailed breath-by-
breath data can be obtained with flow-volume profiles to assist in the initiation, titration 
and monitoring of NIV therapy in individual patients.  This is discussed in more detail in this 
chapter (section 3.9). 
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Table 2-5: Comparison between two commonly used forms of volume assured pressure 
support ventilation; iVAPS (intelligent volume assured pressure support) and AVAPS 
(average volume assured pressure support) 
 iVAPS AVAPS 
 
Manufacturer ResMed Respironics 
Ventilators Stellar 150 
Elisee 150 
VPAP III STA 
Synchrony 
Trilogy 100, 200 and Series 
BiPAP AVAPS and ST 
 
Selection of NIV 
parameter 
settings 
 Clinician  
 Or automated from a 
‘learn period’ (based on 
patients’ wake breathing 
pattern) 
 Clinician 
 
Target 
ventilation 
VA (alveolar ventilation) l/min 
 
Vt (tidal volume) ml 
Setting of target 
ventilation 
100% of patient’s wake Va 
 
 (VA = MV - VD) 
 VD = 100*(H/1.7)
3 
                   H is height (or armspan) in meters;  
                   V
D
 is deadspace ventilation 
 
8 or 10ml/kg (of ideal BMI) 
 Ideal BMI of 23 Kg/m2 
(BMI=weight/height2) 
 
Setting of 
respiratory rate 
(RR) 
Intelligent automated 
adjustment of backup RR.  
During apnoea RR is increased to 
the median learnt  awake RR, 
however during periods of 
effective triggering, the backup 
drops to 2/3 learnt to allow 
spontaneous ventilator 
triggering 
Clinician sets the ventilator to a 
value of patient’s awake RR minus 4 
Algorithm The VA is compared to the target 
ventilation and the PS is then 
adjusted over 2-3 breaths to 
increase or decrease ventilation 
by the magnitude of the 
detected the difference 
The patient’s Vt is estimated at each 
breath and compared with the 
target Vt. IPAP increases or 
decreases (<3cmH2O/min) from 
breath to breath to reach the pre-set 
tidal volume. 
iVAPS= intelligent volume assured pressure support, AVAPS= average volume assured pressure support, NIV= non-
invasive ventilation, IPAP = inspiratory positive airway pressure, VA = alveolar ventilation, Vt = tidal volume, PS = 
pressure support 
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2.3.8 Ventilator initiation and titration protocols 
Patients were initiated on iVAPS ventilation by the same experienced research 
physiotherapist (myself), (or research assistant, JJ – Chapter 5), following pre-specified 
protocols (as discussed in the methods sections of Chapters 3-6). The following describes 
initiation procedures common to all studies. 
 Ventilators were tested by the biomedical department of the RBH. Ventilators and alarms 
were tested for function. 
A ‘Learn circuit’ procedure was performed at iVAPS initiation and after every change to the 
original circuit/interface configuration.  This assists with patient-ventilator synchrony for a 
given circuit and interface. It enables the accurate delivery of set pressures with appropriate 
leak compensation and also accurately senses the start and end of a patient’s inspiratory 
effort for effective breath triggering and cycling. The procedure involved the connection of 
the appropriate circuit and interface. The ventilator then delivered a variety of flow rates to 
calculate the circuit impedance so that the pressure could be accurately estimated at the 
patient’s airway, and thus allow appropriate pressure adjustments.   
Pathology default settings: were used at iVAPS initiation, but then titrated as per study 
protocols to suit individual patient ventilatory and comfort requirements (see Figure 2.6). 
 
Figure 2-6: Pathology default settings are programmed into the software of the Stellar 150; 
Clinicians’ Guide, ResMed. IPAP = inspiratory positive airway pressure, EPAP = expiratory positive airway 
pressure, Ti = inspiratory time, Ttot = time of one breath cycle, PS = pressure support 
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Inspiratory Time (Ti): was controlled by preset minimum and maximum (Timin and Timax) 
inspiratory time limits. These were set to either side of patients’ ideal spontaneous 
inspiratory times. These were typically set at 1.0 to 1.5 (or 2.0) secs, with shorter Timin 
durations for very breathless patients and shorter Timax for patients likely to breath-stack 
and hyperinflate, Timin was set longer in weak patients to prevent premature breath 
cycling. 
Maximum inspiratory fraction of the total one breath cycle (Timax/Ttot ratio): was 
calculated as follows:  Timax = 60/iBR x Timax/Ttot (where iBR is the intelligent backup RR 
and Ttot is the time of a one breath cycle). This was typically set at 40% for patients with 
restrictive pathologies and 30% for obstructive pathologies to allow greater expiratory time 
for lung emptying to prevent hyperinflation and PEEPi.                                                                                                           
Breath trigger and cycle sensitivities:  were nominal settings ranging from very high to very 
low. Both triggering of inspiration as well as cycling into expiration were based on patient 
flow rates. Inspiratory triggering, based on the minimum patient flow required to initate the 
inspiratory support, was set at a higher sensitivity for weaker patients (eg: NMD patients 
unable to generate flow and therefore at risk of ineffective triggering) and at a lower 
sensitivity for patients with high inspiratory flow rates (eg: in COPD exacerbations, to 
prevent double or automatic triggering).  The expiratory cycle was based on the reduction in 
a patient’s peak inspiratory flow  (PIF) rate and could be set to occur at 50% of PIF for 
patients with high flow (COPD exacerbation) to prevent delayed cycling and and  at 8% of 
PIF in weak or restrictive patients with low flow rates, to prevent premature cycling.  
These ‘comfort settings’ were based on patient tolerance and according to observed 
patient-ventilator asynchronies. 
2.3.9 Standard ventilator data output, capture and storage 
All ventilators, VPAP III STA®, AutoVPAP® and the Stellar 150®, have the hardware and 
software ability to measure, monitor and store detailed ventilator data. Real time data 
allows real time titration of settings to achieve optimal patient comfort and patient-
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ventilator synchronisation, while summary data allows optimisation of treatment efficacy 
when combined with clinical outcome data such as blood gas analysis. 
Ventilator parameters measured by the inbuilt pneumotachometer and pressure sensor are 
recorded breath-by-breath (RR, Ti, PS, MV, Vt, flow, leak, I:E ratio, PS).  Pressure and flow 
are sampled at a high rate of 25 Hz, while the leak, Vt, RR and MV are reported per breath. 
Real time breath-by-breath numerical data is displayed on the ventilator screen, and in the 
case of the Stellar 150 there are also real time flow and volume traces, as well as trigger and 
cycle synchronization indicators. These were also available by connection to external 
software for the earlier version ventilators. Overnight trend data for MV and leak, sampled 
at one per minute (low rate) can also be viewed as detailed graphs for single sessions of 
therapy (see Figure 2-7). 
 
Figure 2-7: Detailed overnight trend data from a single patient on iVAPS therapy; graphs 
showing mask leak and minute ventilation values for a single night of therapy from 1.30am – 
7.30am (6 hours). ResScan, ResMed. 
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Summary data provides daily median values (5th and 95th percentiles) of all delivered 
parameters and calculated data on respiratory events are also available [Leak, MV, Vt, RR, 
I:E ratio, PS, AHI]. Treatment adherence is measured by hours used (nightly and week) (See 
Figures 2-8 and 2-9). 
 
Figure 2-8: Original summary data from the Stellar 150 of a single night of ventilation on a 
patient receiving iVAPS therapy. The top section denotes the ventilator settings and the 
bottom section provides nightly median data for the measured ventilatory parameters. 
ResScan, ResMed. 
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Figure 2-9: Original data from a single patient receiving iVAPS therapy from September 21st  
– December 10th; summary graphs showing daily median, 95th percentile and maximum 
values of selected measured ventilatory parameters (Alveolar ventilation, pressure support, 
leak, tidal volume, respiratory rate) and the daily hours of use. 
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2.3.10 Capture detail of ventilator data output 
All ventilators used in this thesis, collected and stored data in two formats: 
1) ‘on-board’ data: was summary data stored within the ventilator and could also be 
downloaded via USB or cable to ResScan software. This included NIV useage and 
summary data for up to 365 treatment sessions. This data is routinely interrogated 
by clinicans in clinical practice.  
2) ‘Hi-res’ data: was high-resolution data detailing breath-by-breath signals, recorded 
onto an external memory; a SmartMedia card (in the ResLink connector for the  
VPAP III STA and AutoVPAP venitlators) or a netbook (via a USB connector for the 
Stellar 150 ventilator).  The ability to capture high resolution data over a three 
month period was paramount for the observational study presented in Chapter 3. 
The laptop ‘Logger Health Montior System’ was specifically developed for this thesis 
working with a team of software engineers at ResMed, Sydney, Australia.  
Progression of this telemedicine technology has since meant that high resolution 
data can now be wirelessly transmitted from the ventilator to a central internet 
‘cloud’ site. Clinicans may thus monitor patients’ ventilator therapy remotely, 
without need for hospital attendance. 
Recorded raw data was then interpreted by the appropriate software for each ventilator 
(see Table 2-6). 
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Table 2-6: Ventilator data capture, storage and download (continued on next page) For more detail see Appendices 7 and 8) 
 Onboard/ Reslink Data High-Resolution Data 
AutoVPAP On-board data  
- recorded during therapy 
- stored ‘on-board’ ventilator 
 - data capacity = 289 hours (36 days @ 8 hours/day) 
- fills and ceases recording 
-‘Data Retrieval Procedure AutoVPAP’: clinician downloads data 
 
High-resolution data  
-recorded if AutoVPAP connected to the notebook (via serial cable), running the correct 
logging application Kevlar 
- AutoVPAP and notebook are correctly connected and configured and high resolution 
data being recorded  moving coloured signal traces in the Kevlar trace panel on the 
notebook screen.  
 
VPAPIII ST-A  ResLink data 
-recorded onto the SmartMedia card via ResLink attachment 
-stored on SmartMedia card 
-data capacity = 30 sessions of data, (maximum of 10 hours each) 
- card fills, then overwrites oldest data on the card  
-‘Data Retrieval Procedure VPAPIII ST-A’:  clinician downloads data from the 
SmartMedia card in a USB card reader.   
 
High resolution data  
-  recorded if the VPAP is connected to the notebook (via serial cable), running the 
correct logging application SCapture.  data will be recorded for the VPAPIII ST-A.   
-VPAPIII ST-A and notebook are correctly connected and configured and high-resolution 
data is being successfully recorded moving coloured trace signals in the SCapture trace 
panel on notebook screen.  
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Stellar 150 Onboard data: 
-stored onboard 
-data capacity = 365 sessions summary data 30  
-data retrieval: clinician downloads data from ventilator to ResScan via: 
 ResMed USB stick (7 sessions high resolution high rate (25Hz) 
breath-by-breath data) 
 Cable (sessions low rate data (1 per minute)) 
 
 
High-Resolution Data 
- Data logged directly onto a netbook via a USB connector 
- The Logger Health Monitor screen icon for the software allowing ventilator data 
storage. 
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2.4 Measurement of sleep during iVAPS therapy 
2.4.1 Polysomnography 
Full overnight polysomnography (PSG) was performed with portable equipment 
(SOMNOscreen; SOMNOmedics GmbH and Co., Germany).  Signals were recorded via 
telemetry with minimal interference to sleep.   Standard monitoring was performed with 
the exception of thermister flow signalling which was replaced by surrogate flow measures 
from a pneumotachometer and mask pressure (to provide vital respiratory information 
during NIV). SOMNOscreen software (Domino v250; S-Med, UK) was used to process and 
analyse signals. 
Sleep Measures: EEG (C3A2, C4A1 and O1A2), right and left EOG, and submental EMG 
recordings were measured to define sleep stage and were made as per the International 10-
20 electrode system guidelines (Klem GH, Luders HO et al. 1999). EEG electrodes were 
placed in the left central (C3), right central (C4) and left occipital (O1) positions and 
referenced to contralateral behind ear mastoid electrodes (A1 and A2). Odd and even 
numbers represent the left and right hemispheres respectively. A ground electrode was 
positioned on the central forehead. EOG measures were made from the outer canthus of 
right and left eyes, both referenced to the right mastoid (A2). 
Electrodes for measuring EEG, EOG and EMG were applied after preparation of the skin sites 
to reduce impedance; abrasive gel (Nuprep; D.O. Weaver and Co., USA) and alcohol swabs 
(Universal Hospital Supplies Ltd, UK) were used. EEG scalp electrodes (C3, C4 and O1) were 
gold cups, filled with Ten20 conductive EEG paste (D.O. Weaver and Co., USA) attached 
using collodian glue and held in place with gauze. Other recording sites used single-use self-
adhesive silver-silver chloride electrodes (Neuroline; Ambu Ltd., UK). All were reinforced 
with micropore tape. 
Raw data signals: Electrical potential between each pair of EEG, EOG and EMG electrodes 
was measured in voltage in AC mode. Electrode impedance was tested to ensure <10kOhms. 
Raw signals were sampled at appropriate sampling rates, then passed through pre-
determined filters to remove external noise prior to digitisation (Domino v250 Software). 
Sample rates and filters are shown in Table 2-7. 
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Table 2-7: Polysomnography (PSG) signal sampling rates and filter settings 
 Sampling 
Rate (Hz) 
Frequency                  
range (Hz) 
Highpass        
Filter (Hz) 
Lowpass        
Filter (Hz) 
EEG 256 Delta (0.5-3);              
Alpha + beta (8-32) 
0.3 30 
EOG 128 0.2 – 35 0.3 10 
EMG 256 1-128 10 75 
ECG 256 1-128 1 75 
SpO2 4 n/a   
RIP 32 0-10 0 1 
Snore 256 40-128 40 150 
Flow 256 0.1-1.6 0.1 1.1 
Pressure 8 0-1.5 0 100 
EEG= electrocephalogram, EOG= electro-occulogram; EMG= electromyogram, SpO2= pulse oxygen saturation; RIP= 
respiratory inductance plethsmography 
Respiratory measures: Respiratory inductance plesthmography (RIP), NIV mask pressure, 
airflow and SpO2 were used to monitor respiration.  
Respiratory inductance plesthmography (RIP, Respitrace, USA) uses 2 bands to measure the 
respiratory excursions of the thoracic cage and the abdomen.  The bands, acting as 
transducers, consisted of elastic bands within which are sewn insulated sinusoid wire coils. 
These were placed around the thoracic cage (under the axilla) and around the abdomen (at 
the level of the umbilicus).  A weak alternating current is passed through the wires creating 
a small magnetic field. During inspiration and expiration, the bands are stretched and 
relaxed, thereby changing the cross sectional area within the bands resulting in changes in 
the frequency of the current. The current change is measured and converted to a voltage 
and then a digitised waveform.   
Arterial oxygen saturation (SpO2) and pulse rate were measured by pulse oximetry, as 
previously described (section 2.7). The Somno Oximeter measured SpO2 using a finger clip 
sensor with range 0 to 100%, with an accuracy (± 1 SD) (±3%) and pulse rate range 18 to 300 
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pulses per minute. It uses light wavelengths of red (660 Nm)  and infrared (910 Nm).  A DC 
constant raw signal is produced. 
A continuous overnight tcPCO2 trace was also measured via an earlobe sensor (TOSCA; Linde 
Medical Sensors, Switzerland) (section 2.6). 
ECG: was recorded continuously by single-use silver-silver chloride electrodes (Blue Sensor 
Electrodes; Medicotest, UK) positioned in the right and left subclavicular notches.  Raw 
signals sampled at a rate of 256Hz. 
Leg EMG and body position were also recorded. Leg EMG was used to quantify any periodic 
limb movements. 
Figure 2-10 shows patients with PSG monitoring in situ. Biological calibrations of each of the 
signals was performed and recorded prior to the patient going to bed. 
  
Figure 2-10: Patients with Somnoscreen PSG monitoring in situ (photos with patient 
permission) (See Figure 2-12 for more detail) 
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PSG was performed at the patient's home or in hospital, according to patient preference. It 
is our experience (Jaye, Chatwin et al. 2009) and that of others, (Fry, DiPhillipo et al. 1998; 
Iber, Redline et al. 2004) that home PSGs performed in the same patient on 2 separate 
occasions yield comparable and valid results, with a similar success rate of 90% (Kapur, 
Rapoport et al. 2000). 
2.4.2 Integrated data: PSG, pneumotachometer and mask pressure, ventilator data 
output, tcPCO2 and SaO2  
Integral to Chapter 4 was the ability to combine respiratory signals collected during sleep 
with the signals outputted by the iVAPS ventilator as explained below. Integrated data was 
used to validate ventilator output data and to measure changes in ventilation during sleep 
stages whilst on iVAPS therapy and the effects that this has on the continuous gas exchange. 
The PSG contained synchronised, incorporated data including: 
Pneumotachometer and mask pressure 
During PSG on a patient who is breathing spontaneously, respiratory airflow is measured by 
nasal pressure and thermister flow transducers at the nose/mouth.  During NIV, 
measurement of patient generated airflow is not feasible as the thermister, if left insitu, 
introduces unintentional mask leak and the measured flow is a combination of the patient 
and ventilator flow.  During CPAP application, flow can be estimated by the mask pressure 
signal. In previous NIV studies (Jaye, Chatwin et al. 2009), mask pressure in conjunction with 
effort bands have been used in an attempt to determine respiratory events. These methods, 
however are not meaningful enough to quantify the breathing signal. The displayed ‘flow 
surrogate’ signal is equivalent to pressure changes but not to the real flow in the case of 
bilevel pressure application.  With a pneumotachometer incorporated into the circuit, there 
is real flow measurement quantified in L/min giving rise to the possible analysis of Vt, MV, 
RR and leakage (difference between Vti and Vte). 
Therefore, I measured airflow using a non-heated pneumotachometer (model 3700A; Hans 
Rudolph Inc., USA), coupled to a differential pressure sensor (SEN632, range ± 2.4mbar; S-
Med, UK) and integrated into the SOMNOscreen software (Domino v2.50, S-Med, UK). 
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Ventilatory air flows through the Fleish tube fitted with 3 fine mesh screens, which present 
a small resistance to the flow. The resulting pressure drop across the mesh was converted to 
a voltage and amplified to a DC signal and is proportional to the flow rate.  The airflow signal 
is digitally integrated by the SOMNOscreen software (Domino v2.50, S-Med, UK) to give 
volume; breath-by-breath tidal volume. 
Integrated calibration was performed with a known 3 litre volume through the Fleish head.  
This pneumotacometer is recommended for paediatric use, or adults at rest, and calibrated 
to a flow range of 0-160L/min. Adult patients were studied during sleep and flow rates did 
not exceed this limit.  
The pneumotachometer was fitted between a non-vented mask and an intentional leak 
(Whisper swivel exhalation valve; Respironics, USA) (See Figure 2-11). As the patients used 
their normal interface, which was vented, the intentional leaks from the mask were sealed 
in order to prevent air escape before the flow and pressure measures were taken. 
 
Figure 2-11: The integration of a pneumotachometer and mask pressure sensor into the NIV 
circuit to measure respiratory airflow and mask pressure during NIV therapy. The mask 
exhalation ports were sealed and a whisper swivel expiratory port was added to the circuit 
proximal to the measurements of flow and pressure. 
Mask pressure, measured by a differential pressure transducer (SEN635, range ± 24mbar; S-
Med, UK) and compared to the reference measure of atmospheric pressure, was measured 
from a port on the side of the mask, via a thin tubing.  
Non-vented face mask 
Pneumotachometer  
Exhalation valve 
connected to tubing 
to ventilator 
Mask pressure line 
attached to pressure 
transducer 
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The patient setup of is shown in Figure 2-12. This set up allows analysis of actual delivered   
leakage airflow, Vt and MV and RR.  
 
Figure 2-12: Patient with PSG monitoring in situ, including NIV and integrated 
pneumotachometer and mask pressure measurement. Earlobe clip in situ ready for TOSCA 
sensor for integrated O2/CO2 monitoring. (Photo with patient permission).  
EEG= electrocephalogram, EOG= electro-occulogram; EMG= electromyogram, SpO2= pulse oxygen saturation; RIP= 
respiratory inductance plethsmography 
Ventilator output: Data from the Stellar 150 ventilator was synchronised with the PSG data. 
Real-time signals were relayed by the Tx Link connection module (ResMed, Australia) to 
EasyCare Tx software and concurrently to the SOMNOscreen Domino software (S-Med, UK). 
Connections between ventilator, Tx module and laptop were via either a serial or USB ports 
(See Figure 2-13). Due to multiple integrations, including PSG telemetery monitoring, 
TOSCA, ventilator, a multi-connection hub was required. 
EEG electrodes 
Non-vented face mask 
Pneumotachometer  
EMG electrodes 
Exhalation valve 
RIP bands – thoracic and 
abdominal breathing 
effort 
Mask pressure line 
EOG electrodes 
ECG electrode 
Oximeter 
SomnoScreen recorder 
Transcutaneous CO2 / 
SpO2 monitoring site 
Snore microphone 
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Figure 2-13: The ventilator connected via the Tx-link connection module to the laptop, 
where the realtime ventilator-measured parameters were synchronised in the 
SOMNOscreen software; 1 =Stellar 150 ventilator, 2=Tx-link, 3=laptop, 4=PSG telemetry 
receiver, 5=multi-connection hub 
The TxLink was configured to acquire a common IP Address with the laptop supporting the 
SOMNOScreenDomino software. The output configuration for the ventilator data signals are 
shown in Table 2-8. 
Table 2-8: TxLink output configurations for ventilator data signals, which were integrated 
into the PSG SOMNOscreen software. 
Parameter Value Voltage range 
Mask Pressure 0 to 30 cmH2O 0 to 1 V DC 
Patient Flow -120 to 120 L/min -1 to 1 V DC 
Leak 0 to 60 L/min 0 to 1 V DC 
Inspiratory Pressure 0 to 30 cmH2O 0 to 1 V DC 
Expiratory Pressure 0 to 30 cmH2O 0 to 1 V DC 
Minute Ventilation 0 to 30 L 0 to 1 V DC 
V= volts, DC= direct current 
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Continuous tcPCO2 and SaO2  
SaO2, HR and tcPCO2 were measured using a tcPCO2 monitor (TOSCA; Linde Medical Sensors 
AG, Switzerland) as previously described (section 2.6). tcPCO2 data was incorporated into 
the SOMNOscreen software by an analogue opto coupler (S-med, UK). The SOMNOscreen 
software was calibrated to support the TOSCA signal, through a voltage range -33.33 to 
+33.33 for TOSCA with range 0-250 mmHg.  Digital display was then converted to kPa to 2 
decimal points, and accurate to within 2%. 
Integrated data output and software 
Thoughout the initial stages of my PhD, I liased closely with industry representatives, 
specifically software engineers from both ResMed and SomnoMed. The aim was to achieve 
compatability between the software supporting the PSG analysis (Domino version 250; S-
Med, UK) and the Stellar 150 ventilator (EasyCare Tx v5.1; ResMed, Australia).  Previous 
versions of these software had been compatible, but compatability no longer existed for 
later versions. Industry partnerships no longer allowed compatability to be maintained, thus 
I was required to record the PSG data (with tcPCO2, external pneumotachometer and mask 
pressure data) and the ventilator data (as measured internally by the ventilator software) 
into separate data files (see Fig 2-14). I then later exported separate data files in European 
Data File (EDF) format and integrated individual patient data by synchronising the time 
stamps on both data sets. 
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Figure 2-14: Original patient recording during slow wave sleep : 1 minute epoch of synchronous a) Sleep data (on Domino software) and b) 
Stellar 150 ventilator data (on EasyCare Tx software) aligned by time stamping.  
(Sleep data included monitoring of EOG= electroocculargram, EEG=electroencephalogram, ECG=electrocardiogram, PLM= periodic limb movement, snore, delivered airflow, SpO2= pulse 
oxygen saturation, pulse, mask pressure, body position, RIP= respiratory impedance plethsmography for thorax and abdomen measuring patient effort, Co2= transcutaneous carbon dioxide, 
and integrated ventilator data (uncalibrated due to lack of software compatability). Ventilator data was recorded simultaneously in the EasyCare Tx software and included traces of ventilator-
measured parameters – minute ventilation, mask pressure, filtered leak, respiratory rate, tidal volume and patient flow. 
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2.5 Diaries, Questionnaires and Scales 
2.5.1 Daily Symptom diary 
Daily symptom diaries were used in this thesis In order to identify exacerbations of chronic 
respiratory disease, and thereby assess ventilator performance during both stable disease 
and during exacerbations. To be consistent with COPD literature, adapted from the London 
COPD cohort diary card (See Appendix 9).  
Symptoms: Patients recorded their daily symptoms from a predetermined list (see Table 2-
9). They recorded any increase or new appearance of any symptom over their usual chronic 
stable state that had occurred in the preceding 24 hours. They continued recording until the 
symptom had resolved back to stable state. Patients were encouraged to visit their GP as 
normal for any concerns regarding symptom development. 
Respiratory symptoms were divided into major and minor symptoms: 
Table 2-9: Respiratory symptoms, divided into major and minor, as self-recorded by patients 
in their daily symptom diary 
 
In addition, they reported on sleep disruption due to night time symptoms and a decreased 
physical activity level compared to their usual stable state.  
Treatment: Patients recorded any change to their usual treatment for as many days as it 
applied.  This included an increase in their usual inhaled therapies as well as new antibiotic 
and/or oral or intravenous steroid therapy. They also recorded their healthcare utilization; 
GP visits and hospital admissions.  
Letter Major Symptoms  Minor Symptoms 
 A increased BREATHLESSNESS. C a COLD (such as a runny or blocked nose). 
 B1 increased SPUTUM COLOUR. D increased WHEEZE or CHEST TIGHTNESS. 
B2 increased SPUTUM AMOUNT. E1 SORE THROAT. 
  E2 increased COUGH. 
  F FEVER. 
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Exacerbation indentification:. Exacerbations were identified by a single researcher, blinded 
to the ventilator data, in accordance with a pre-specified standardised protocol (see 
Appendix 10). 
Advantages: Daily diaries are a patient reported tool for direct measures of the signs and 
symptoms of an exacerbation. They are standardised, particularly with the use of a pre-
determined list of symptoms. Recall bias is reduced by their daily use. Events can be 
determined by an a-priori scoring algorithm.  They provide a means of identification and 
assessment of the frequency and duration of an exacerbation. They are also helpful in the 
evaluation of treatment efficacy. 
Limitations: There is no standardised diary in use in respiratory disease, nor in COPD in 
particular. Diary cards began in intial studies investigating the effects of antibiotics and 
focussed on the triad of symptoms including breathlessness, sputum volume and colour 
(Stockley and Burnett 1979; Anthonisen, Manfreda et al. 1987). Other diaries used in COPD 
studies in the detection and description of exacerbations or the efficacy of other treaments 
have included other symptoms including cough, wheeze, fever and ‘cold-like’ symptoms 
(Seemungal, Donaldson et al. 2000; Donaldson, Seemungal et al. 2002; Cazzola, MacNee et 
al. 2008; Vijayasaratha and Stockley 2008). Other disease groups might not experience the 
same symptoms, nor prioritise them similarly. For example, in NMD breathlessness might be 
initially more disabling and identifiable than sputum, and wheeze may be more prevalent in 
asthma. However these rely on patient recognition of symptoms whereby patients might 
otherwise ignore or compensate for symtpoms such as reducing activities to prevent 
breathlessness. Diary response options and scoring algorithms may also differ between 
diary cards. Patients may also not complete diary data. 
London COPD cohort diary card versus EXACT: A more recent patient reported diary, the  
EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) (Leidy, Wilcox et al. 2010). It is a 
14-item e-diary that assesses breathlessness, cough and sputum, chest symptoms, difficulty 
bringing up sputum, feeling tired or weak, sleep disturbance, and feeling scared or worried 
about the condition.  Each item is assessed on a 5 or 6 point scale which are summed to give 
a total score which is converted to a 0-100 score, with higher scores indicating greater 
symptom burden. The EXACT has been shown to be reliable and valid when compared to 
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already validated tools such as the St George Respiratory Questionnaire (SGRQ). It has also 
been shown to be sensitive to improvement of exacerbations with treatment (Leidy, Wilcox 
et al.; Patrick, Burke et al. 2011; Leidy, Murray et al. 2014; Leidy, Sexton et al. 2014). Borel et 
al. used the EXACT questionnaire to detect exacerbations in their COPD population who 
were also undergoing ventilator monitoring (Borel, Pelletier et al. 2015), however each 
event detected using the EXACT was then validated by two chest physicians. 
The EXACT was recently compared to both physician assessment, and the London COPD 
cohort diary card in the detection of symptom defined events in COPD (Mackay, Donaldson 
et al. 2014). It did identify exacerbations with mean(SD) scores rising from baseline to 
exacerbation onset (43 (9) v 48(9); p<0.001). It was also shown to be an effective method of 
evaluating COPD exacerbation severity with significantly higher scores recorded in treated 
than untreated events. However, there was an under-detection of exacerbations when 
compared to exacerbations detected by the London COPD cohort diary cards with only 50% 
of both diary card-defined and healthcare utilisation exacerbations crossing the EXACT 
event threshold. And only 30% of diary card-defined and 35% of healthcare utilisation 
exacerbations fully met the criteria for an EXACT event.  
Daily monitoring may increase patients’ anxiety about their condition, or it may provide a 
false sense of security causing a patient to delay seeking advice for deterioration in clinical 
condition. In Chapter 3 I monitored anxiety and depression scores as well as health related 
quality of life. I also stressed that the ventilator was monitoring the situation and not 
treating deteriorations. 
2.5.2 SGRQ 
Health related quality of life (HRQoL) was measured with the disease-specific St George's 
Respiratory Questionnaire (SGRQ; St George’s Health Status Research Team, UK) (Jones, 
Quirk et al. 1992). It is a self-administered 50 item questionnaire taking approximately 10-15 
minutes to complete. The SGRQ was chosen for its sensitivity to specific respiratory issues.  
It assesses the following 3 domains: Symptoms (frequency and severity), Activity and Impact 
(social functioning, psychological disturbances) as well as a total score. 
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Patients, or their immediate carer were asked to answer the questionnaire at study visits to 
determine changes in HRQoL in relation to the iVAPS therapy compared to standard PS 
therapy (interventional studies) or in relation to daily subjective and objective disease 
monitoring in the 4 month observational study. 
Scoring: Total score, out of 100, is calculated from all three domains, where 0 indicates no 
health impairment and 100 represents maximum impairment, thus a decrease in score 
reflects an improvement. The minimal clinically important difference (MICD) in the SGRQ is 
a change of 4 points of the Total Score (Jones 2005). 
Advantages: The reliability and validity of the SGRQ has been widely tested in a range of 
disease groups including asthma (Bae, Kim et al. 2011), chronic obstructive pulmonary 
disease (COPD) and bronchiectasis (Wilson, Jones et al. 1997) and it correlates significantly 
with other measures of disease activity;  cough, dyspnoea, 6-minute walk test and FEV1 as 
well as other measures of general health such as the Short Form 36 (SF36). It has also been 
shown to be sensitive to change with interventions such as pulmonary rehabilitation and 
NIV application (Guyatt, Berman et al. 1987). There is one question regarding sleep 
disturbance as a result of cough and breathing problems. 
Limitations: The SGRQ is not validated in restrictive respiratory disorders (ie. NMD and 
CWD), particularly those that do not have typical chronic respiratory symptoms such as 
cough, sputum and as such has limited application in these patient groups. The COPD 
Assessment Test (CAT) score (Jones, Harding et al. 2009) is shorter 8-item self-completion 
questionnaire but is specific to COPD and hence not used in this thesis due to the 
homogenous ventilatory failure populations studied.  
Care must be taken with interpretation in research as false improvements in SGRQ score, 
indicating improved HRQoL, may be attributed to a placebo effect of trial participation.  
2.5.3 HADS  
The Hospital Anxiety and Depression scale (HADS) (Zigmond and Snaith 1983) was also used  
in Chapter 3 to monitor the pyschological well-being of the patients both at baseline and 
throughout their participation in the 4 months followup. Consisting of 14 questions, 7 
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anxiety related and 7 relating to depression, the HAD scale generates ordinal data. Each 
answer has 4 options and is scored 0-3, with a total score out of 21 (anxiety and depression 
scored separately). Scores of ≥8/21 are considered the threshold for determing the 
presence of anxiety or depression. 
Advantages and limitations: The HAD is a validated generic psychiatric screening tool, 
designed to assess symptom severity rather than providing a definitive diagnosis. It has a 
sensitivity and specificity of approximately 80% for both domains (Bjelland, Dahl et al. 
2002). It is quick and easy to administer and to score.  
Chronic respiratory disease, in particular COPD, can have a high psychological burden 
accompanying the physical symptoms and patients frequently suffer from anxiety and 
depression (Wagena, Arrindell et al. 2005; Ries 2006). In this thesis the HAD scale was used 
to monitor change in patients with chronic respiratory disease, who were asked to consider 
and identify their symptoms on a daily basis, as well as make an objective measure of PEF.     
2.5.4 VAS 
Analogical scales were used to determine patient experience during NIV (see Appendix 11). 
In Chapters 5 and 6, subjective tolerance of ventilator modes (standard PS and iVAPS) was 
assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of 
breath, ease of falling asleep, use of ventilator, and mode preference. The VAS was a closed 
scale; a horizontal line with 2 delineated ends corresponding with maximum agreement 
with each statement and the absence of agreement. It was scored from 0–100 for each 
question (0 - negative and 100 - positive).  
VAS scales are reliable and valid descriptors of breathlessness (ATS 1999) and have been 
used for such since initial NIV therapy trials (Bott, Keilty et al. 1993). In previous studies  NIV 
comfort and tolerance have been evaluated by VAS (Vitacca, Bianchi et al. 2004; Jaye, 
Chatwin et al. 2009).  
Advantages and limitations: These scales are inexpensive and easy to administer, however 
patients require a certain level of understanding and abstract thinking to complete. 
Conditions leading to confusion, such as acute hypercapnia (as in Chapter 6), or increasing 
 97 
age can make completion difficult, or even inaccurate as patients ‘guess’ what is required of 
them, without due understanding. 
2.5.5 Borg breathlessness Scale 
The Modified Borg breathlessness scale (MBS) (Mahler and Horowitz 1994) is a subjective 
measure of a patient’s self-rated dyspnoea, or difficulty of breathing. It is a 10 point 
categorical scale (0-10), starting at 0 where breathing is causing no difficulty at all and 
progresses to 10 where breathing difficulty is maximal (See Table 2-10). It is a descriptive 
scale to anchor responses, where adjectives aid patients in rating their breathlessness. A 
reduction of 2 units is associated to the sensation of perceived improvement (Ries, Bauldoff 
et al. 2007). The MBS is a modified version of the Borg Scale of perceived exertion, which is 
used to monitor the intensity or effort of exercise or activities of daily living. 
Table 2-10: Modified BORG breathlessness scale 
SCALE SEVERITY 
0 No Breathlessness At All 
  0.5 Very Very Slight (Just Noticeable) 
1 Very Slight 
2 Slight Breathlessness 
3 Moderate 
4 Somewhat Severe 
5 Severe Breathlessness 
6   
7 Very Severe Breathlessness 
8   
9 Very Very Severe (Almost Maximum) 
10 Maximum 
Advantages and limitations: The MBS has been widely used in both research and clinical 
applications of NIV. Its use in pulmonary rehabilition has been well validated (Mador, Rodis 
et al. 1995)  In more acute circumstances, such as in Chapter 6, where patients were acutely 
unwell with hypercapnic acidotic respiratory failure, the MBS provides a quick and easy 
 98 
assessment to measure and evaluate dyspnoea. Validated in breathless patients with COPD 
and asthma admitted to emergency deparments, it is a reliable tool, sensitive to change 
with treatment eg. bronchodilators (Kendrick, Baxi et al. 2000).  NIV literature frequently 
reports on the MBS as a measure of acute NIV treatment efficacy, both in clinical use and 
research. Faster recovery of breathlessness in acute exacerbations of COPD has been 
measured by MBS (Bott, Keilty et al. 1993) as well as longer term reductions of chronic 
dyspnoea in stable patients receiving domicillary NIV (Casanova, Celli et al. 2000). 
2.6 Data and statistical analysis 
Data processing and analysis is described in more detail in the appropriate study chapters; 
only that which is applicable across studies is described here.  
2.6.1 Continuous transcutaneous SaO2/ tcPCO2 analysis  
Transcutaneous SaO2/ tcPCO2 trends were analysed by an independent technician, blinded 
to the ventilator used to provide therapy. This prevented ventilator bias and also 
standardised the removal of artefact from the traces. 
2.6.2 Sleep 
Sleep study data was analysed by a single blinded PSG technician, independent to each 
study (Chapter 4: VR and Chapter 5: RP).  Sleep was analysed from the time of NIV initiation. 
Sleep staging: was scored in 30 second epochs as per  standard Rechtschaffen and Kales 
(R&K) criteria (Rechtschaffen A and Kales A 1968). Sleep staging is summarised in Table 2-11  
In Chapter 4, periods of continuous stable state were selected in each sleep stage. Selected 
period sleep stages were further verified by comparison of the percentage of delta wave 
activity. Delta (slow) waves are considered as EEG activity with a frequency ≤2Hz and an 
amplitude ≥75μV. Delta sleep, or slow wave sleep (SWS), is therefore sleep in which EEG 
delta waves predominates (≥20% of the epoch). For each 30 second epoch, the percentage 
of delta wave activity was calculated (ie the time occupied by the high amplitude, slow 
waves). 
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Table 2-11: Sleep stages adapted from AASM Manual for the Scoring of Sleep and 
Associated Events (2012) 
 EEG activity EOG EMG 
Wake Alpha (8-13Hz), Beta (>13 Hx) Variable Variable 
 
NREM:    
Stage 1 Low voltage, mixed frequency theta 
(4-7Hz), vertex sharp waves(<0.5s) 
 
Slow rolling eye 
movements(>500ms) 
Reduced 
Stage 2 Low voltage, mixed frequency theta 
(4-7Hz), K complexes (≥0.5s), 
spindles (11-16Hz; ≥0.5s) 
 
Absent Reduced 
SWS >20% epoch high voltage, slow wave 
delta activity (≤ 2Hz, ≥75μV) 
 
Absent Reduced 
REM Low voltage, mixed frequency (alpha 
and theta), sawtooth waves (2-6Hz) 
Intermittent rapid 
eye movements 
(<500ms) 
Markedly 
reduced 
REM= rapid eye movement, NREM= non rapid eye movement, SWS = slow wave sleep 
Arousal scoring: arousal frequency by scored according to AASM (American, Sleep et al. 
1992)  criteria . These were identified when there was an abrupt shift in EEG frequency for 
≥3 seconds. 
Respiratory event scoring: a SpO2 desaturation of 4% considered significant.  
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2.6.3 Statistics 
All statistical analysis was performed using SPSS v19 and v21 (IBM, USA) or Stata v13 
(StataCorp, USA). A summary of analysis is described here Statistical significance was 
considered as p<0.05. Multiple comparisons were adjusted by Bonferroni correction. In 
exploratory analysis using multiple comparisons, a more stringent level of significance was 
assumed (P<0.01). 
Data are described by means and standard deviations (SD) or medians and interquartile 
ranges (IQR) for continuous variables, depending on sample size and distribution. 
Categorical variables are described as number and percentage. Normality testing of 
distributions was examined both visually (histogram and Q-Q plots) as well as by Shapiro-
Wilk testing.  
Comparisons between patients with obstructive and restrictive pathologies were made by 
independent t-test for normally distributed data, and Mann Whitney tests for non-
parametric data. Categorical data was compared by Chi2 or Fisher’s exact test.  
Comparisons between disease states, ie exacerbation onset, stable (symptom-free) and 
symptom days were made by ANOVA with repeated measures or Friedmans Test.  
Correlations were examined by Pearson tests.  
Further details of analysis for each study given in the appropriate chapters. 
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3  USE OF VENTILATION MONITORING FOR EARLY DETECTION OF EXACERBATIONS OF 
CHRONIC LUNG DISEASE  
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3.1 Introduction 
Chronic respiratory disease progression is marked by exacerbations that are described as 
‘periods of acute, sustained worsening of the underlying condition from the stable state and 
beyond normal day to day variability, which may require a change in treatment’ (Rodriguez-
Roisin 2000; Bilton, Canny et al. 2011) (see Chapter 2, section 5.1 for more details). 
Exacerbations can manifest differently, but all are detrimental to patients’ morbidity with 
increased lung function decline, decreased HRQoL and increased mortality (Donaldson, 
Seemungal et al. 1999; Kanner, Anthonisen et al. 2001; O'Donnell and Parker 2006). They 
are also a burden on healthcare resources, (Wedzicha and Seemungal 2007) with 
exacerbations of COPD in the UK leading to £800 million in direct healthcare costs (National 
Institute for Clinical Excellence 2004).   
To date no standardised, reliable, valid method exists for the assessment of the frequency, 
severity or duration of exacerbations in COPD (Rodriguez-Roisin 2000; Cazzola, MacNee et 
al. 2008). There is a lack of concensus for a formal definition of exacerbations and there is 
no definitive biomarker.  This is an important issue in clinical practice and research studies, 
where timely and correct identification of exacerbations with early treatment provides 
favourable results (Wilkinson, Donaldson et al. 2004) and also prevents potentially harmful 
treatment of ‘non-exacerbations’.  
Markers that may identify or even predict exacerbations and have been used with varying 
success include: symptoms (Anthonisen, Manfreda et al. 1987; Seemungal, Donaldson et al. 
1998; Vijayasaratha and Stockley 2008), events or therapies (Rodriguez-Roisin 2000; 
Vijayasaratha and Stockley 2008) and measures of physiological lung function (indices of 
expiratory flow limitation and airways resistance) (Tattersfield, Postma et al. 1999; 
Seemungal, Donaldson et al. 2000). Symptom diaries are direct measures of the symptoms 
of an exacerbation and there have been several studies published in this area (Leidy, Wilcox 
et al.; Seemungal, Donaldson et al. 1998; Seemungal, Donaldson et al. 2000; Seemungal, 
Harper-Owen et al. 2001; Vijayasaratha and Stockley 2008; Leidy, Wilcox et al. 2010; Leidy, 
Murray et al. 2014). Cardinal symptoms and scoring systems are used to detect the 
presence, severity and duration of exacerbations. However symptoms are subjective and 
there is a heterogeneity of symptom presentation across patient populations, and wide day-
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to-day variation in symptom load for each patient. Patients often find it difficult to 
differentiate a worsening in their symptoms from a background of day to day variation. They 
also compensate for symptoms, by reducing activity. Therefore worsening of their condition 
is often delayed or unreported leading to an under diagnosis of exacerbations by up to 50% 
(Seemungal, Donaldson et al. 1998).  
Therapy and event based detection of exacerbations (antibiotics or oral steroid use, GP 
visits or hospital admissions) are also reliant on reporting an identification of symptoms in 
the first instance and in approximately half of symptom-based exacerbations, patients do 
not change their therapy, thus leading to an under-reporting  (Vijayasaratha and Stockley 
2008).  
Exacerbations can also be characterised by changes in respiratory function; detected by 
changes in lung volumes, flows and breathing pattern. The pathophysiology of an 
exacerbation involves not only changes in lung mechanics, but secondary phenomena such 
as dynamic hyperinflation, development of intrinsic PEEP, sputum plugging and recruitment 
of abdominal expiratory muscles (O'Donnell and Parker 2006). Furthermore total airways 
resistance will include changes in upper airways resistance. However, differentiation from 
normal day-to-day variation is key to using these criteria.    
In COPD, several objective respiratory physiological measures have been investigated to 
determine their reliability to detect exacerbation onset, or resolution (Tattersfield, Postma 
et al. 1999; Seemungal, Donaldson et al. 2000). Unlike in asthma, these measures of lung 
function have shown no prodromal decrease. On the first day of exacerbation onset PEF and 
FEV1 fall significantly from baseline (Tattersfield, Postma et al. 1999; Seemungal, Donaldson 
et al. 2000). Clinically, however, these changes are small and cannot be used in isolation to 
detect exacerbations (Seemungal, Donaldson et al. 2000; Donaldson, Seemungal et al. 
2002).  For patients receiving long term oxygen therapy (LTOT), respiratory rate (RR) may be 
observed via the oxygen delivery system, and in the 24 hours prior to hospital admission for 
acute exacerbations of COPD, a mean increase of 4.4bpm (30% from baseline) has been 
observed, however, the sensitivity of this measure was only 66% (Yanez, Guerrero et al. 
2012). Recently, pulse oximetry has also been used to develop a composite score 
incorporating daily HR and SpO2 measures, which could differentiate between exacerbation 
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onset and normal symptom variation with 71% sensitivity, but as yet this calculated 
measure has not been used widely in the clinical setting (Hurst, Donaldson et al. 2010).  
Home ventilators have the ability to monitor and store data on a wide range of respiratory 
parameters in patients requiring NIV (see Chapter 2, section 3.7). Ventilator-measured 
respiratory parameters may change with variations in respiratory function, specifically the 
physiological changes observed with exacerbations. Since the conception of the current 
study, Borel et al. have investigated the daily variation of parameters recorded by standard 
PS NIV (Borel, Pelletier et al. 2015). The authors have suggested that daily variations in 
ventilator-measured RR and percentage of respiratory cycles triggered by the patient (% 
patient triggered) can be used as predictors of an exacerbation, but only with sensitivities of 
46% and 53% respectively. iVAPS is an autotitrating mode of ventilation that aims to achieve 
and maintain a target alveolar (VA) ventilation despite changes in the patient ventilatory 
requirements, physiology and effort (see Chapter 2, section 3 for further description of 
iVAPS). PS and RR are constantly and automatically adjusted. Therefore, I wanted to test the 
notion that changes in the pattern of ventilatory support, measured by the iVAPS ventilator 
during an acute exacerbation, may be of value in the timely detection of exacerbations, and 
may even occur prior to the development of symptoms. 
In this chapter, a hypothesis generating study is presented in patients with chronic HRF and 
receiving domiciliary NIV therapy. I aimed to test the hypothesis that VA would remain 
stable during exacerbation and that other ventilator-measured parameters may identify 
exacerbation in patients with chronic HRF. I was also able to report on the normal day-to-
day variation of PEF and ventilator-measured parameters including minute alveolar 
ventilation, tidal volume, respiratory rate, pressure support, inspiratory time, mask leak and 
hours of use during stable state. 
3.2 Methods 
3.2.1 Patients  
Patients were recruited from the RBH NIV clinics over 18 months between June 2012 and 
December 2013. Patients with both obstructive and restrictive respiratory disorders were 
included as the mechanisms of NIV therapy are different in these groups and it was 
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considered likely that the ventilatory parameters measured longitudinally would follow 
different trends. To maximize the number of exacerbations for analysis, frequent 
exacerbators, defined as patients experiencing 2 or more exacerbations per year, were 
specifically recruited (see Table 3.1). 
Table 3-1: Inclusion and exclusion criteria for study: Use of ventilator monitoring for early 
detection of exacerbations of lung disease 
Inclusion criteria Exclusion criteria 
 Severe chronic respiratory 
disease; obstructive or restrictive, 
FEV1<40% predicted 
 Poor NIV adherence (<3hrs/night 
for >10days/month) 
 established on NIV for chronic 
respiratory failure or nocturnal 
hypoventilation 
 ventilation efficiency decrease in 
mean SaO2 >3%  with iVAPS 
ventilation despite greatest effort 
to ventilate effectively 
 ≥18 years  cognitive impairment sufficient to 
interfere with comprehension of 
study or use of ventilator  
 IPAP requirement < 30cmH2O  lack of capacity to give informed 
consent 
 
The study was approved by the NRES Committee London- Chelsea (REC: 11/LO/1777) and all 
patients gave written informed consent. 
3.2.2 Protocol 
This was a hypothesis generating study. Patients already established on NIV were switched 
from their usual ventilator to an autotitrating iVAPS ventilator (Stellar 150; ResMed, 
Australia) for 4 months, inclusive of a 1 month run-in period. During this time, ventilatory 
parameters were continuously monitored by the ventilator.  
Initiation and titration of NIV: The Stellar 150 ventilator was set to the iVAPS mode. The 
initial EPAP setting was identical to patients’ previous value or was set at 5cmH2O and later 
refined to alleviate obstructive events or flow limitation. The patient performed a ‘learn 
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period’ during which the ventilator monitored the patient’s wake resting ventilation with 
the goal of learning the target alveolar ventilation (Tgt VA) and target respiratory rate (tgt 
RR) (as described in Chapter 2, section 3.6). During the learn period the PS was kept to a 
minimum for comfortable breathing (4cmH2O) unless there was evidence of daytime 
hypercapnia in which case a PS of 6-10cmH2O was used according to tcPCO2 levels (TOSCA; 
Radiometer, UK). The 5 minute ventilatory learn portion that best represented stable VA and 
RR was accepted and used as target parameters for subsequent ventilation. Maximum and 
minimum PS values were set to maximize tolerated PS variability to allow VA to be met, 
whilst care was given to consider patient comfort and tolerance, lung mechanics, age, mask 
seal etc.  The maximum inspiratory time as a fraction of total breath time (Max Ti/ Ttot) was 
set according to pathology and comfort (30% obstructive; 40% restrictive). Other ventilator 
settings were set to pathology defaults, then adjusted as required. Patients’ existing 
interface was assessed.  
After iVAPS initiation, patients were asked to carry out an overnight sleep study, with 
capnography/oximetry, at one week and a subsequent one month visit to ensure optimal 
ventilation therapy. Ventilator alterations were made at either of these visits to improve 
ventilator efficacy and/or patient comfort.   
3.2.3 Measurements 
Baseline measures, including daytime SaO2 and tcPCO2, were repeated after the 1-month 
run-in period and at 4 months (trial cessation). Anxiety and depression scores and health-
related quality of life (HRQoL) were monitored throughout (See Figure 3-1 for protocol). 
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Figure 3-1: Study protocol: ventilator monitoring during stable state and exacerbations of 
lung disease.  
Patient diaries: Patients completed daily self-reported symptom diaries, including any 
change in symptoms above normal baseline level in the preceding 24 hours, any change in 
medication as well as their PEF (best of 3) and the hours that were spent out of the home 
(See Appendix 9). 
Ventilator data: NIV data was automatically transferred from the Stellar 150 ventilator to a 
laptop as described in the general methods (See Chapter 2, section 3.10). On study 
completion, ventilator data was downloaded via ResScan software (ResMed, Australia) to 
provide summary statistics on the ventilator useage and the nightly median values of each 
ventilator parameter including VA, PS, RR, Vt, Ti and calculated mask leak. (5
th, 95th 
percentiles and max daily values also recorded). The high resolution breath-by-breath 
ventilator data underwent processing providing derived parameters indicative of patient-
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ventilator interactions, including ineffective efforts, % of patient triggered breaths versus 
machine triggered. Ineffective efforts are a measure of patient ventilator interaction where 
the patient makes an effort to breathe that does not trigger the ventilator and thereby goes 
unrewarded. 
On completion of the 4 month data collection period, hospital admissions, GP consults and 
healthcare visits were recorded from GP and hospital records. 
3.2.4 Data analysis 
Exacerbation analysis:  Exacerbations and periods of stable state were identified by a single 
researcher, blinded to the ventilator data, from the self-reported symptom diary using a 
validated protocol adapted from research performed by investigators of the London COPD 
cohort (Seemungal, Donaldson et al. 2000; Hurst, Donaldson et al. 2010). (Appendix 10) 
Symptoms: were classified as major (breathlessness, sputum volume and sputum 
purulence) and minor (cough, wheeze, sore throat and coryza). Symptoms were binary 
coded and summed daily to give a daily symptom count. ‘Baseline symptom count’ was the 
mean total daily symptom count over days 7 to 14 pre-exacerbation onset.  
Symptom-days: were those days on which symptoms were recorded but did not meet the 
exacerbation criteria. These represented day-to-day symptom variation.  
Symptom-free days: recorded as no symptoms. 
Exacerbation Definition: Exacerbations were defined as the presence for at least 2 
consecutive days of increase in any 2 symptoms (with at least one major symptom) 
according to criteria modified by Anthonisen et al (Anthonisen, Manfreda et al. 1987)  and 
used extensively in the London COPD cohort (Seemungal, Donaldson et al. 2000; Donaldson, 
Seemungal et al. 2002; Hurst, Donaldson et al. 2009) . The day of onset was the first of these 
days and recovery was recorded when a 3-day moving average of daily symptom count had 
returned to baseline. 
Exacerbations were defined as: 
 Untreated  
 109 
o If exacerbation criteria were met but no treatment was started prior to 
recovery 
 Self-treated  
o If treatment initiated in the community by the patient without review from 
health care professional 
 Physician treated exacerbation  
o If patient is reviewed by a health care professional and additional course of 
steroids and or antibiotics  
 Hospitalisation  
o If patient is admitted to hospital for treatment for their exacerbation 
 
The exacerbation criteria were hierarchical, if the symptom score did not reach recovery 
prior to escalation, the event was defined by the highest level reached. Therefore each 
event was only recorded once even if the exacerbation was initially self-treated in the 
community and then there was a subsequent hospital admission prior to recovery the event 
was defined by the hospital admission. 
Time course of exacerbation: was comprised of prodrome, onset and recovery. 
Exacerbation timeline is shown in Figure 3.2 
Stable state: After the one month run-in, the next 30 symptom-free days were considered 
as ‘stable state’. Data from 7 days preceding exacerbation to 14 days following exacerbation 
recovery were excluded and symptom days were excluded. 30 days was chosen to be 
consistent with data reported by Hurst et al. to allow stabilisation of the SD of physiological 
parameters (HR, SpO2 and PEF) which can take up to 3 weeks (Hurst, Donaldson et al. 2010). 
When it was not possible to achieve 30 consecutive stable days with both diary and 
ventilator data, additional symptom-free days were included. 
Day of onset: is the first of the 2 consecutive days of the presence of increased symptoms 
from the stable state. The change in any parameter at exacerbation is taken as the 
difference between the values of the parameter at onset of exacerbation and baseline 
stable state. 
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Recovery: number of days from start of an exacerbation to the return of the daily symptom 
score (3 day moving average) to return to stable baseline (average value for score on 7 
consecutive days of stable state) despite any ongoing medication or day 35/7 post onset 
(stability reached in clinical studies 4-6weeks).  A second exacerbation is only when there 
had been 5 consecutive days free of all symptoms (Hurst, Donaldson et al. 2009)  to exclude 
symptom relapse.  
Treatment and Healthcare Utilization: was also considered including times when antibiotics 
and/or corticosteroids were administered either by the patient themselves or by a 
physician, but when there was no preceding increase in symptoms recorded in the diary. 
These were defined as self-treated, physician-treated or hospitalisation.  
Day of onset: was the first day of treatment initiation for those who did not record any 
symptoms prior to treatment. 
 
 
 
Figure 0-1: Symptom-defined exacerbation time course, adapted from (Seemungal, 
Donaldson et al. 1998; Donaldson, Wilkinson et al. 2005; Hurst, Donaldson et al. 2010) 
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Ventilator data: Ventilator-measured parameters were taken as the median overnight value 
for each night of analysis. Analysed periods included data from both the patient diary and 
downloaded ventilator data, and were free from ventilator setting changes. As the 
symptoms reported on any particular day were representative of the 24 hours preceding, 
these were aligned with the previous night’s ventilation therapy.  Morning PEF measures 
were also aligned with the ventilator data from the preceding night. 
3.2.5 Statistical analysis 
Data are described by means and standard deviations (SD) or medians and interquartile 
ranges (IQR) for continuous variables, depending on sample size and distribution, and as a 
number and percentage for categorical variables. Normality testing of distributions was 
examined both visually (histogram and Q-Q plots) as well as by Shapiro-Wilk testing. 
Coefficients of variation (CV), expressed as a percentage, allowed comparison of the 
variability of ventilator-measured parameters. Highly variable data was considered when 
the CV was greater than 15%. 
Comparisons between patients with obstructive and restrictive pathologies were made by 
independent t-test for normally distributed data, and Mann Whitney tests for asymmetric 
data. Categorical data was compared by Chi2 or Fisher’s exact test. Comparisons between 
disease state, ie exacerbation onset, stable (symptom-free) and symptom days, were made 
by ANOVA with repeated measures. Correlations were examined by Pearson tests. All p 
values are asymptotic two-sided and a value of p<0.05 was considered significant.  
Day-to-day variation: was assessed for the PEF and ventilator-measured parameters (both 
raw data and derived measures). Individual mean and SD was calculated for each parameter 
over the 30 days of symptom-free stable state. It was then assumed that on subsequent 
‘stable’ (symptom-free) days, 95% of values would be expected to lie between the mean +/- 
1.96 SD. 
Time course of exacerbation: Exacerbation onset was determined from the symptom diaries. 
Some patients experienced multiple exacerbations; in these patients only the first 
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exacerbation was used in this analysis. Data from subsequent exacerbations were used in 
analysis differentiating symptom free, symptom and exacerbation onset days (as described 
below).  
Data from 7 days prior to and 7 days following the onset were examined to investigate the 
changes in PEF and ventilator-measured parameters. Individual patient daily data was 
expressed as multiples of that patient’s stable SD for each parameter. This was calculated by 
the formula (VD-VM)/ VSD where VD is that day’s measure and VM and VSD are the mean and 
SD of each variable (PEF and ventilator-measured parameter) based on previous methods 
published by Hurst et al. (Hurst, Donaldson et al. 2010). 
Differentiation of exacerbation onset from stable (symptom-free) days and symptom days: 
To determine if changes in ventilator-measured parameters could reliably differentiate 
between exacerbation onset, symptom days and symptom-free days, all remaining data 
from non-exacerbators and exacerbation data subsequent to the first exacerbations of each 
patient was analysed. All days were classified as symptom-free, symptom or exacerbation 
onset. At exacerbation onset, the day with the higher score of the first 2 days was selected 
for analysis. Other exacerbation days were not included (Hurst, Donaldson et al. 2010).  
All data were analysed by SPSS v 21.0 (IBM, USA). 
3.2.6 Power calculation  
This was a hypothesis generating observational study.  Based on the frequency of 
exacerbations requiring hospitalisation in the RBH NIV patient population, we anticipated 2 
exacerbations per year in COPD patients, and 4 per year in unstable bronchiectasis and 
severe asthma patients. If 30 patients were studied over 3 months we expected on average 
between 22 and 23 exacerbations requiring hospitalisation (COPD 0.5 exacerbations over 3 
months/pt x 15 = 7.5 + bronchiectasis/cystic fibrosis/asthma 1 exacerbations per 3 
months/pt x15 = 15. Total 22 or 23), and around twice this for minor exacerbations 
managed at home. Allowing for drop-out, 37 patients were recruited.  This would allow us 
pilot data on >20 exacerbations, in line with data reported on exacerbation prediction data 
reported in the literature (Yanez, Guerrero et al. 2012; Borel, Pelletier et al. 2015). 
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3.3 Results 
3.3.1 Patient Demographics 
1051 patients attended 37 clinics and of these patients, 435 were randomly screened. 77 
were eligible, 37 patients were recruited and 30 completed the 4 month follow-up (See 
Figure 3-3). 
 
Figure 0-2: Flow diagram of study: Ventilator monitoring during stable state and 
exacerbations of chronic respiratory disease.  
NIV= non-invasive ventilation, iVAPS = intelligent volume assured pressure support ventilation, PEF = peak expiratory flow. 
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The baseline characteristics are summarised in Table 3-2. Patients were 50% male, 61 (14) 
years old and had very good self-reported adherence to NIV therapy; 8.4 (2) hrs/night. 
Patients reported an exacerbation frequency of 4 (3 to 6.3)/yr.  Nearly half were on LTOT 
(43%). 
Obstructive patients had a greater BMI (p=0.04) and airway obstruction (p<0.01) plus worse 
daytime gas exchange (SaO2; p<0.01, tcPCO2; p=0.06). There was no difference in the 
exacerbation frequency between pathologies, or the adherence to NIV therapy. Further 
details on symptom burden, health-related quality of life and medications are provided in 
Appendix 12. 
Previous NIV settings, and those of the Stellar 150 ventilator used during the study, are 
reported in Table 3-3. Obstructive patients had higher Target VA (8.9 v 5.5L/min; p<0.001) 
but similar pre-set PS boundaries. They had higher EPAP levels (p=0.04) and faster rise times 
(p=0.002). These data were in keeping with potentially higher levels of intrinsic PEEP 
combined with faster inspiratory flow rates observed with high lung compliance in COPD. 
Lower trigger (p=0.03) and higher cycle sensitivities (p=0.002) were also more common for 
patients with obstructive pathologies allowing for early cycling into expiration to reduce risk 
of hyperinflation. They also had more O2 entrained due to their worse gas exchange. 
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Table 3-2: Baseline characteristics of n=30 patients who completed the 4 month follow-up, also comparing differences between patients with 
restrictive and obstructive pathologies. 
 Total  
(n=30) 
Restrictive 
(n=10) 
Obstructive 
(n=20) 
p 
Male (n) 15 (50) 4 (40) 11 (55) 0.70 
Age (yrs) 60.6 (13.9) 60.6 (17.9) 60.6 (11.9) 0.99 
BMI (kg/m2) 30 (22 to 39) 24 (21 to 32) 33 (24 to 42) 0.04 
FEV1% predicted 38 (19) 43 (17) 35 (19) 0.25 
FVC% predicted 51 (22) 41 (17) 56 (23) 0.05 
FEV1/FVC 63 (23) 88 (12) 51 (17) <0.01 
PEF (L/min) 179 (120 to 237) 188 (152 to 239) 161 (109 to 257) 0.42 
SpO2 (on air) (%) 96 (95 to 98) 98 (97 to 99) 95 (92 to 97) <0.01 
PtcCO 2 (on air) (kPa) 6.1 (1) 5.7 (0.7) 6.3 (1.1) 0.06 
Heart Rate (on air) (bpm) 86 (14) 87 (13) 85 (15) 0.76 
Self-reported NIV adherence (hrs/night) 8.4 (1.9) 8.4 (2.3) 8.4 (1.8) 0.98 
Exacerbation frequency (/yr) 4 (3 to 6) 5 (4 to 8) 4 (3 to 7) 0.81 
Data are presented as n (%), mean (SD) or median (IQR). Differences between pathologies were compared by unpaired t-tests or Mann-Whitney. Categorical data are presented as n (%) 
and compared by Chi2 or Fischer’s exact test. P<0.05 was considered significant. BMI = body mass index, FEV1 = forced expiratory volume in 1 second, FVC = forced expiratory volume, 
SpO2 = arterial oxygen saturation, tcPCO2 = transcutaneous carbon dioxide. 
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Table 0-1: Ventilation details of n=30 patients, restrictive (n=10) and obstructive (n=20); pre-study NIV settings and Stellar 150 settings 
 Total Completed (n=30) Restrictive (n=10) Obstructive (n=20) p 
Previous NIV Mode:      
          -PCV 1 (3) 1 (10) 0 (0) 0.23 
          -PSV 2 (7) 0 (0) 2 (10)  
          -ST 27 (90)  9 (90) 18 (90)  
IPAP (cmH2O) 23 (5.6) 23.4 (5.5) 22.9 (5.7) 0.83 
EPAP (cmH2O) 5 (3 to 6) 4.5 (0 to 5) 5 (5 to 6) 0.04 
RR (bpm) 15 (14 to 16.3) 16 (13.8 to 18) 15 (14 to 15.8) 0.27 
O2 entrained into NIV (n) 11 (37) 2 (20) 9 (45) 0.25 
O2 level entrained (L/min) 1.4 (0.8) 0.8 (0.4) 1.6 (0.8) 0.09 
Study Stellar 150 Settings:     
EPAP (cmH2O) 5 (5 to 6) 5 (4.8 to 5) 5.5 (5 to 6.8) 0.04 
Learn PS min (cmH2O) 4 (4 to 6) 4 (4 to 5) 6 (4 to 6) 0.14 
Target RR (bpm) 16 (15 to 17.3) 16 (15 to 18) 16 (15 to 16.8) 0.62 
Target VA (L/min) 8.1 (6 to 9.7) 5.5 (3.5 to 6.5) 8.9 (7.9 to 10.9) <0.001 
Baseline Weight 84.6 (31.3) 65.1 (22) 94.3 (31) 0.01 
Ti min (s) 1 (1 to 1) 1 (1 to 1) 1 (1 to 1.2) 0.31 
Ti max (s) 1.5 (1.5 to 2) 1.6 (1.5 to 2) 1.5 (1.5 to 1.9) 0.78 
Rise Time (ms) 200 (150 to 300) 300 (250 to 375) 150 (150 to 238) 0.002 
Fall Time (ms) 200 (200 to 200) 200 ( - ) 200 (200 to 200) 1.00 
Minimum PS (cmH2O) 9.5 (5.3) 8.2 (5.3) 10.2 (5.3) 0.35 
Maximum PS (cmH2O) 19.1 (4.4) 20 (4) 18.6 (4.6) 0.42 
O2 entrained (n) 11 (37) 2(20) 9 (45) 0.04 
O2 entrained (L/min) 1.5 (0.7) 1 (-) 1.5 (0.7) n/a 
Mask: oronasal/ nasal/ nasal pillows (n) 22/ 5/3 7/ 1/ 2 15/ 4/ 1 0.39 
Data are presented as mean (SD) or median (IQR). Differences between pathologies were compared by unpaired t-tests or Mann-Whitney. Categorical data are presented  as n (%) and 
compared by Chi2 or Fischer’s exact test. P<0.05 was considered significant. NIV = non-invasive ventilation, PCV= pressure control ventilation, PSV= pressure support ventilation, ST= 
spontaneous timed ventilation, IPAP = inspiratory positive airway pressure, EPAP = expiratory positive airway pressure, RR = respiratory rate, O2 = oxygen., PS = pressure support, VA = 
alveolar ventilation, Ti= inspiratory time
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3.3.2 Normal variation of ventilator-measured parameters and PEF in ‘stable’ (symptom- 
free) respiratory disease 
PEF (the surrogate measure of airways’ resistance) and ventilator-measured data were 
analysed to determine normal day-to-day variability. Variability during ‘stable state’ was 
assessed by the analysis of data on 30 symptom-free days. One patient was excluded from 
the stable state analysis due to insufficient symptom-free days. Data analysed was therefore 
based on n=29 patients studied for 30 days each; a total of 870 symptom-free days. Table 3-
3 reports the group means for PEF and ventilator-measured parameters over symptom-free 
days. Only PEF, hours of ventilator use and PS were normally distributed, therefore care 
must be taken when interpreting results of other ventilation parameters.  
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Table 0-2: Means of individual patient mean, SD and CV for ventilator-measured parameters and PEF over 30 stable symptom-free days; n=29 
(Obstructiven=29 and restrictive n=10) 
 TOTAL          
(n=29) 
    Obstructive 
(n=19) 
    Restrictive 
(n=10) 
   
 Grand 
Mean (SD) 
Mean 
SD 
Mean 
CV (%) 
1.96*SD  Grand 
Mean (SD) 
Mean 
SD 
Mean 
CV (%) 
1.96*SD  Grand 
Mean (SD) 
Mean 
SD 
Mean 
CV (%) 
1.96*SD 
PEF (L/min) 208 (84) 16 8 31   199 (86) 17 9 33  225 (83) 13 6 26 
Nightly ventilator use (mins) 504 (115) 81 17 159   486 (118) 87 19 171  539 (105) 70 12 137 
VA (L/min) 8.58 (3.59) 0.97 11 1.90   9.9 (3.62) 1.1 11 2.2  6.06 (1.76) 0.8 11 1.5 
PS (cmH2O) 13.3 (5.4) 1.0 14 2   15.1 (4.4) 1.1 8 2.2  10 (5.7) 0.7 26 1.4 
Vt (ml) 642 (262) 74 11 145   738 (255) 81 11 159  459 (161) 60 11 118 
RR (bpm) 17 (3) 0.6 4 1.2   16 (1) 0.7 4 1.4   18 (4) 0.6 3 1.1 
Ti (sec) 1.3 (0.3) 0.1 7 0.2   1.3 (0.2) 0.1 7 0.2   1.3 (0.3) 0.1 6 0.2 
Leak (L/min) 8 (11) 5.2 125 10.2   7 (10) 5 146 10   10 (12) 6 86 12 
% Patient Triggered Breaths 0.1 (0.2) 0.03 31 0.06   0.1 (0.1) 0.03 35 0.1   0.2 (0.3) 0.03 23 0.1 
Ineffective  Efforts (n) 337 (286) 175 56 343   323 (303) 177 59 347   368 (260) 170 49 333 
SD= population standard deviation, CV= coefficient of variation, PEF= peak expiratory flow, VA = alveolar ventilation, Vt= tidal volume, RR = respiratory rate, PS= pressure support, Ti = 
inspiratory time. 
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Airway resistance and ventilation had low within patient day-to-day variability as expressed 
by the low CV (<15%) for the measured parameters. PEF was reasonably constant with an 
8% mean day-to-day variability. There was large inter-patient variability (CV range: 3- 19%) 
in the heterogenous patient group. Ventilator use varied night-to-night by 17%. The most 
variable ventilator parameter was the unintentional leak (125%) which was highly variable in 
all patients. Other raw ventilator-measured parameters remained relatively stable. Derived 
ventilation parameters, such as triggered breaths and ineffective efforts, varied significantly 
more than the raw parameters (CV >15%).  Of note, the CV of PS was greater in the 
restrictive patients, however this might be explained by the lower mean PS with a higher SD. 
‘Normal’ variability of each ventilator parameter during ‘stable’ state was assumed to be 
within 1.96*SD above and below the patients’ stable means. ie. representing 95% of 
measures on symptom-free days (see Table 3-3).  Therefore, on 95% of symptom-free days, 
patients would expect to have PEF measures within ±31L/min around their stable mean 
value. As a group, the ‘normal’ range of ventilation parameters above and below stable 
mean values were; VA ±1.9L/min, PS ±2cmH2O, Vt ±145ml, and RR ±1.2bpm. Leak had 
greatest variability (CV 125%) equating to a variation of ±10.2L/min around the mean. 
Factors that could affect absolute measures or day-to-day variation in PEF and ventilator-
measured parameters, particularly the VA, were investigated further and are presented in 
Table 3-4. A stringent threshold for significance was set at p<0.01 due to the explorative 
nature of this analysis. 
Mean VA was greater in obstructive patients than restrictive patients (p=0.04). A higher 
mean overnight PS (p=0.001) led to higher Vt (p=0.004) and ultimately the higher VA. 
Variability of these parameters (represented by the group SD) did not vary between 
pathologies. 
A higher baseline tcPCO2 was correlated with a lower mean PEF (r=-0.48; p=0.008) but not 
with day-to-day variability of PEF. Patients with worse baseline gas exchange (tcPCO2 and 
SpO2) had a higher mean PS (p=0.03 and p=0.006 respectively), but no greater variability of 
PS. Therefore, no measure was predictive of the variability of parameters during stable 
state.  
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Table 0-3: Correlation in absolute and day-to-day variation (mean (SD)) during stable state in PEF and ventilator-measured parameters (VA, Vt, 
RR, PS) with patient characteristics; n=29 
 Pathology: Obstructive (19) v  
Restrictive (10) 1 
Baseline  
tcPCO2 (kPa)
2 
Baseline  
SpO2 (%) 
2 
Baseline PEF 
(L/min)2 
 
Mean PEF (L/min) 199 v 225 
p=0.45 
r= -0.48 
p=0.008* 
r= 0.31 
p=0.1 
r= 0.70 
p<0.001* 
 
SD PEF (L/min) 17 v 13 
p=0.38 
r= -0.16 
p=0.42 
r= 0.15 
p=0.44 
r= 0.40 
p=0.03 
 
Mean VA (L/min) 9.9 v 6.1 
p=0.004* 
r= -0.11 
p=0.59 
r= 0.02 
p=0.92 
r= 0.38 
p=0.04 
 
SD VA (L/min) 1.1 v 0.8 
p=0.48 
r= 0.25 
p=0.19 
r=  -0.08 
p=0.7 
r= -0.10 
p=0.62 
 
Mean Vt (ml) 738 v 459 
P=0.004* 
r= -0.19 
p=0.33 
r= 0.05 
p=0.78 
r= 0.43 
p=0.02 
 
SD Vt (ml) 81 v 60 
p=0.55 
r= 0.19 
p=0.32 
r= -0.03 
p=0.9 
r= -0.06 
p=0.74 
 
Mean RR (bpm) 16 v 18 
p=0.04 
r= 0.12 
p=0.52 
r= 0.06 
p=0.76 
r= -0.21 
p=0.29 
 
SD RR (bpm) 0.7 v 0.6 
p=0.8 
r= -0.12 
p=0.53 
r= 0.26 
p=0.18 
r= -0.07 
p=0.71 
 
Mean PS (cmH2O) 15 v 10 
p=0.01* 
r= 0.4 
p= 0.03 
r= -0.5 
p=0.006* 
r= -0.19 
p=0.32 
 
SD PS (cmH2O) 1 v 1 
p= 0.30 
r= 0.06 
p=0.75 
r= 0.26 
p=0.18 
r= -0.00 
p=0.99 
 
Statistics: 1=t-test, 2= Pearson correlation. Due to the explorative nature of this analysis, a more stringent threshold for significance was set at p=0.01 rather than performing formal 
corrections for multiple analyses. SD= standard deviation, PEF= peak expiratory flow, VA = alveolar ventilation, Vt= tidal volume, RR = respiratory rate, PS= pressure support, tcPCO2 = 
transcutaneous carbon dioxide, SpO2= oxygen saturation.
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The a priori notion that the variability in day-to-day PEF may influence the variability of the 
ventilator-measured parameters was not substantiated during stable (symptom-free) state. 
No ventilator measure correlated with variability of PEF during stable state as can been seen 
by the low r values and the p values > 0.01 in Table 3-5.   
Table 0-4: Correlation of the day-to-day variability in stable state PEF (SD stable PEF) with 
absolute and day-to-day variation (mean (SD)) in PEF and ventilator-measured parameters 
(VA, Vt, RR, PS); n=29 
 SD Stable PEF (L/min) 
Mean PEF (L/min) r= 0.40 
p=0.03 
SD PEF (L/min) n/a 
n/a 
Mean VA (L/min) r= 0.43 
p=0.02 
SD VA (L/min) r= -0.16 
p=0.42 
Mean Vt (ml) r= 0.06 
p=0.78 
SD Vt (ml) r= 0.15 
p=0.45 
Mean RR (bpm) r= 0.46 
p=0.01 
SD RR (bpm) r= -0.16 
p=0.41 
Mean PS (cmH2O) r= -0.26 
p=0.17 
SD PS (cmH2O) r= 0.09 
p=0.63 
Pearson correlation. Due to the explorative nature of this analysis, a more stringent threshold for significance was set at 
p<0.01. SD= standard deviation, PEF= peak expiratory flow, VA = alveolar ventilation, Vt= tidal volume, RR = respiratory 
rate, PS= pressure support, tcPCO2 = transcutaneous carbon dioxide, SpO2= oxygen saturation. 
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3.3.3 Time course of changes in PEF and ventilator-measured parameters prior to, at 
onset, and with recovery of exacerbation 
Nineteen of the 30 patients exacerbated at least once; 75% of obstructive patients and 50% 
of restrictive patients. There were a total of 42 exacerbations; median (range) of 2 (1 to 8) 
per patient. 22 were untreated. Treated exacerbations were self-treated (n=12), physician-
treated (n=7) and there was one hospital admission. Antibiotics and oral steroids were used 
separately in 7 and 3 exacerbations respectively and combined therapy (antibiotic and 
steroid) was used in 10 exacerbations. Median (range) delay in treatment from onset was 
2.85 (0 to 11) days. There were 5 further instances when patients initiated treatment 
(antibiotics and/or oral steroids) but did not report an increase of symptoms in their diary 
(n=4 self-treated). 
Only the first exacerbation in each patient was considered for this analysis.  Of the 19 
exacerbators, three patients did not use their ventilator on all 15 days of exacerbation 
monitoring and one patient did not perform PEF measures during their exacerbation. Data 
from a total of 15 exacerbations in 15 subjects was therefore used for subsequent analysis; 
240 patient days of exacerbation monitoring. 
Of the 15 included exacerbations, 4 were untreated, 7 were self-treated, 4 were physician-
treated and there were no hospital admissions. In the 11 treated exacerbations, 5 used 
antibiotics, 1 used oral steroids and 5 used combined antibiotics and oral steroids. These 
findings were consistent with the events not included in this analysis. 
The time course through the prodrome (days -7 to -1), onset (day 0) and recovery (days 1 to 
7) of 15 exacerbations is shown in Figures 3-4 and 3-5. The day of exacerbation onset was 
symptom-defined. Symptom count and the SD units (representing variation from the stable 
state mean) of PEF and ventilator-measured parameters are plotted for each day. At 
baseline (Day -7), these would be expected to be zero.  Obstructive and restrictive patients 
are compared in Figure 3-6.  
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Figure 0-3: Time course of symptoms, PEF and ventilator-measured parameters at 
exacerbation.  
Time course of symptom count, peak expiratory flow (PEF) and ventilator parameters, alveolar ventilation (VA), pressure 
support (PS), respiratory rate (RR), and tidal volume (Vt) from seven days prior (-7) to exacerbation onset (day 0, vertical 
line) and seven days into exacerbation (+7) of chronic respiratory failure. Mean ventilator values from 15 exacerbations 
in 15 patients are expressed as SD multiples away from each patient’s stable mean. Dashed lines represent ± 1.96 
standard deviations away from a mean, where 95% of all stable measures would be expected to fall.  The symptom 
count is the overall mean of the daily symptoms recorded. 
 124 
a) 
 
b) 
 
Figure 0-4: Time course of a) PEF and b) ventilator-measured parameters at exacerbation 
(n= 15 exacerbations in 15 patients)  
Time course of peak expiratory flow (PEF) and ventilator parameters, alveolar ventilation (VA), pressure support (PS), 
respiratory rate (RR), and tidal volume (Vt) from seven days prior  (-7) to exacerbation onset (day 0, vertical line) and 
seven days into exacerbation (+7) of chronic respiratory failure. Values are expressed as mean and 95% CI (in SD 
multiples away from each patient’s stable mean) for each variable. Dashed lines represent ± 1.96 standard deviations 
away from a mean, where 95% of all stable measures would be expected to fall.   
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a) 
 
b) 
 
 
Figure 0-5: Time course of a) PEF and b) ventilator-measured parameters at exacerbation in 
patients with obstructive and restrictive lung disease; n=12 obstructive (black lines) and n= 3 
restrictive (pale grey lines).  
Time course of peak expiratory flow (PEF) and ventilator parameters, alveolar ventilation (VA), pressure support (PS), 
respiratory rate (RR), and tidal volume (Vt) from seven days prior  (-7) to exacerbation onset (day 0, vertical line) and 
seven days into exacerbation (+7) of chronic respiratory failure. Values from 15 exacerbations in 15 patients are 
expressed as mean and 95% CI (in SD multiples away from each patient’s stable mean) for each variable. Dashed lines 
represent ± 1.96 standard deviations away from a mean, where 95% of all stable measures would be expected to fall.   
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PEF during exacerbations: There was already an increase in symptoms and a decrease in 
PEF at 7 days prior to the symptom-defined onset of exacerbation (day 0), as seen in Figure 
3-4 suggesting deterioration in respiratory function prior to the identification of 
exacerbations by the symptom-diary protocol.  
The maximal magnitude of change in any variable was the reduction in PEF on the day of 
onset of exacerbation. However this did not fall outside of the 1.96*SD normal variability. 
PEF remained low throughout the following 7 days, with the lowest deviation away from the 
patients’ mean recorded on day 3 of the exacerbation (an average reduction in PEF of 
<30L/min). 
Maintenance of VA during exacerbations: VA was maintained throughout the prodrome and 
during the exacerbation, despite the variability in PEF. Surprisingly, no ventilator-measured 
parameter had greater variation in SD units than the PEF. RR and PS were relatively stable 
over the 15 days. No difference between obstructive and restrictive pathologies was seen in 
the variability of parameters over the time course of the exacerbation (see Figure 3-6). 
The Vt, however, displayed a sharp decrease at days 3 and 4 followed by a sharp increase on 
day 5. When data from individual patients were examined (Figure 3-7), the sharp decline in 
Vt was observed only in a single patient with COPD GOLD stage III; Day 4 represented her 
peak symptom count totalling 5 new symptoms and on day 5 she saw her GP and started 
antibiotics. If excluded from analysis, there was obviously less variation in the overall mean 
of the Vt, consistent with the stability in other parameters (see Appendix 13). 
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Figure 0-6: Individual patient data for the time course of ventilator-measured parameters 
during exacerbation (alveolar ventilation (VA), and tidal volume (Vt)); n=15. 
Data from 15 exacerbations in 15 individual patients from seven days prior (-7) to exacerbation onset (day 0, vertical line) 
and seven days into exacerbation (+7).  The outlier (blue line) is a patient with COPD GOLD 3; Day 4 represented her peak 
symptom count totalling 5 new symptoms and on day 5 she saw her GP and started antibiotics. Her Vt dropped from 610ml 
on day 2 to 530ml on day 3, then sharply increased to 720ml on days 5 and 6.  She had a productive cough with copious 
sputum.  
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Mechanisms of maintenance of VA during exacerbation: Other possible mechanisms were 
investigated to explain how the VA was maintained despite no change in PS, Vt or RR.  These 
included the inspiratory time (Ti) and unintentional mask leak (See Figure 3-8). High 
resolution breath-by-breath data was also analysed to calculate percentage of patient 
triggered breaths and ineffective efforts, however there was no significant changes in the SD 
units in any of these variables with the time course of the exacerbation. 
 
 
Figure 0-7: Time course of symptoms and ventilator-measured parameters at exacerbation 
(n= 15 exacerbations in 15 patients)  
Time course of ventilator parameters, inspiratory time (Ti), unintentional mask leak, percentage of patient triggered 
breaths and ineffective efforts from seven days prior  (-7) to exacerbation onset (day 0, vertical line) and seven days into 
exacerbation (+7) of chronic respiratory failure. Values are expressed as mean and 95% CI (in SD multiples away from 
each patient’s stable mean) for each variable. Dashed lines represent ± 1.96 standard deviations away from a mean, 
where 95% of all stable measures would be expected to fall.   
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3.3.4 The ability of ventilator-measured parameters and PEF to differentiate 
exacerbation onset from a) stable (symptom-free) days and b) symptom days 
Following the analysis of a 15 day time series during prodrome, onset and recovery of 
exacerbation, I compared all 3 months of monitored days according to the presence (or not) 
of symptoms. This analysis was based on 1153 days of followup; 767 symptom-free days, 
370 symptom days, and 16 exacerbation onset days. The means of the nightly SD units of 
the PEF and ventilator parameters were compared across each of these disease states by 
ANOVA and post hoc t-tests were performed with Bonferroni correction (See Table 3-6). 
Post hoc paired t-tests revealed significant differences in PEF with lower measures recorded 
on both symptom days and exacerbation onset days than on symptom-free days (p<0.001). 
The only ventilator-measured parameters that showed a difference between symptom-free 
days and symptom days were unintentional mask leak, which decreased (p=0.001), and the 
percentage of breaths triggered by the patient, which increased (p=0.001). These changes 
however were not significant on the day of exacerbation onset suggesting that physiological 
changes and their associated ventilator reactions occur prior to exacerbation onset when 
perhaps only a single symptom is apparent, or symptoms presence is labile. 
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Table 0-5:  Comparison of ventilator parameters (nightly SD units) on symptom-free days, 
symptom days and exacerbation onset days by ANOVA.  
 Symptom-free 
days 
(n=767) 
Symptom 
days 
(n=370) 
Exacerbation 
onset 
(n=16) 
p 
PEF (SD units) 0.06 (1.3)*‡ -0.72 (1.8) * -0.94 (1.2) ‡ <0.001 
Nightly NIV Use (SD units) -0.16 (1.3) -0.16 (1.5) 0.07 (1.3) 0.80 
VA (SD units) 0.21 (1.5) -0.29 (6.7) -0.43 (1.4) 0.12 
PS (SD units) -0.23 (2.5) -0.46 (3.4) -0.18 (0.7) 0.41 
Vt (SD units) 0.16 (1.6) -0.28 (8.3) -0.68 (1.2) 0.31 
RR (SD units) 0.06 (2.1) -0.09 (1.4) 0.2 (0.8) 0.45 
Ti (SD units) 0.07 (1.1) 0.1 (1.3) 0.25 (0.7) 0.78 
Leak (SD units) 0.55 (1.7)* 0.16 (1.6)* 0.05 (1.0) 0.001 
% Patient Triggered Breaths 
(SD units) 
-0.1 (1.5)* 0.24 (1.6)* -0.2 (1.7) 0.002 
Ineffective Efforts (SD units) 0.08 (1.6) 0.29 (1.5) 0.61 (2.3) 0.54 
Post hoc analysis with Bonferonni correction: * significant between symptom-free and symptom, †  significant between 
symptom-free and onset;  p<0.05 considered significant. SD= standard deviation, PEF= peak expiratory flow, NIV = non-
invasive ventilator, VA = alveolar ventilation, Vt= tidal volume, RR = respiratory rate, PS= pressure support, Ti= 
inspiratory time 
 
 131 
3.3.5 The ability of ventilator-measured parameters to differentiate between days with 
maximal difference in airways resistance – ie. between days recording highest and 
lowest PEF 
In the previous analysis an assumption was made; that Day -7 (ie. 7 days before 
exacerbation onset) was representative of ‘baseline’ and therefore should record zero SD 
units (ie. stable state). However, neither the symptom count, PEF nor any ventilator-
measured parameters were at a baseline of zero at the beginning of the 15 day time course 
of the exacerbations examined. Therefore, a symptom-defined exacerbation may not have 
represented the time at which the ventilator had to overcome greatest respiratory 
physiological changes. 
To determine the maximum physiological change that the iVAPS ventilator would have to 
account for during the analysis period, I examined the ventilation delivered on the day of 
the highest reported PEF (maximum PEF) and the lowest (minimum PEF) for each individual 
patient over the entire follow up period. All 30 patients were included in this analysis. 
By design, there was obviously a significant difference in PEF between the maximum and 
minimum days (p<0.01) as seen in Table 3-7. There were more symptoms reported (1 (0 to 
3) v 0 (0 to 1); p<0.01) and more treatments recorded on the day that patients measured 
their minimum PEF when compared to the day that they measured their maximum.  Again 
the VA was similar on both days, and there was surprisingly still no difference in any of the 
ventilator parameters between these two days. 
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Table 0-6: Comparing the group median (IQR)s of daily measures on the days an individual 
measured their minimum and maximum peak expiratory flow (PEF) measures during the 
analysis period; n=30 
 Minimum PEF Day 
(n=30) 
Maximum PEF Day 
(n=30) 
p 
Daily patient diary:    
Peak Flow (L/min) 145 (100 to 200) 225 (170 to 303) <0.01 
Daily Hours Out Of House 2.3 (0.0 to 5.8) 1 (0.0 to 2.8) 0.08 
No. of symptoms reported (n) 1 (0 to 3) 0 (0 to 1) <0.01 
No. of treatments 0 (0 to 1) 0 (0 to 0) 0.03 
    
Ventilator-measured parameters:    
Nightly Ventilator Use (mins) 501 (408 to 597) 526 (427 to 570) 0.68 
Minute Ventilation (L/min) 9.9 (7.5 to 12.6) 9.8 (7.9 to 11.5) 0.78 
Alveolar Ventilation (L/min) 8 (5.6 to 10.5) 8 (6.2 to 9.6) 0.74 
Tidal Volume (ml) 615 (440 to 743) 565 (458 to 668) 0.26 
Respiratory Rate (bpm) 16 (15 to 18) 16 (15 to 19) 0.07 
IPAP (cmH2O) 19 (16 to 22.3) 19.3 (15 to 22.7) 0.68 
Pressure Support (cmH2O) 13.3 (10.5 to 15.7) 13.6 (10 to 16.7) 0.57 
Inspiratory Time (sec) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 0.83 
I:E 0.5 (0.5 to 0.7) 0.6 (0.5 to 0.7) 0.13 
Leak (L/min) 2 (0 to 10.5) 2 (0.8 to 10) 0.71 
% patient triggered breaths (%) 0.05 (0.03 to 0.08) 0.05 (0.03 to 0.10) 0.76 
Ineffective efforts (n) 402 (122 to 748) 333 (101 to 572) 0.61 
Data expressed as median (IQR) and days were compared by Wilcoxon signed rank (non-parametric related samples). 
PEF= peak expiratory flow, IPAP = inspiratory positive airway pressure, I:E = inspiratory to expiratory ratio. 
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3.3.6 Individual variation in ventilator responses to exacerbations 
 
Ten of the 19 exacerbators went on to have further exacerbations during the follow-up 
period. Figure 3.9 compares individual patient data during repeat exacerbations. PEF and 
ventilator-measured parameters are shown for days -14 to 14 of exacerbations. 
There appears to be within patient consistency in both the PEF response and the ventilation 
delivered during exacerbations. Each patient, however, displays individual day-to-day 
variations in each of the ventilator parameters. This is in keeping with the wide range of CV 
values for the ventilator parameters between patients. 
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Figure 0-8 Individual patient data (PEF and ventilator-measured parameters) during the time course of repeat exacerbations.  
Time course of peak expiratory flow (PEF) and ventilator parameters, alveolar ventilation (VA), pressure support (PS), respiratory rate (RR), and tidal volume (Vt) from fourteen days prior  
(-14) to exacerbation onset (day 0, vertical line) and fourteen days into exacerbation (+14) 
a) Patient with variable PEF: VA varies with the changing Vt, as the PS appears to have reached the maximum tolerated and is unable to further respond 
b) Patient with steady PEF: VA remains stable, with large fluctuations in the PS which maintain Vt; RR remains steadily high 
Continued on next page 
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Figure 0-9 Individual patient data (PEF and ventilator-measured parameters) during the time course of repeat exacerbations.  
Time course of peak expiratory flow (PEF) and ventilator parameters, alveolar ventilation (VA), pressure support (PS), respiratory rate (RR), and tidal volume (Vt) from fourteen days prior  
(-14) to exacerbation onset (day 0, vertical line) and fourteen days into exacerbation (+14) 
c) Patient with variable PEF: VA remains stable; PS fluctuates to maintain Vt in the presence of a stable RR 
d) Patient with steady PEF: VA has large fluctuations due to fluctuations in Vt with not a lot of response by either the RR or PS to correct and maintain VA 
Continued from previous page 
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3.3.7 Longterm outcome of NIV 
Switching from standard PS ventilation to iVAPS did not result in any changes in daytime 
blood gases. Ventilatory control was maintained with no change in either SaO2 or tcPCO2 
from baseline to 4 months. This was the same for both obstructive and restrictive 
pathologies. There was no significant change in the BMI, lung function, or health-related 
quality of life measures across the 4 months, except for the SGRQ symptom domain which 
was significantly lower at 4 months than at baseline (p= 0.04). Therefore, daily self-
monitoring of health status did not cause psychological detriment in these patients with 
chronic disease (Data presented in Appendix 14). 
3.4 Discussion: 
The main finding of this study was that stable-state alveolar ventilation is maintained during 
exacerbations in patients receiving domicillary autotitrating iVAPS ventilation.  This occurs 
despite increasing airway resistance measured by PEF. The mechanism for maintenance of 
VA is likely to be a combination of factors including patient-ventilation interaction, 
specifically patient triggering of the ventilator. The study did not find any one ventilator-
measured parameter that could differentiate between exacerbation and stable state, or 
signal the onset of an exacerbation. Exploratory data reveal inter-patient differences in 
ventilatory responses to changes in airway resistance. However individual patients tend to 
respond similarly during repeat exacerbations identified by symptom diaries. 
Timely detection and early treatment of exacerbations plays an important role in the 
management of chronic respiratory disease, resulting in more favourable outcomes 
(Seemungal, Donaldson et al. 1998). However, exacerbations are often unreported or 
diagnosis is delayed, potentially delaying or even preventing treatment and thereby 
worsening their effect (Wilkinson, Donaldson et al. 2004).  In the absence of a biomarker or 
reliable objective lung function measure, recent studies have investigated the feasibility of 
using data acquired from ventilatory support devices (LTOT and NIV) to monitor patients 
over time and even predict exacerbations (Yanez, Guerrero et al. 2012; Borel, Pelletier et al. 
2015). Subjectivity of symptom recognition and additional monitoring of daily observations 
can therefore be avoided. Both studies have reported that increasing patient RR can be 
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predictive of an impending exacerbation. The current study did not support this. Indeed 
none of the ventilator-measured parameters observed could either detect or predict 
exacerbations. There can be several reasons for this. 
Ventilator mode: In standard PS ventilation, Vt (and therefore VA) for a given level of PS may 
decrease with increases in airway resistance (eg. during bronchospasm, sputum plugging 
and inflammation) associated with respiratory exacerbations. To maintain VA, patients will 
increase RR due to the high WOB associated with increasing their own Vt. This is true also of 
patients without ventilatory support and RR was observed to increase pre hospitalisation 
with an exacerbation in patients with COPD (Yanez, Guerrero et al. 2012).  In the NIV study 
performed by Borel and colleagues, standard PS was the mode in use (Borel, Pelletier et al. 
2015). They observed that RR increased in patients prior to an exacerbation as detected by 
either an increase in the ventilator-measured RR or by an increase in the percentage of 
patient-triggered breaths. In the current study, ventilator-measured RR did not increase 
during exacerbations. However the percentage of patient triggered breaths observed on 
symptom days was greater when compared to symptom-free days, suggesting that RR did 
contribute to VA maintenance as reported by Borel et al. In VAPS ventilation, however, the 
targeted VA can be maintained by not only an increase in RR, but also in PS. Previous bench 
testing of volume-asssured (VAPS) ventilators, has shown successfully maintained target 
volumes (Vt and VA) during different conditions associated with alveolar hypoventilation, 
namely increased airways resistance, decreased lung compliance (Fauroux, Leroux et al. 
2010) and leak (Oscroft and Smith 2010).  Reponse to an acute increase in Raw (and 
resultant reduction in Vt by one third) was typically an increase of IPAP by 3-10cmH2O. In 
the current in vivo study, however, there was no significant increase in PS observed, even 
between the days of maximum difference in a patient’s PEF (representing greatest 
difference in Raw). The lack of acute change could be due to a more graduated response 
over time or attributable to a combination with changes in other parameters also played a 
role in VA maintenance (eg: RR, Ti).  
Patient diagnosis: The pathologies of the patients included in the study were heterogenous 
and the severity of exacerbations varied. Mechanisms of respiratory failure, and the action 
of NIV, differs between diseases, therefore the postulated changes to ventilator support 
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may also have varied. In exacerbations of COPD, a rapid shallow breathing pattern often 
occurs due to the increased work of breathing associated with increased airflow limitation 
(O'Donnell and Parker 2006). Indeed in exacerbating COPD patients, this may explain the 
increases in RR observed by both Yanez et al and Borel et al. (Yanez, Guerrero et al. 2012; 
Borel, Pelletier et al. 2015).   
In patients with NMD, parameters such as RR may be underreported and as such prevent 
detection of change. Muscle weakness is accentuated by exacerbation (Poponick, Jacobs et 
al. 1997), and the patient’s own inspiratory flow rate may be insufficient to trigger the 
ventilator-supported breath. Insufficient patient efforts might also go undetected by the 
ventilator, with a subsequent under-reporting of both actual RR and of patient ventilator 
asynchronies (including ineffective efforts). Additionally, patients with restrictive disease 
have small lung capacities and variations in airflows and volumes are small. This may have 
resulted in ventilator changes, including PS alterations, which were small and difficult to 
detect. 
Individual variation: To date there have been no published data on the normal variability of 
ventilator parameters during auto-titrating ventilation in VAPS mode where PS and RR are 
automatically adjusted to maintain VA. Normal variation of PEF during stable state in a 
homogenous COPD group is reported as PEF 20L/min above and below patient mean (Hurst, 
Donaldson et al. 2010). In the current study, higher variability was observed (±36L/min), 
potentially due patients with mixed pathologies (incorporating asthma) and also potentially 
due to more severe disease. The high variability of PEF seen in stable state, when VA is 
maintained, suggests that constant titration of ventilator support is taking place during 
stable state as well as during exacerbation. Indeed, the normal variation of PS during stable 
state was 2cmH2O above and below the mean, supporting the notion that the ventilator is in 
a state of constant adjustment.  
Additionally, exploratory analysis has revealed a distinct individuality of breathing patterns 
between patients, and the ventilator response to changes in Raw. iVAPS ventilation may 
therefore magnify individual differences.  
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Exacerbation definition and analysis: in exacerbation research studies remains inconsistent, 
and can therefore affect interpretation. Baseline ‘stable state’ in the current study was 
calculated from a 30 day period and ‘exacerbations’ were symptom-defined as per 
Seemungal et al. (Seemungal, Donaldson et al. 2000). Standardisation of parameters, by the 
use SD units, allowed comparison of all parameters, accounting for individual patient 
differences. Borel et al. (Borel, Pelletier et al. 2015) used a moving 5 day average of raw 
values of parameters to determine stable state. They had exacerbation onsets validated by 
2 chest physicians, potentially capturing only more severe exacerbations.  
The time course of exacerbations also presents analytical challenges. The timeframe and 
characteristics of the prodrome, onset and recovery from exacerbations can vary greatly 
between patients. In the existing literature, 5, 7 and 14 day periods are frequently chosen 
for examination in the attempt to detect changes. Alternatively moving daily/ weekly 
averages allow a less time constrained analysis. Yanez et al. (Yanez, Guerrero et al. 2012) 
have shown increased sensitivity and specificity of using RR to predict exacerbations as 
onset approaches (greatest at 24 hours prior to admission). Borel et al. (Borel, Pelletier et al. 
2015) demonstrate increasing risk of exacerbation with abnormally high RR values (or % 
patient triggered breaths) on 2 or 3 days out of 5.    
Heterogenous pathophysiology could also have affected the time course of exacerbations in 
the current study. In COPD, it has been shown that symptoms do not reflect changes in lung 
function (Seemungal, Donaldson et al. 1998; Seemungal, Donaldson et al. 2000). Symptoms 
including dyspnoea, sore throat, cough and cold, begin 7 days prior to exacerbation onset 
and increase significantly. However, there is with no decline in physiology observed until the 
day of onset of exacerbation; PEF has been shown to fall by averages ranging from 6.6 to 
8.6L/min. This is consistent with the reduction from stable state of 7L/min observed in the 
current study. This equates to a reduction of only 5% from baseline, however in asthma 
significantly greater reductions in PEF of up to 50% can be detected. Changes in asthma are 
also present from 10 days pre exacerbations increasing rapidly within 2-3 days of the onset 
(Tattersfield, Postma et al. 1999).  
In the current study a prodrome of 7 days was used in keeping with literature (Seemungal, 
Donaldson et al. 2000; Donaldson, Seemungal et al. 2002; Hurst, Donaldson et al. 2010).  
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This may not have been sufficient time to observe changes in some of the patients studied. 
However in exploratory analyses I examined 14 days either side of the day of onset, and also 
14 days prior until exacerbation resolution. There was no change in the results with either 
approach (see Appendices 15 and 16). 
Maintenance of VA: To my knowledge, the present study is the first to report on the 
maintenance of VA in vivo during exacerbation of respiratory disease. Respiratory function 
worsens during exacerbations, which may reduce efficacy of standard ventilatory support. 
The findings of this study enable clinicians to be confident that during NIV in iVAPS mode, 
the patients’ minute alveolar ventilation will be maintained even if their respiratory function 
deteriorates. This was shown to occur both when patients were aware of deterioration of 
their symptoms and also during times when airway resistance was increased, independent 
of symptoms.  
3.4.1 Methodological issues and study limitations 
In this study, there was a lack of homogeneity in pathology, exacerbation severity 
(untreated vs hospitalisation), and treatment. I have addressed each of these issues with a 
structured analysis plan. I have also considered alternative options for ‘exacerbation’ 
identification.  
Exacerbations are difficult to define, and therefore to diagnose, not least for the patients 
who often have limited function and a high symptom burden even during periods of relative 
stability.  A feature of exacerbations is an increased symptom burden which can be 
monitored by a symptom diary. To be consistent with literature on COPD exacerbations, I 
used the definition employed by the London COPD cohort group which is a symptom-based 
definition. However, this definition was only validated in COPD and not other disease groups 
which made up half of this cohort. The EXAcerbations of Chronic Pulmonary Disease Tool 
(EXACTPro) as used by Borel et al. (Borel, Pelletier et al. 2015) is a 14-item patient reported 
outcome-diary that has recently been validated in COPD patients (Leidy, Wilcox et al. 2010) 
and is described in Chatper 2, section 5.1). It can be used to reliably evaluate disease 
exacerbation severity and is sensitive to change, but when compared to the widely validated 
London COPD cohort diary cards, less than a third of exacerbations were identified (Mackay, 
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Donaldson et al. 2014). Therapy and event based exacerbations may represent greater 
severity, however using this definition may miss the numerous (but just as harmful) 
unreported exacerbations. Indeed, in the relatively sick patients recruited to this study, with 
a level of respiratory dysfunction necessitating nocturnal ventilatory support, and known 
frequent exacerbators, we observed relatively few hospital admissions for their 
exacerbations. This, too might explain the higher exacerbation rate (63% v 48%) in 
comparison to Borel et al. (Borel, Pelletier et al. 2015). 
This was a real world study that had to incorporate clinical practice. Patient adherence to 
treatment was a key factor, therefore patient comfort, tolerance and safety was paramount 
in determining ventilator settings, in particular the maximum and minimum PS. This meant 
that the settings were not always set to support maximum PS variability, and a relatively 
lower RR than was learnt from the patients’ own wake spontaneous breathing pattern.  
3.5 Conclusion 
iVAPS was successful in maintaining VA during exacerbations, both symptom-defined and 
during peak physiological change, in patients receiving chronic NIV therapy.  However, I 
have been unable to define the exact mechanism responsible for this.  Potential reasons for 
this may be the heterogenous casemix as well as individual variation. I did not identify any 
changes in ventilator parameters that could be used to signal exacerbations prior to 
symptom identification During exacerbations, airway physiology and the associated 
ventilator responses, are likely to be different across pathologies and within individual 
patients. iVAPS ventilation, which autotitrates both PS and RR, may therefore exaggerate 
the differences of normal variations.  
Therefore, one could recommend studying a larger cohort of patients with obstructive 
disease who have larger volumes and greater variation in their airway function. Patients 
with COPD GOLD stage III would be ideal. The numbers required to detect smaller changes 
in ventilatory parameters in restrictive pathologies would make such an exploratory study 
less feasible. Using time-series analysis would not restrict the prodrome to a single time 
period. Limiting analysis to exacerbations severe enough to require hospitalisation may 
enable periods of greater physiological change to be examined.  
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4 THE EFFECTS OF SLEEP ON ALVEOLAR VENTILATION DURING AUTOTITRATING iVAPS 
NIV  
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4.1 Introduction 
Sleep is a physiological challenge to patients with chronic respiratory failure. During sleep, 
minute ventilation decreases due to the combined effects of reduced chemosensitivity, 
respiratory muscle responsiveness and increased upper airway resistance (Phillipson 1978; 
Douglas, White et al. 1982; Douglas, White et al. 1982; Douglas, White et al. 1982). Tidal 
volume is reduced progressively across sleep stages, with a further reduction during the 
REM-induced hypotonia of accessory respiratory muscles. The net effect of this 
hypoventilation is a rise in PCO2 of approximately 1.1kPa.  In patients with lung disease, 
nocturnal hypoventilation may lead to or worsen existing respiratory failure (McNicholas 
2003).  
Nocturnal NIV is used to augment a patient’s own insufficient minute ventilation thus 
preventing arterial blood gas disturbance during sleep (Mehta 2001). However, standard PS 
NIV has previously been shown to incompletely ameliorate hypoventilation during sleep, 
with reductions in minute ventilation between 10-24% observed despite NIV therapy 
(Milross, Piper et al. 2001; Ambrogio, Lowman et al. 2009). Additionally, a reduction of Vt by 
33% during NIV therapy has been shown to lead to persistent hypercapnia (Rabec, Georges 
et al. 2009). 
It has been suggested that volume-limited ventilation may give a more stable minute 
ventilation in the face of changing physiology, however these fixed modes of ventilation 
have been less well tolerated (MacIntyre 1986). VAPS ventilation is a more recent hybrid 
mode of NIV that targets a pre-determined minute VA through the constant autotitration of 
the pressure support delivered within preset boundaries (see Chapter 2, section 3). This 
mode of ventilation has potential benefit during sleep, while still providing the comfort 
benefits of pressure-limited ventilation.  However, NIV is usually intiated during wakefulness 
with empirical or default parameters, suited to underlying disease and patient tolerance.  
While adequate ventilation might be achieved during supported daytime wake ventilation, 
therapy may be inadequate during sleep. With the new intelligent autotitrating ventilator, 
automatic setting selection after a learn period allows the ventilator to set a target VA 
equivalent to an individual’s daytime ventilation requirement.  
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Studies of VAPS modes of ventilation have had mixed outcomes in the control of nocturnal 
hypoventilation in comparison to standard PS NIV therapy, however notable benefits have 
been observed particularly in OHS (Murphy, Davidson et al. 2012). Only one trial has 
compared ventilation across individual sleep stages (Ambrogio, Lowman et al. 2009). In this 
prospective crossover study of 28 patients with chronic respiratory failure, VAPS (AVAPS; 
Respironics, USA) provided significantly greater MV than standard PS. This study also found 
a smaller decrease in MV during sleep compared to wakefulness and less variability of MV 
during AVAPS compared to standard PS. The clinical implications of this however are not 
clear. Continuous nocturnal CO2 monitoring was not performed and oxygen saturation was 
not compared across sleep stages. However, a 230ml decrement in MV was associated with 
a 1% decrement in SpO2 (r
2 = 0.01; p=0.04) and AVAPS tended to keep minimum SaO2 higher 
than standard PS suggesting that the higher nocturnal MV during AVAPS  would have a 
similar advantageous effect on the maximum overnight PCO2. In summary, a ventilator that 
targets, and achieves, constant VA across wake and sleep stages may provide improved 
blood gas homeostasis. 
The aim of this study was to determine the effect of sleep on ventilator-measured 
parameters and physiological outcomes in patients with obstructive and restrictive 
pathologies receiving nocturnal iVAPS NIV.  I tested the hypothesis that VA would be 
maintained during sleep with iVAPS therapy. I also investigated the clinical effect on the 
control of nocturnal hypoventilation (O2/CO2). The underlying mechanism for the assumed 
maintenance of VA was also investigated. Additionally, I determined the ‘normal’ variation of 
ventilator-measured parameters across sleep stages during iVAPS therapy. 
The ventilator mode used in the study presented in this chapter (iVPAS) contrasts with the 
one used by Murphy et al. (AVAPS) in that it targets VA rather than MV or Vt, thus negating 
the effect of changes in RR on MV (see Chapter 2, section 3.4) . Additionally, iVAPS has the 
benefit of an intelligent automatic selection of ventilation parameters based on a learn 
period. The nocturnal ventilation targets are thus set equivalent to the individual patient’s 
daytime ventilation requirement and breathing pattern.  
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4.2 Methods 
4.2.1 Patients 
Thirty adult patients were studied as a subset of the patients studied in Chapter 3. Patients 
had heterogenous chronic respiratory disease and were already established on NIV for 
either CRF or nocturnal hypoventilation. Diagnoses included severe COPD, chronic asthma, 
NMD, OHS or CWD. 
Patients were treated with long-term NIV, but were swapped to iVAPS ventilation (Stellar 
150; ResMed, Australia) one week prior to the sleep study (PSG). The PSG together with 
overnight capnography and oximetry were performed on NIV for titration purposes.  
Patients were stable, free from acute exacerbation. 
4.2.2 Protocol and measurements 
Patients underwent a single night PSG using iVAPS ventilation, up to one week after 
swapping to this new ventilation mode. Full PSG (SOMNOscreen; SOMNOmedics GmbH and 
Co., Germany) was performed with simultaneous O2/tcPCO2 and breath-by-breath ventilator 
data monitoring (see Chapter 2, section 4) Mask pressure and patient flow were also 
measured externally to the ventilator (by pneumotachometer (model 3700A; Hans Rudolph 
Inc., USA) and pressure transducer (SEN635, range ± 24mbar; S-Med, UK)). This overnight 
study was performed as a titration study to ensure optimal hypoventilatory control. 
Adjustments were made to the ventilator settings as required by the O2/tcPCO2 trace either 
during the course of the evening or the next morning.  
Physiological measures:  Nocturnal sleep monitoring is described in more detail in Chapter 
2, section 4. In brief, EEG, EOG, and submental EMG recordings were measured to define 
sleep stage. Standard respiratory monitoring was performed, with the exception of the 
thermister, which was replaced by the pneumotachometer and mask pressure to provide 
vital respiratory information during NIV. Respiratory effort was monitored by respiratory 
inductance plesthmography (RIP), and SpO2.  ECG, leg EMG and body position were also 
recorded.  A continuous overnight tcPCO2 trace was measured via an earlobe sensor 
(TOSCA; Linde Medical Sensors, Switzerland) and integrated into the PSG data. 
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Ventilator-measured parameters: were monitored breath-by-breath by the Stellar 150 
ventilator including Vt, MV, RR, VA achieved, filtered leak, IPAP, EPAP, target inspiratory 
pressure, % patient triggered breaths. Real-time signals were relayed by the Tx Link 
connection module (ResMed, Australia) to EasyCare Tx software (EasyCare Tx v5.1; ResMed, 
Australia) as well as the SOMNOscreen Domino software (S-Med; UK).  
4.2.3 Data analysis 
PSG Analysis: Analysis of the EEG was made by a single, experienced technician blinded to 
the ventilator data (VR). Sleep-wake status was scored according to standard criteria 
(Rechtschaffen A and Kales A 1968; American, Sleep et al. 1992).  Arousal frequency was  
scored by ASDM criteria (American, Sleep et al. 1992). An oxygen desaturation of 4% 
considered significant. Patients whose PSG data was missing vital signals or was <4 hours 
were excluded. Only periods without change to ventilation settings were used in the 
analysis for this study. 
Data selection: Periods of 7 continuous minutes of stable state were selected in each sleep 
stage; stage 2, SWS and REM plus wakefulness (as done in our previous studies that 
compared sleep stages (Goff, O'Driscoll et al. 2008; Goff, Nicholas et al. 2009; Goff, Nicholas 
et al. 2012)).  Periods selected were free from arousal and movement artefact on visual 
inspection; and had both SaO2 and tcPCO2 measures if possible. Two minutes of stable state 
prior to analysis allowed blood gas equilibrium. The following 5 minutes were analysed 
breath-by-breath. Stage 1 was not used for analysis.  Selected period sleep stages were 
further verified by comparison of the percentage of delta wave activity. See Chapter 2, 
section 6.2 for more details of this analysis.  
To account for any time of night effect, ie sleep in early and later parts of the night, 2 
periods of each wake-sleep stage were selected in each patient if possible. Repeated 
measures during wake were taken as the last 7 minutes pre-sleep, and another on waking in 
the morning or a wake period with wake after sleep onset (WASO). Repeated measures 
during Stage 2, SWS and REM were attempted using data from different periods of the 
night. 
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4.2.4 Statistical analysis 
To investigate the effect of sleep stage on ventilator-measured parameters and 
physiological measures (SpO2, tcPCO2 and HR) I used one-way repeated measures ANOVA 
(Friedman repeated-measure ANOVA on ranks for non-parametric data) with statistical 
significance assumed with a p value of <0.05. Identification of significant effects were 
explored by t-tests with Bonferroni correction. I also analysed the effect of wake-sleep stage 
on ventilator-measured parameters and physiological measures in obstructive v restrictive 
patients using 2x2 ANOVA with repeated measures, where within factor was (sleep stage) 
and between factors was (disease). 
To compare the variability of ventilation parameters during each wake-sleep stage, the CV 
of each parameter was compared. 
4.2.5 Power calculation 
A previous analysis investigating MV across sleep stages in NIV therapy reported on 28 
patients (Ambrogio, Lowman et al. 2009). This was a heterogenous population with chronic 
respiratory failure but the sample size captured a significant difference in MV from wake to 
sleep: wake (8.7± 2.3L/min), stage 1 sleep (7.8±1.8L/min), stage 2 sleep (7.4±1.6L/min) and 
REM sleep (7.3±1.7L/min) (p<0.0001 ANOVA).  Therefore to detect a significant difference (p 
<0.05) in MV of 1.4L/min in a population with a wake mean (SD) MV of 8.7 (2.3)L/min with a 
power of 80%, a sample size of at least 22 patients was needed. 
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4.3 Results 
4.3.1 Patient Demographics 
34 patients of the 37 patients who completed the study in Chapter 3 had an overnight sleep 
study. Of these 34 patients, O2/CO2 analysis was obtained in three and full sleep data was 
obtained in 31 patients. Five patients were excluded (2 with poor EEG signals, 2 with 
ventilator trace recording failure and 1 with insufficient sleep).  Therefore 26 patients (17 
obstructive) with full PSG and ventilator data were included in the analysis (See Figure 4-1). 
 
 
Figure 4-1: Consort diagram for the investigation of effects of sleep on iVAPS ventilation 
NIV= non-invasive ventilation; PSG = polysomnography 
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Baseline demographics and sleep architecture are summarised in Table 4-1. Patients were 
54% male, 60(14) years old and had very good self-reported adherence to NIV therapy; 
8.4(2)hrs/night. Nearly half were on LTOT (46%) with 38% entraining O2 into their NIV 
overnight. Obstructive patients had worse daytime gas exchange compared to restrictive 
patients spontaneously breathing room air (SpO2: 95(93-96) v 97(97-99)%; p<0.001 and 
tcPCO2 6.3(0.9) v 5.7(0.7)kPa; p=0.05).  
Sleep architecture was relatively normal for age. There were no differences in the sleep 
architecture between the disease pathologies. Median overnight tcPCO2 for all patients was 
6.45 (6.10 to 7.7)kPa; however, this was a titration to optimise settings, and changes were 
made in the morning after the study. 
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Table 4-1: Baseline Demographics and sleep architecture of patients with overnight data from a full PSG, O2/CO2 monitoring and simultaneous 
breath-by-breath ventilator data collection.  
 TOTAL 
(n=26) 
Restrictive        
(n=9) 
Obstructive  
(n=17) 
Ostructive v 
Restrictive 
p values 
Gender (Male) 14 (54) 4 (44) 10 (59) 0.68 
Age (yrs) 59.7 (14.4) 60.4 (19) 59.3 (12) 0.87 
Patients with LTOT prescribed (n) 12 (46) 2 (22) 10 (59) 0.11 
Home O2 (L/min) 1.7 (0.8) 1.3 (1.1) 1.8 (0.8) 0.59 
FEV1 % predicted 35.1 (15.6) 41.2 (16.8) 31.9 (14.5) 0.18 
FVC % predicted 49.1 (19.4) 39 (16.2) 54.4 (19.2) 0.04 
FEV1/FVC 62.3 (24.6) 88.3 (12.4) 48.6 (17) <0.01 
PEF (L/min) 174 (120.3 to 195.8) 184 (148 to 209) 155 (112 to 197) 0.10 
Day SaO2 (air) (%) 96 (95 to 98) 97 (97 to 99) 95 (93 to 96) <0.01 
Day tcPCO2 (air) (kPa) 6.1 (0.9) 5.7 (0.7) 6.3 (0.9) 0.05 
Overnight Seep Architecture      
TST (hh:mmins) 5:28(3:44 to 6:10) 4:55 (3:19 to 6:04) 5:44 (3:49 to 6:16) 0.46 
Sleep Efficiency (%) 65 (52 to 80) 64 (54 to 80) 65 (48 to 80) 1.00 
Stage 2 Sleep (% TST) 
SWS (% TST) 
35 (29 to 41) 
28 (22 to 40) 
30 (24 to 42) 
32 (17 to 43) 
37 (31 to 43) 
26 (22 to 39) 
0.24 
1.00 
REM Sleep (% TST) 16(0 to 22) 15 (7 to 16) 16 (10-22) 0.43 
Arousal Index (events/hr) 12 (6 to 17) 15 (6 to 22) 12 (6 to 16) 0.57 
ODI (events/hr) 
Time SaO2<90% (%TST) 
Average overnight SaO2 (%) 
Average overnight tcPCO2 (kPa) 
1.7 (0.7 to 4.3) 
2 (0 to 11) 
93 (92 to 95) 
6.45 (6.10 to 7.7) 
2.2 (0.6 to 5.2) 
1 (0 to 6)  
94 (89 to 96) 
6.80 (5.35 to 7.40) 
1.6 (0.7 to 2.8) 
2 (0 to 24) 
93 (92 to 95) 
6.30 (6.10 to 8.00) 
0.37 
0.63 
0.62 
0.83 
Data presented as Mean(SD) or Median(IQR) or n(%). Comparisons between restrictive and obstructive lung pathologies were made by independent t-tests or Mann-Whitney test or 
Fisher’s exact test for categorical data. P>0.05 is considered as significant. NIV = non-invasive ventilation, LTOT= long term oxygen therapy, BMI= body mass index, FEV1 = forced 
expiratory volume in one second, FVC= forced vital capacity, PEF= peak expiratory flow, SaO2= pulse oxygen saturation, tcPCO2 = transcutaneous carbon dioxide, TST= total sleep time, 
SWS= slow wave sleep. REM = rapid eye movement sleep, ODI = oxygen desaturation index 
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4.3.2 Identification of the effect of sleep on ventilator-measured parameters and 
physiological outcomes 
Ventilation parameters (VA, IPAP, EPAP, Vt, RR, Ti, Leak, % spontaneously triggered breaths) 
and physiological measures (HR, SaO2, tcPCO2) were compared across wake-sleep states. 
Adequate data from each sleep stage was obtained in 20 patients (14 obstructive). 
Individual patient medians for each parameter for each wake-sleep state (wake, stage 2, 
SWS and REM) were used to generate overall group means.  Group mean (SD) data are 
shown in Table 4-2.  These data are also displayed graphically in Appendices 17 and 18. 
Wake-sleep stages are confirmed by significant differences observed between the 
percentages of EEG delta waves in each sleep stage.  
Time effect was analysed by comparison of two 5 minute periods of each sleep stage for 
each parameter (Table 4-3).  HR and RR were significantly lower in period 2 than period 1 
during SWS; (Mean (SD) HR 72(14) v 69(13) bpm, p = 0.001; RR 16.9 (3.5) v 16.2 (3.2) bpm, 
p=0.002). These differences were likely to be of minimal clinical importance therefore I 
combined the data from both periods for the overall analysis. This provided me with at least 
10mins of stable state data for each patient for wake and sleep stages 2, SWS and REM 
(Table 4-2). 
Further examination of Table 4-2 showed that VA was maintained during sleep compared to 
wake and across sleep stages. Ventilation parameters, Vt, RR and IPAP measured by the 
ventilator, also did not differ from wake to sleep or across sleep stages. Only the 
unintentional leak increased significantly from wake to sleep.  The percentage of ventilator 
breaths triggered by the patients changed significantly decreasing during sleep compared to 
wake, but only the trending decrease from wake to Stage 2 approached significance 
(p=0.06) in post hoc analysis.  
The clinical effect of maintaining a constant overnight VA was examined by analysis of the 
concurrent transcutaneous CO2 data. HR was lower during sleep than wake as expected 
(p=0.005), remaining significant only between wake and stage 2 in post hoc analysis 
(p=0.02). tcPCO2 increased and SaO2 decreased during sleep (p=0.01). In post hoc analyses 
between wake-sleep stage, the changes in SaO2 were not significant after Bonferonni 
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correction. The rise in tcPCO2 however remained significantly increased during Stage 2 and 
SWS compared to wake (both p=0.01) and a trend towards significant increase during REM 
(p=0.07). This CO2 increase, however, was clinically modest from 6.39 (1.02)kPa in wake to 
6.66 (1.18)kPa in REM and is in the order of the normal rise in CO2 that may be expected 
during unassisted ventilation during sleep in a healthy person. 
 
 153 
Table 4-2: Physiological and ventilator-measured parameters during wake and sleep (n=20) 
 Wake Stage 2 SWS REM ANOVA  
P values 
Ventilator-measured parameters:      
Minute Ventilation (L/min) 10.8 (3.5) 11.1 (4.8) 10.8 (4.2) 10.3 (4.3) 0.37 
Achieved VA (L/min) 9.0 (3.4) 9.5 (4.8) 9.0 (4.0) 8.6 (4.1) 0.32 
Tidal Volume (L) 0.69 (0.25) 0.78 (0.43) 0.68 (0.31) 0.68 (0.31) 0.10 
Respiratory Rate (bpm) 16.2 (2.9) 15.5 (3.2) 16.6 (3.4) 15.8 (2.6) 0.30 
Target inspiratory pressure (cmH2O) 17.8 (6.2) 18.3 (5.5) 18.6 (6.0) 18.2 (5.6) 0.54 
IPAP (cmH2O) 18.7 (6.2) 19.1 (5.6) 19.5 (6.0) 19.4 (5.8) 0.52 
EPAP (cmH2O) 4.8 (1.1) 4.6 (1.1) 4.6 (1.0) 4.6 (1.1) 0.34 
Maximum inspiratory flow (L/min) 53 (20) 58 (31) 56 (26) 53 (25) 0.32 
Filtered Leak (L/min) 4 (10) *†‡ 15 (21) * 15 (23) † 15 (21) ‡ 0.004 
% Patient Triggered Breaths 51 (10) 31 (39) 39 (10) 29 (8.4) 0.02 
% Patient Cycled Breaths 45 (8) 34 (7) 35 (8) 38 (8) 0.53 
Physiological Outcomes:      
Heart Rate (bpm) 73 (14)* 68 (14)* 71 (14) 70 (12) 0.005 
SaO2 (%) 94 (2) 93 (3) 93 (2) 93 (3) 0.01 
tcPCO2 (kPa) 6.39 (1.02)*† ‡ 6.60 (1.13)* 6.64 (1.19) † 6.66 (1.18) ‡ 0.004 
EEG (% delta) 1 (2)*†‡ 9 (8)* § ll 32 (18) †§** 3 (3) ‡ ll** <0.001 
Comparisons across sleep stage made by repeated measures ANOVA or Friedman’s test if non-paramateric. The mean difference is singnificant at the 0.05 level. Significant results were 
further analysed by paired t-tests (or Wilcoxon signed rank) between individual wake-sleep states, adjustment for multiple comparisons by Bonferroni. Significant difference between 
stages denoted by: *=wake and stage 2, † = wake and SWS, ‡=wake and REM, §=stage 2 and SWS, ll =stage 2 and REM, **= SWS and REM. SWS = slow wave sleep, REM = rapid eye 
movement sleep, SaO2= pulse oxygen saturation, tcPCO2 = transcutaneous carbon dioxide, EEG + electroencephalogram, VA = alveolar ventilation,  EPAP = expiratory positive airway 
pressure, IPAP = inspiratory positive airway pressure 
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Table 4-3: Paired t-tests between group means (SD) for the two 5 minute periods of all wake-sleep states and the individual wake-sleep stage. 
  Wake   Stage 2   SWS   REM  
 n Period1 Period2 n Period1 Period2 n Period1 Period2 n Period1 Period2 
Ventilator-measured parameters:             
Achieved VA (L/min) 21 8.7(3.1) 8.5(3.1) 18 8.1(3.4) 8.7(4.9) 25 9.2(4.9) 8.6(3.3) 18 8.8(4) 8.8(4) 
Minute Ventilation  (L/min) 21 10.5(3.3) 10.2(3.3) 19 9.4(3.8) 9.8(5.3) 25 11(5) 10.3(3.5) 18 10.6(4.2) 10.5(4.3) 
Tidal Volume (L) 21 0.66(0.24) 0.65(0.22) 19 0.63(0.37) 0.65(0.41) 25 0.68(0.36) 0.66(0.26) 18 0.67(0.28) 0.69(0.27) 
Respiratory Rate(bpm) 21 17(3) 16(3) 19 16(4) 16(3) 25 17(4)* 16(3)* 18 16(2) 16(2) 
Target Insp Pressure 21 17(5) 18(7) 19 18(6) 18(6) 25 19(6) 18(6) 18 18(5) 18(5) 
IPAP (cmH2O) 21 18(5) 19(7) 20 19(6) 19(6) 25 19(6) 19(6) 18 19(5) 19(5) 
EPAP (cmH2O) 21 5(1) 5(1) 20 5(1) 4(1) 25 5(1) 5(1) 18 5(1) 5(1) 
Max Insp Patient Flow (L/min) 21 50(19) 50(21) 20 49(27) 56(39) 25 56(25) 54(24) 18 57(24) 58(25) 
Leak (Ventilator) (L/min) 21 5(13) 7(14) 19 16(20) 16(23) 25 13(18) 15(28) 18 19(27) 12(19) 
Physiological outcomes:             
Heart Rate (PSG) (bpm) 22 73(13) 71(14) 22 68(12) 69(15) 25 72(14)* 69(13)* 20 72(13) 71(11) 
 SaO2 (%) 20 94(3) 94(3) 19 93(3) 93(3) 21 93(2) 93(3) 16 93(4) 93(3) 
tcPCO2 (kPa) 21 6.35(1.02) 6.34(0.92) 21 6.67(1.06) 6.68(1.18) 23 6.73(1.1) 6.65(1.25) 19 6.6(1.24) 6.81(1.25) 
EEG (%Delta) 22 0(2) 1(3) 21 10(8) 8(8) 25 29(19) 35(19) 20 4(4) 3(3) 
SWS = slow wave sleep, REM = rapid eye movement sleep, SaO2= pulse oxygen saturation, tcPCO2 = transcutaneous carbon dioxide, EEG + electroencephalogram, VA = alveolar ventilation,  
EPAP = expiratory positive airway pressure, IPAP = inspiratory positive airway pressure
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4.3.3 The effect of sleep on ventilator-measured parameters and physiological outcomes 
in obstructive and restrictive pathologies 
Ventilator-measured parameters and physiological outcomes were compared between 
pathologies (obstructive and restrictive) during sleep. Table 4-4 summarises p values for 
pathology by wake-sleep stage (2x4 repeated measure ANOVAs). There was no combined 
effect of sleep stage and pathology on the VA, which remained constant; however 
unsurprisingly, obstructive patients were trending towards higher VA (p=0.06). There was no 
significant interaction between diseases states and sleep stages for any other ventilator-
measured parameter. 
The main effects of pathology on ventilator-measured parameters were on the Vt (p=0.03) 
and maximum inspiratory flow (p=0.01); both higher in obstructive disease. Physiological 
variables HR and tcPCO2 were influenced by changes in sleep stage independent of disease 
state. However when considered separately, it was only the obstructive patients who 
showed any changes in blood gases across the sleep stages. Additionally, the changes in leak 
and percentage of patient triggered breaths only remained significant in obstructive 
patients.  
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Table 4-4: Significance values from ANOVAs assessing wake-sleep stage and pathology on ventilation and physiological outcomes. 
 p value 
  
Sleep stage 
 
Pathology 
(obstructive/restrictive) 
 
Sleep stage* 
Pathology 
Ventilator-measured parameters:    
Minute Ventilation (L/min) 0.60 0.07 0.53 
Achieved VA (L/min) 0.57 0.06 0.50 
Tidal Volume (L) 0.39 0.03 0.31 
Respiratory Rate (bpm) 0.37 0.14 0.32 
Target inspiratory pressure (cmH2O) 0.38 0.17 0.49 
IPAP (cmH2O) 0.36 0.15 0.48 
EPAP (cmH2O) 0.52 0.58 0.74 
Maximum inspiratory flow (L/min) 0.79 0.01 0.19 
Filtered Leak (L/min) 0.04 0.78 0.61 
% Patient Triggered Breaths 0.14 0.87 0.36 
% Patient Cycled Breaths 0.78 0.50 0.58 
Physiological Outcomes    
Heart Rate (bpm) 0.003 0.59 0.09 
SaO2 (%) 0.10 0.36 0.64 
tcPCO2 (kPa) 0.002 0.18 0.18 
EEG (% delta) <0.001 0.37 0.58 
 p values for main effects and interactions from a 2 x 5 stage ANOVA with repeated measures on the stages factor on ventilation parameters and physiological outcomes. SaO2= pulse 
oxygen saturation, tcPCO2 = transcutaneous carbon dioxide, EEG + electroencephalogram, VA = alveolar ventilation, EPAP = expiratory positive airway pressure, IPAP = inspiratory positive 
airway pressure 
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4.3.4 The variability of ventilator-measured parameters and physiological outcomes 
across wake-sleep stages 
The variability of the parameters during wake (expressed as coefficients of variation CV(%)) 
are shown in Figure 4-2.  A coefficient of variation of >15% was considered to be highly 
variable. Only the EEG and the ventilator leak had high variability. Other physiological and 
ventilator-measured parameters had low variability (CV<15%). Maximum patient inspiratory 
flow rate was more variable than other measures, just reaching the 15% threshold. 
CV (%) is shown across wake-sleep stages for all patients in Table 4-5.  Ventilator-measured 
parameters were stable during sleep compared to wakefulness, except RR which was more 
variable during wake than sleep. However this only remained significant when comparing 
the variability of RR during wake and SWS during post hoc testing; 11(8-14)% v 6 (0-10)%, 
p<0.01.  
Variability of the percentage of delta activity on EEG was different across sleep stages, with 
most stability observed during SWS as expected (Table 4-5). Variability of other physiological 
parameters, HR, tcPCO2 and SaO2, was low and also constant across wake and sleep. 
In summary, there was little difference in the variability of ventilation and physiological 
parameters between wake and sleep.  
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Figure 4-2: Variability of physiological and ventilator-measured parameters during 
wakefulness expressed as coefficient of variation (%) 
.Mean (minimum – maximum) values of CV are represented by the horizontal (vertical) lines; Dashed line represents CV 
of 15%. Values > 15% represent high variability. SaO2= pulse oxygen saturation, CO2 = transcutaneous carbon dioxide, 
EPAP = expiratory positive airway pressure, IPAP = inspiratory positive airway pressure. EEG = electroencephalogram.
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Table 4-5: Variability expressed as coefficient of variation (%) of physiological and ventilator-measured parameters during wakefulness and 
across sleep stages in all patients (n=20) 
 Wake Stage 2 SWS REM ANOVA 
p value 
Ventilator data:      
Minute Ventilation (L/min) 11 (8 to 14) 9 (6 to 17) 10 (7 to 12) 8 (4 to 13) 0.58 
Achieved VA (L/min) 12 (8 to 15) 10 (6 to 26) 11 (8 to 15) 9 (5 to 16) 0.83 
Tidal Volume (L) 8 (7 to 13) 10 (6 to 22) 11 (6 to 14) 7 (4 to 15) 0.71 
Respiratory Rate (bpm) 11 (8 to 14) § 8 (4 to 16) 6 (0 to 10) § 6 (0 to 14) 0.008 
Target inspiratory pressure (cmH2O) 4 (1 to 12) 6 (1 to 12) 6 (1 to 11) 5 (1 to 8) 0.44 
Maximum inspiratory flow (L/min) 18 (15 to 24) 15 (9 to 25) 14 (11 to 21) 16 (9 to 21) 0.29 
EPAP (cmH2O) 4 (4 to 6) 4 (3 to 6) 4 (2 to 7) 3 (2 to 6) 0.83 
IPAP (cmH2O) 6 (2 to 12) 7 (3 to 12) 6 (2 to 11) 5 (2 to 9) 0.60 
Filtered Leak (L/min) 63 (0 to 200) 58 (3 to 98) 71 (3 to 115) 38 (3 to 116) 0.34 
% Patient Triggered Breaths 6 (4 to 9) 7 (4 to 10) 7 (5 to 7) 6 (4 to 8) 0.28 
% Patient Cycled Breaths 1 (1 to 2) 1 (1 to 2) 1 (1 to 1) 2 (1 to 2) 0.89 
Physiological Outcomes      
Heart Rate (bpm) 6 (4 to 9) 7 (4 to 10) 7 (5 to 7) 6 (4 to 8) 0.73 
SaO2 (%) 1 (1 to 2) 1 (1 to 2) 1 (1 to 1) 2 (1 to 2) 0.24 
tcPCO2 (kPa) 2 (2 to 3) 2 (1 to 3) 2 (1 to 4) 1 (1 to 2) 0.48 
EEG (% delta) 0 (0 to 211) 58 (26 to 81)* † 25 (20 to 34)* ‡ 114 (35 to 131) †‡ 0.01 
Comparisons across sleep stage made by repeated measures ANOVA or Friedman’s test if non-paramateric. The mean difference is singnificant at the 0.05 level. Significant results were 
further analysed by paired t-tests (or Wilcoxon signed rank) between individual wake-sleep states, adjustment for multiple comparisons by Bonferroni. Significant difference between 
stages denoted by: *=wake and stage 2, † = wake and SWS, ‡=wake and REM, §=stage 2 and SWS, ll =stage 2 and REM, **= SWS and REM.  SWS = slow wave sleep, REM = rapid eye 
movement sleep, SaO2= pulse oxygen saturation, tcPCO2 = transcutaneous carbon dioxide, EEG + electroencephalogram, VA = alveolar ventilation, EPAP = expiratory positive airway 
pressure, IPAP = inspiratory positive airway pressure.  
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4.4 Discussion 
The main findings of this study were that iVAPS ventilation, was able to maintain a stable 
alveolar ventilation from wake to sleep and across sleep stages; in patients with both 
obstructive and restrictive pathologies. The blood gas changes that were observed were in 
keeping with the small nocturnal variations that are seen in healthy sleep. Stable minute VA 
was achieved with modest PS. However, as in Chapter 3, I found no single mechanism for 
the maintenance of VA. Furthermore, normal sleep stage distribution was achieved in these 
patients recieiving domicillay iVAPS. 
MV and Vt decrease progressively from wakefulness throughout sleep stages in healthy 
subjects, particularly from wake to non-REM, and also from non-REM to REM sleep 
(Phillipson 1978; Douglas, White et al. 1982; Douglas, White et al. 1982; Douglas, White et 
al. 1982). The result is a reduction of MV of ~ 15-20% and is accentuated in respiratory 
disease. In COPD, reductions of MV of up to 35% have been observed during sleep 
compared to wakefulness (Ballard, Clover et al. 1995). In patients with nocturnal hypoxia, a 
fall of 25% during NREM is further reduced to 45% in REM (Becker, Piper et al. 1999).  This 
relative nocturnal hypoventilation  is accompanied by a rise in CO2 (up to 1kPa) and slight 
decrease in oxygen which can be deleterious to the overnight gas exchange in patients with 
respiratory disease (Douglas, White et al. 1982).  In COPD, the maximum pO2 reduction 
during sleep has been observed to be 1.8kPa greater than controls (Koo, Sax et al. 1975) 
NIV, usually initiated during wakefulness, is used to maintain, or in patients with daytime 
hypercapnia to increase, MV with the aim of preventing nocturnal blood gas derangement. 
Standard PS ventilators with fixed levels of support (a fixed PS and fixed backup RR) may not 
respond adequately to the physiological changes in ventilation that occur during sleep. 
Indeed, Ambrogio et al (Ambrogio, Lowman et al. 2009) have shown reducing trends in MV 
during sleep in a mixed population of patients with HRF receiving standard PS NIV therapy. 
This finding was related to reductions in Vt across the stages of sleep during stable PS, and 
RR did not alter.  Similarly, decrements in MV in patients with cystic fibrosis receiving NIV 
have also been shown, leading authors to suggest that addressing the variance in volume 
that occurs during sleep may be beneficial to maintain more adequate control of 
hypoventilation (Milross, Piper et al. 2001).  
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VAPS adjusts PS levels aiming to achieve constant minute alveolar ventilation. It has been 
postulated that this volume assured mode may better ameliorate the decrease in MV 
observed across sleep stages compared to fixed pressure devices. Only one study to date 
has reported on the impact of VAPS ventilation across sleep stages (Ambrogio, Lowman et 
al. 2009). These authors showed that the changes in MV across sleep-wakefulness states 
were significantly different between standard PS and AVAPS with less variability of MV 
observed with the use of AVAPS.  The results of the current study showed greater stability of 
MV during VAPS ventilation. I observed non-significant changes in MV from wake to sleep 
and across sleep stages, with a maximum reduction of MV during REM from wakefulness of 
only 4.4%.  There was, however no increase in PS or RR to account for this maintenance of 
both Vt and MV respectively.  
Decrements in MV have been attributed to decreases in Vt rather than RR in previous NIV 
studies (Ambrogio, Lowman et al. 2009). Although Vt remained stable in the present study, I 
observed a reduction in the percentage of patient-triggered breaths from 50% during wake 
to 33% in REM. This increase in ventilator work may therefore conceal the decrease in the 
patients’ own RR as they became more reliant on the back-up RR.  This may suggest that in 
this circumstance, the back-up RR may play a more significant role than the PS in 
maintenance of MV during nocturnal IVAPS therapy. In this study, back up RR was set 
automatically by the ‘learn’ function from the patients’ wake spontaneous RR.  
While the results support the notion that MV is essentially maintained during sleep with 
iVAPS therapy, individual patients may have very different responses and present differing 
mechanisms for their stable ventilation, specifically in relation to patient-ventilator 
interaction. Indeed, in a previous population of stable patients on NIV, whose longterm 
ventilator data was interrogated, differences were observed, specifically triggering of the 
ventilator (Pasquina, Adler et al. 2011). Patients with NMD triggered their ventilators less 
and tended to be ‘captured’, while patients with other diseases triggered at least half of 
inspiratory cycles. 
NIV therapy may also unmask (or even cause) sleep disruption, which could be detrimental 
to NIV efficacy, such as mask leak and patient-ventilator asynchrony. Unintentional leaks 
have been shown to be significant in around a third of stable NIV patients (Gonzalez-
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Bermejo, Perrin et al.; Rabec, Georges et al. 2009). Leaks however, can lead to ventilation 
inefficiency and worsened sleep (Teschler, Stampa et al. 1999). In the current study I 
observed a threefold increase in unintentional leak from wake to sleep.  Importantly 
however, the mean leak remained below 20L/min, a typically accepted threshold. 
Ventilators are less able to compensate for leak greater than this, thereby reducing the 
volumes delivered to the patient.  iVAPS, however has previously been shown to maintain 
Tgt VA with varying lung resistance and compliance, and additional leak had little effect on 
delivered MV (Oscroft and Smith 2010). This finding may explain why the increased leak 
observed in the current study was not of detriment to the overall MV received by the 
patients during sleep. Indeed, normal sleep stage distribution was achieved, including the 
preservation of SWS and REM sleep. 
Patient-ventilator asynchrony, specifically ineffective efforts have also previously been 
shown to significantly increase during sleep (Fanfulla, Taurino et al. 2007) however these 
were not specifically measured in this study. Manual adjustment of PS during sleep has been 
previously successful in increasing patient-ventilator synchrony (Adler, Perrig et al. 2011). In 
patients with COPD, a manual reduction of PS (and thus Vt) with concurrent increase in RR 
was seen to reduce ineffective efforts and patient-ventilator asynchrony, with similar 
tcPCO2 control. This finding was specific to a subgroup of patients affected adversely by high 
levels of intrinsic PEEP (Adler, Perrig et al. 2011). The automatic adjustment of PS by iVAPS 
may therefore improve patient ventilator synchrony, which may manifest in less residual 
respiratory events during chronic NIV during sleep. It has, however, been suggested by 
Janssens et al (Janssens, Metzger et al. 2009) that pressure swings during fluctuating PS 
during autotitration may independently cause arousals from sleep and this has been 
supported by a case report (Carlucci, Fanfulla et al. 2012). In the present study, analysis was 
during steady state. 
Sleep reduces both O2 consumption and metabolic CO2 production (by 10 -30%) compared 
to wakefulness. However, the reduction of MV observed in sleep exceeds that which can be 
attributed to the decrease in the metabolic production of CO2, with a net effect of a slight 
nocturnal rise in PCO2 (Robin, Whaley et al. 1958). This is detrimental to patients who have a 
high resting daytime CO2, particularly when combined with the relative nocturnal hypoxia 
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observed. Hypoxia may be particularly evident in patients with a baseline PO2 close to the 
steep portion of the oxygen dissociation curve where further decrease in alveolar PO2 
results in significant desaturation. Indeed, a decrease in PO2 in sleeping patients with COPD 
has been measured as 1.8kPa greater than controls (Koo, Sax et al. 1975). VAPS has been 
shown to be as effective as standard PS in the control of overall nocturnal hypoventilation 
(mean overnight tcPCO2 and SaO2) and diurnal ABGs (Crisafulli, Manni et al. 2009; Murphy, 
Davidson et al. 2012; Briones Claudett, Briones Claudett et al. 2013; Ekkernkamp, Kabitz et 
al. 2014; Kelly, Jaye et al. 2014). AVAPS has even had a beneficial effect with a greater 
correction of hypercapnia in OHS, however higher pressures were required and this was at 
the expense of sleep quality (Storre, Seuthe et al. 2006).  In the study by Ambrogio et al. 
(Ambrogio, Lowman et al. 2009) gas exchange (measured by morning ABG) were also similar 
during AVAPS to those values achieved by standard PS ventilation. However, despite 
analysis of individual sleep stages, the authors did not monitor the continuous effect on 
blood gases and so the real time significance of the lesser reduction in MV was not known. 
In the current study, I continuously monitored both oxygenation saturation and tcPCO2 
during iVAPS therapy and showed changes similar to those expected in normal sleep. The 
maximum increase of mean(SD) tcPCO2 was between wake and REM; 6.39(1.02) to 6.66 
(1.18)kPa, which despite reaching statistical significance, is less than the 1.1kPa nocturnal 
rise expected in normal healthy subjects. I also showed a maximum reduction in the 
mean(SD) SaO2 between wake and all sleep stages of only 1(2)%, which again though 
statistically significant, is clinically acceptable. 
As the VAPS algorithm aims to maintain constant VA, continual PS and RR adjustments are 
made, in response to changes in the patients’ pattern of breathing. Large variation in the 
amount of PS adjustment by the algorithm both within and between individual has been 
observed; in awake ITU patients, some individuals’ ventilation displayed little change in PS 
but others had frequent changes, perhaps an indication of labile airway function (Battisti, 
Tassaux et al. 2007). The amount of variation in ventilator parameters required to attempt 
to maintain constant MV has not been quantified to my knowledge nor has normal variation 
overnight or between sleep stages. The results of the current study have shown a low CV of 
all of the ventilator parameters, which do not alter from wake to sleep or across sleep 
states.  
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Nocturnal monitoring is recommended for optimal therapy in patients requiring domicillary 
NIV therapy. Overnight polysomnography (PSG) during NIV is the gold standard for titration 
of optimal settings. Simple monitoring tools are used with varying accuracy, including 
subjective symptom improvement, daytime ABG changes, overnight oximetry, and 
capnography (Janssens, Howarth-Frey et al. 1998; Janssens, Borel et al. 2011). In iVAPS 
mode, where clinicians can be confident that VA will be maintained from wake to sleep, the 
combination of daytime NIV initiation and automatic PS titration may provide adequate   
expertise.   
4.4.1 Methodological issues and study limitations 
Patients were a non-homogenous group, with both obstructive (n=14) and restrictive (n=6) 
diseases. While differences between obstructive and restrictive pathologies were 
investigated, the small sample number in this study prevented further disease group 
comparisons. 
The effects of body position were not accounted for in this analysis. It is widely accepted 
that body positions cause changes in ventilation, independent of other factors. Reductions 
in Vt in the supine position have been observed in normal subjects (Behrakis, Baydur et al. 
1983), patients with OSA (Younes 2003) and with obesity (Steier, Jolley et al. 2009). During 
supported ventilation, however, the effect of position appears to be attenuated, both in 
COPD patients during wake PS ventilation (Porta, Vitacca et al. 1999) and during sleep with 
VAPS ventilation (Ambrogio, Lowman et al. 2009). Notably during VAPS ventilation, while 
stable across sleep stages in the supine position, MV tended to decrease in the lateral 
position by up to one litre compared to wakefulness. The lesser 400ml decrease that I 
observed may be, in part, due to the higher BMI of their patients (BMI 39kg/m2). 
Additionally, in the current study patients with OHS could not tolerate the increase in WOB 
on assuming the supine position when only receiving minimal pressure support. Thus the 
minimum PS boundary, usually set at 4cmH2O above the PEEP, was titrated upwards until 
tolerance was achieved. 
While transcutaneous measurement of CO2 is reliable, continuous and non-invasive, there is 
a time lag determined by circulation time, approximating 2 minutes. (Storre, Magnet et al.; 
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Janssens, Howarth-Frey et al. 1998). Therefore 2 minutes of stable sleep stage, was 
observed prior to each analysis period, to allow ABG homeostasis. Additionally during the 
selected analysis period, there were no arousals, sleep state or position changes that would 
effect the CO2. 
4.5 Conclusion 
The results of this study have shown that MV is maintained from wakefulness to sleep and 
across sleep stages with iVAPS ventilation, in particular preventing hypoventilation often 
associated with REM in respiratory disease. This has had the clinical effect of maintaining 
blood gas homeostasis between sleep-stages to within limits that would be expected with 
normal sleep. This may contribute to the reported benefits in sleep quality (Crisafulli, Manni 
et al. 2009; Ekkernkamp, Storre et al. 2014). Confidence in the ability of this mode of 
ventilation to maintain daytime ventilation during sleep might ameliorate the need for 
followup titration studies at initiation or as disease progresses.  
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5 RANDOMISED TRIAL OF ‘INTELLIGENT’ AUTOTITRATING VENTILATION 
VERSUS STANDARD PRESSURE SUPPORT NON-INVASIVE VENTILATION: 
IMPACT ON ADHERENCE AND PHYSIOLOGICAL OUTCOMES 
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5.1 Introduction 
NIV is well-established therapy for nocturnal hypoventilation in chronic respiratory disease 
(Leger, Bedicam et al. 1994; Simonds and Elliott 1995; Janssens, Derivaz et al. 2003; Lloyd-
Owen, Donaldson et al. 2005). Effective treatment relies on a balance between 
improvements in ABG tensions, symptomatic benefit and tolerance of NIV. New intelligent 
ventilator technologies aim to optimise patient-ventilator interaction by responding to the 
individual patient’s breathing patterns and ventilatory requirements (servoventilation), as 
well as using automated ventilator settings (see Chapter 2, section 3) . These technological 
developments may have theoretical benefits in improving patient comfort, but an overview 
of previous servoventilation studies produced mixed results (Windisch and Storre; Windisch 
and Storre 2012). VAPS ventilation is a hybrid mode of ventilation that might combine the 
benefits, while reducing the limitations of both pressure and volume pre-set ventilation. 
During VAPS servoventilation, an automated algorithm adjusts PS in an attempt to provide a 
constant target volume in the face of changing lung mechanics and patient effort, especially 
during sleep and in the presence of leak (Chapter 1, section 4). VAPS has previously been 
shown to reduce work of breathing during invasive ventilation (Dojat, Harf et al. 2000) and 
has also produced comparable outcomes to standard PS NIV in acute and chronic nocturnal 
hypoventilation due to restrictive and obstructive respiratory disease (Oscroft, Ali et al.; 
Storre, Seuthe et al. 2006; Battisti, Tassaux et al. 2007; Ambrogio, Lowman et al. 2009; 
Crisafulli, Manni et al. 2009; Janssens, Metzger et al. 2009; Jaye, Chatwin et al. 2009). In the 
previous chapters I have shown that VAPS does maintain VA, even in the presence of 
exacerbations (Chapter 3) and during sleep (Chapter 4). 
Initiating NIV requires specialist knowledge and expertise (Mehta and Hill 1996; Lopez-
Campos, Garcia Polo et al. 2006). Patient intolerance of the level of pressure support judged 
appropriate for therapeutic benefit is common, and NIV initiation is unsuccessful in up to 
10% of patients (Criner, Brennan et al. 1999; Chatwin, Nickol et al. 2008; Murphy, Davidson 
et al. 2012). An intelligent ‘learn’ feature has been incorporated into the ventilator 
technology, for the automated selection of ventilator settings based on the patient’s wake 
breathing pattern. Consequently patients receive the minimum pressure required to 
maintain optimal alveolar ventilation at a RR matched to their own. This may offer increased 
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comfort and potentially improve NIV uptake and adherence, while aiding NIV initiation in 
centres with less experienced staff.  
5.1.1 Aims 
The aim of this study was to investigate the effects of an intelligent bilevel ventilator mode 
with two combined technologies (ResMed Ltd, Australia) - iVAPS servoventilation mode plus 
an intelligent ability to ‘learn’ from a patient’s wake breathing pattern to automate the 
selection of target ventilation (ie. VA and RR). I tested the hypothesis that iVAPS can 
ventilate a patient naive to NIV at least as effectively as standard PS NIV with settings 
titrated by an experienced healthcare professional. 
5.2 Methods 
5.2.1 Patients 
Consecutive patients who fulfilled inclusion criteria were approached and recruited from the 
RBH sleep and ventilation department, between May 2009 and January 2011. Inclusion and 
exclusion criteria are shown in Table 5.1. Inclusion criteria were the following: >18 years of 
age, newly diagnosed nocturnal hypoventilation (confirmed by daytime PaCO2>6.0 kPa, or 
overnight sleep study with mean tcPCO2>6.0 kPa or peak of tcPCO2>6.5kPa) (Ward, Chatwin 
et al. 2005), and naïve to domiciliary nocturnal NIV. Exclusion criteria were: acute 
exacerbation of chronic respiratory failure (PaO2<7.5kPa and pH<7.36), uncontrolled cardiac 
failure or arrhythmia, moderate or severe bulbar weakness or inability to consent to the 
study. 
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Table 5-1: Inclusion and exclusion criteria for study: iVAPS versus standard PS in patients naïve to non-invasive 
ventilation 
Inclusion criteria Exclusion criteria 
 aged > 18 years   acute exacerbation of respiratory 
failure (PaO2<7.5kPa and pH<7.36) 
 restrictive or obstructive ventilatory 
disorder 
 uncontrolled cardiac failure or 
arrhythmia 
 newly diagnosed nocturnal 
hypoventilation (confirmed by 
daytime PaCO2>6.0 kPa, or overnight 
sleep study with mean tcPCO2>6.0 
kPa or peak of tcPCO2>6.5kPa) 
 moderate or severe bulbar weakness 
 no evidence of uncontrolled cardiac 
failure or arrhythmia 
 inability to understand rationale 
and/or consent form for study 
 never used domiciliary nocturnal 
non-invasive ventilation (NIV) 
 
Ethical approval was granted by the Brompton, Harefield and NHLI Research Ethics 
Committee. Medicines and Healthcare products Regulatory Agency (MHRA) approval was 
obtained. The study was registered with ClincialTrials.gov; trial identifier NCT00901485. 
5.2.2 Protocol and Measurements 
Patients were randomised to iVAPS or standard PS ventilation, then received the crossover 
treatment (AutoVPAP v VPAP III ST-A; ResMed Science Center, Australia) each for one 
month. Measurements are summarised here and described in more detail in Chapter 2. 
Awake baseline blood gas tensions were measured by arterialised earlobe capillary sampling 
on air (Chapter 2, section 2.6). Spirometry was measured (Microlab; Carefusion, UK) (Miller, 
Hankinson et al. 2005) and global respiratory muscle strength was assessed noninvasively by 
SNIP, MIP and MEP measures (Micro RPM; Micromedical, UK) (ATS/ERS 2002) (Chapter 2, 
section 2.5). These were measured before and after each one month of NIV intervention.  
Sleep quality and ventilatory control were monitored by PSG (SOMNOscreen, S-Med, UK) 
plus tcPCO2 and oximetry (TOSCA, Linde Medical Sensors, Switzerland) at the end of each 
month’s therapy (Chapter 2, section 4.1).  
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Ventilator initiation: Patients naive to NIV were set-up during the day following a standard 
protocol by the same skilled sleep technician. Randomisation was by opaque sealed 
envelope allocation; 12 iVAPS and 12 standard PS.  
Standard PS therapy: was delivered in the spontaneous/timed mode with maximum 
tolerated IPAP. Settings were determined to reduce the work of breathing during daytime 
spontaneous breathing (i.e. to visibly decrease accessory muscle activity) with IPAP titrated 
to patient comfort. An initial EPAP of 4 cmH2O was used and back-up RR was set to just 
below patients’ spontaneous rate. IPAP minimum (minimum inspiratory time) was set to 
1.0secs and all other values were set to defaults.  
iVAPS:  settings were automatically determined following a 60 minute ‘learn’ period during 
awake spontaneous breathing, on the ventilator with 4 cmH2O EPAP. The ventilator 
automatically determined the treatment target VA and backup RR based on the patient’s 
spontaneous RR and flow rates, together with the estimated anatomical dead space (as 
described in Chapter 2, section 3). EPAP was initially set to 4 cmH2O and titrated with 
attention to residual obstruction. PS minimum and maximum boundaries were set to allow 
the ventilator the greatest degree of freedom to achieve the target ventilation, according to 
patient tolerance and underlying disease. Minimum PS was only increased from the 
minimum possible value of 3 cmH2O if the patient displayed a rapid sleep onset and the 
automatic PS response was too slow to prevent respiratory events.  
Further titration of settings was performed taking into account overnight saturation and 
tcPCO2 (for inpatients), ventilator data and/or patient symptoms and tolerance. The 
number, type and rationale for adjustments were recorded. Major adjustments were 
considered those that would directly affect the minute ventilation (ie. target VA, PS, EPAP, 
RR, inspiratory:expiratory ratio). Minor adjustments were those related to patient comfort 
(ie. rise time, fall time, mask). 
Supplemental Oxygen:  was entrained into NIV for 3 patients. The same oxygen flow rate 
was used during both ventilator modes. 
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5.2.3 Data analysis 
Standard PSG analysis (Rechtschaffen A and Kales A 1968) was performed by two 
technicians blinded to patient identity and ventilator mode.  
Summary data from the ventilators were downloaded after each month’s therapy, including 
adherence (hours of use), and ventilator output (nightly mean PS, MV, RR and leak).  
Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) 
as described in Chapter 2, section 5.4 and Appendix 11 (Jaye, Chatwin et al. 2009). 
5.2.4 Statistical analysis  
To test for non-inferiority, a sample size of 36 (18 patients completing both arms of the 
crossover) was calculated to provide 80% power to detect a 2.5% drop in the primary 
outcome, mean overnight SpO2, with a SD of 3% at a significance level of 0.05. 
Sleep and breathing parameters at the end of each treatment period were compared using 
Wilcoxon Signed Rank test. The median difference between treatments with 95% 
confidence intervals was then compared by related-samples Hodges-Lehman test; 
spirometry and RMS data were compared at baseline and end of treatment periods using 
Friedman’s repeated measures test. Mixed linear modelling was used to assess for 
ventilator mode order effect, with patients as random variables. Post hoc correlations for 
ventilator adherence were performed by regression analysis. Comparisons of adherence 
between ventilator modes were made by Fisher transformed correlation coefficients. 
Statistical analyses were performed using SPSSv19.0 (IBM, USA). 
5.3 Results 
5.3.1 Patient Demographics 
Twenty-three patients were enrolled and randomised; 18 completed both treatment 
periods. 8 patients were randomised to receive iVAPS first. It was not possible to initiate 
ventilation in three patients; one patient from each treatment arm withdrew (See Figure 
5-1). Baseline demographics and patient diagnoses are shown in Table 5-1. Median (IQR) 
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FEV1% predicted was 51 (25-72) % and FEV1/FVC% ratio was 70 (60-80)%, however the 
majority of patients had a restrictive ventilatory disorder.   
 
Figure 5-1: Consort diagram for 23 patients enrolled and 18 completing both iVAPS and 
standard PS ventilation periods for one month each.  Paired data available for analysis 
includes n=18 overnight tcPCO2, n=16 polysomnography (PSG), n=17 ventilator data. 
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Table 5-2: Demographic data of study subjects  
 
 
Enrolled 
(n=23) 
Completed protocol 
(n=18) 
Age (years) 54 (43 - 61) 54 (41-61) 
Male/female 14/9 10/8 
BMI (kg/m2)* 
PO2 (kPa) 
33 (24 - 41) 
9.31 (8.62 - 10.81) 
36 (28 - 54) 
9.25 (8.59 -10.31) 
PCO2 (kPa) 6.37 (5.88 - 6.61) 6.38 (5.93 - 6.65) 
SaO2 (%) 94 (92 - 96) 93 (91 - 96) 
HCO3
- (mEq/L) 28.2 (26.8 - 31.2) 28.4 (27.7 - 30.8) 
H+ (nmol/L) 
FVC (litres)* 
40.8 (37.3 - 41.7) 
1.9 (1.4 - 2.7) 
41.2 (37.2 - 42.8) 
2.1 (1.3 - 2.8) 
FVC (% predicted)* 46 (34 - 77) 49 (36 - 79) 
FEV1 (litres)* 1.5 (0.8 - 1.9) 1.7 (0.8 - 2.3) 
FEV1 (% predicted)* 43 (26 - 64) 51 (25 - 72) 
FEV1/FVC* 0.75 (0.64 - 0.82) 0.71 (0.59 - 0.82) 
MIP (cmH2O) 50 (30 - 72) 62 (34 - 82) 
MEP (cmH2O) 118 (59 - 143) 123 (64 - 153) 
SNIP (cmH2O) 39 (23 - 56) 39 (25 - 67) 
Supplementary O2 4 3
# 
Diagnosis (n)   
COPD  3 2 
Chest wall disorder 
      -scoliosis/ end stage restrictive 
      -OHS 
 
2 
8 
 
1 
8 
Muscle weakness  10 7 
Values expressed as median (IQR).  FVC = forced vital capacity, FEV1 = forced expiratory volume in 1 second; MIP = 
maximal inspiratory pressure at mouth; MEP= maximal expiratory pressure at mouth; SNIP = sniff nasal inspiratory 
pressure. COPD – chronic obstructive pulmonary disease, OHS – obesity hypoventilation syndrome *Data reported for 
n=22 and 17 respectively. Height measured either conventionally or by armspan for wheelchair users. Patients whose 
daytime gas was normocapnic, had previously displayed nocturnal hypoventilation on clinical diagnostic overnight 
tcPCO2 monitoring.
 #
Two patients had oxygen entrained into their NIV (for persistent hypoxia due to pulmonary 
hypertension and patent foramen ovale), one had ambulatory oxygen only.  
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5.3.2 Ventilator Settings and Output  
Ventilator Settings: are summarised in Table 5-3. For standard PS ventilation median(IQR) 
pressure support was 10 (9-11) cmH2O. For iVAPS ventilation, PS was set to vary between 
boundaries of a minimum 5 (range: 3-6) and maximum 18 (range: 10-20)cmH2O to achieve 
the previously ‘learnt’ target VA. EPAP was similar for both ventilators.  
Ventilation output: Mean overnight PS delivered during iVAPS ventilation was significantly 
lower than that delivered during standard PS ventilation (8 (6-10) v 10 (9-11) cmH2O; 
p=0.001). Delivered MV, Vt, RR and leak did not differ between modes (See Table 5-3). 
Period effect, analysed by mixed linear modelling,  did not reveal any difference between 
receiving iVAPS first or second in  mean overnight measures of SpO2 (Coeff (SE) (0.55 (0.95); 
p=0.57), tcPCO2; (0.03 (0.17);  p=0.86),  adherence (-0.08 (0.29); p=0.79) or any other 
measure of ventilatory delivery, treatment efficacy or tolerance. Thus there was no ‘learning 
effect’ despite previous naïvity to NIV (see Appendix 19). 
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Table 5-3: Ventilator output and adherence to therapy following treatment with iVAPS and standard PS non-invasive ventilation  
 
Ventilator settings (n=18) iVAPS Standard PS 
Median difference between 
treatments  
(95% CI) p 
PS minimum and maximum         
boundaries (iVAPS) (cmH2O) 
5.0 (5.0 to 5.0) - 
17.5 (15.0 to 18.0) 
n/a n/a n/a 
PS (standard PS) (cmH2O) n/a 10.0 (9.0 to 11.4) n/a n/a 
EPAP (cmH2O) 7.8 (6.0 to 9.0) 7.3 (6.0 to 9.0) 0 (0 to 1) 0.77 
RR (bpm) 16.5 (14.0 to 21.0) 12.0 (12.0 to 13.0) 4.7 (2.3 to 7.3) 0.001* 
Target VA (l/min) 4.9 (4.1 to 6.1) n/a n/a n/a 
Ventilator output  (n=16)     
PS delivered median (cmH2O)
#  8.3 (5.6 to 10.4) 10.0 (9.0 to 11.4) -2.2 (-4.5 to 0.3) 0.001* 
Median leak (l/min) – vent 6.5 (3.5 to 26) 3.6 (0.2 to 9.6) 3.5 (-2.5 to 9.6) 0.23 
Median Tidal Volume (ml)  421 (321 to 521) 400 (300 to 575) -10 (-54 to 23) 0.47 
Median Minute Ventilation (l/min)  6.8 (5.3 to 8.3) 6.2 (5.4 to 9.4) -0.2 (-1.2 to 0.5) 0.50 
Median RR (bpm)  16.7 (13.2 to 18.4) 15.5 (13.5 to 17.0) 0.3 (-0.7 to 2.2) 0.41 
Adherence (n=17)     
Mean Vent Usage Time (hh:mm/day) 5:40 (4:42 to 6:49) 4:20 (2:27 to 6:17) 01:04 (00:27 to 1:44) 0.004* 
% days used in study 91 (64 to 98) 92 (70 to 99) -1 (-15 to 7) 0.53 
% days used ≥4/24 74 (49 to 92) 60 (27 to 85) 8 (-2 to 17) 0.1 
     
Results are presented for paired data sets in all 18 patients for ventilator settings, n = 17 for ventilator adherence, and n = 16 for downloaded ventilator output data (
#
median PS available 
for n=18). Values expressed as median (IQR). P value <0.05 was considered significant, * indicates difference between ventilators was statistically significant.  EPAP: expiratory positive 
airway pressure; IPAP: inspiratory airway pressure; RR: respiratory rate.  
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5.3.3 Ventilation Efficacy, Sleep and Respiratory Function 
Ventilation Efficacy: Overnight oxygenation and tcPCO2 did not differ between ventilator 
treatment modes (See Table 5-3). The lower limit of the 95% CI of the median difference 
between ventilators for overnight mean SaO2 was -0.2%, less than the inferiority margin of -
2.5%, thus iVAPS can be considered non-inferior to standard PS. 
Sleep: Total sleep time, sleep latency, sleep efficiency and architecture, and arousals were 
comparable between treatment modes (See Table 5-3). 
Respiratory Function: There were no significant changes in spirometry or RMS (see Table 
5-5). 
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Table 5-4: Overnight sleep parameters following treatment with iVAPS and standard PS non-invasive ventilation. 
 iVAPS Standard PS Median difference between 
treatments  
(95% CI) 
p 
Sleep study results  (n=18)     
Mean Overnight SpO2 (%) 96 (95 to 98) 96 (93 to 97) 0.4 (-0.2 to1.0) 0.13 
Min Overnight SpO2 (%) 86 (71 to 91) 80 (66 to 90) 2.5 (-3 to 11) 0.34 
SpO2 Desaturation Index (<4%) (events/hour) 2.5 (1.3 to 12.2) 5.0 (1.5 to 11.6) -1(-2 to 1) 0.42 
Mean Overnight tcPCO2 (kPa) 6.5 (5.8 to 6.8) 6.2 (5.8 to 6.9) 0.0 (-0.3 to 0.4) 0.54 
Max Overnight tcPCO2 (kPa) 7.1 (6.3 to 7.6) 6.9 (6.3 to 7.5) 0.0 (-0.5 to 0.5) 0.94 
PSG (n=16)     
Total Sleep Time (TST) (hh:mm) 6:17 (4:56 to 7:05) 5:43 (5:07 to 7:12) 00:15 (-00:31 to 01:00) 0.46 
Stage 1 Sleep (% of TST) 11 (8 to 15) 8 (6 to 16) 1 (-2 to 3) 0.52 
Stage 2 Sleep (% of TST) 59 (51 to 65) 57 (49 to 63) 1 (-2 to 6) 0.47 
Stage 3 & 4 Sleep (% of TST) 16 (12 to 22) 18 (12 to 25) -2 (-6 to 2) 0.27 
REM Sleep (% of TST) 14 (9 to 17) 11 (7 to 17) -3 (-1 to 6) 0.11 
Arousal Index (events/hour) 17 (8 to 24) 14 (10 to 26) 0 (-8 to 4) 0.82 
SpO2 Desaturation Index (<4%) (events/hour) 4 (3 to 11) 4 (1 to 8) 1 (-2 to4) 0.45 
Values expressed as median (IQR). P value <0.05 was considered significant, however there were no statistically significant differences in sleep or hypoventilation control between 
ventilators.  SpO2 = oxygen saturation; tcPCO2 = transcutaneous carbon dioxide; TST = total sleep time; REM = rapid eye movement sleep. Paired PSG data reported on 16 patients due to 
loss of signals in 2 sleep studies 
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Table 5-5: Pulmonary function and respiratory muscle strength test results following 
treatment with iVAPS and standard PS non-invasive ventilation compared to baseline – 
Friedmans repeated measures test (n=18)   
Variable n Baseline iVAPS Standard PS p 
FEV1 (litres) 16 1.6 (0.8 - 2.3) 1.8 (1.1 - 2.1) 1.5 (0.9 - 2.0) 0.47 
FVC (litres) 16 2.0 (1.3 - 2.7) 2.2 (1.2 - 2.6) 2.1 (1.5 - 2.4) 0.94 
SNIP (cmH2O) 17 39 (25 - 59) 41 (37 - 58) 51 (36 - 62) 0.10 
MIP (cmH2O) 18 62 (35 - 78) 59 (28 - 88) 60 (36 - 88) 0.85 
MEP (cmH2O) 18 123 (66 - 150) 134 (60 - 174) 134 (72 - 152) 0.15 
Values expressed as median (IQR). P value <0.05 was considered significant.  FVC = forced vital capacity, FEV1 = forced 
expiratory volume in 1 second; MIP = maximal inspiratory pressure at mouth ; MEP= maximal expiratory pressure at 
mouth; SNIP = sniff nasal inspiratory pressure. 
 
5.3.4 Adherence and Tolerance 
Mean night-time use for iVAPS mode was greater than for standard PS mode (5:40(4:42–
6:49) v 4:20(2:27–6:17) hh:mm/night; p=0.004) (Figure 5-2); although the percentage of 
nights on which the ventilator was used did not differ between treatment modes.  
Subjective measurements of ventilator comfort are reported in Table 4. Patients expressed a 
preference for iVAPS over standard PS ventilation (Figure 5.3). 
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Figure 5-2: Median (IQR) showing ventilator adherence (hh:mm/ night).  Patients 
significantly used their iVAPS ventilators for over an hour longer each night compared to 
standard PS ventilators (p=0.004) 
 
 
 
Figure 5-3: Patients expressed a preference for iVAPS over standard PS ventilation on the 
Visual analogue scale 0 – 100,  0 being negative and 100 being a positive response (n=18)  
Preferences have also been shown according to disease group (OHS = obesity 
hypoventilation syndrome (8); NMD = neuromuscular disease (7); obstructive (2); CWD = 
chest wall disease (1)) 
    
 180 
5.3.5 Predictors of Adherence 
Post hoc regression analysis was performed to determine correlates with adherence (see 
Appendix 21). Data from all patients (n=23) were used on an intention to treat analysis. 
Correlations were made for each ventilator independently and between ventilator 
correlates were compared after Fisher conversion for standardisation interpretation. 
Overall mean hours of use was correlated with the percentage of nights used (r=0.48; 
p=0.005) which remained true for both ventilators. 
Predictors of Adherence: There were no relationships between adherence and age, gender 
or BMI. Mean overnight tcPCO2 was related to nightly hours of use (r = -0.51; p=0.003).  
Adherence by Disease: The majority of patients (n=16/18) used iVAPS for longer, except one 
with scoliosis and one with OHS but small numbers limit statistical comparisons between 
disease groups  (see Appendix 22). 
5.3.6 Titration and clinical expertise  
After initial set up, adjustments to the ventilator settings were made in 12 patients during 
iVAPS therapy compared to nine patients during standard PS therapy (p=0.16) with a greater 
median(IQR) number of major adjustments per patient during iVAPS compared to standard 
PS (2.6(1.6-3.7) v 1.1(0.4-1.8); p=0.02). During iVAPS therapy, however, there was no 
difference in adjustments required in daytime hypercapnic compared to normocapnic 
patients (2.5(0-6) v 3(0-6); p=0.38). 
Adjustments to settings during iVAPS and standard PS therapies were made based on 
overnight oximetry/tcPCO2 monitoring in 4 v 1 cases, downloaded ventilator data in 4 v 1 
cases and persistent symptoms in 9 v 5 patients.  The majority of changes to settings were 
increased EPAP in both machines, a decrease in max PS in the iVAPS and an increase in IPAP 
in standard PS ventilation. 
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5.4 Discussion 
The main findings of this study was that nocturnal hypoventilation and oxygenation were 
controlled equally effectively by the iVAPS servoventilator with automated set-up and by 
standard PS ventilation with settings determined by an experienced healthcare professional 
in CRF patients, naive to NIV. Mean PS delivered during iVAPS ventilation was lower with no 
detriment to gas exchange, sleep efficiency or sleep quality. Nightly adherence was higher 
by over one hour with iVAPS ventilation in this predominantly restrictive population.  
This study adds to the evidence of VAPS ventilation as an alternative mode, with similar 
physiological gas exchange and sleep outcomes, to standard PS. Equivalent control of 
nocturnal hypoventilation has been previously demonstrated in CRF in COPD (Oscroft, Ali et 
al.; Crisafulli, Manni et al. 2009), OHS (Murphy, Davidson et al. 2012) and mixed diagnoses 
(Ambrogio, Lowman et al. 2009). Additionally, significantly greater reductions in PCO2 by 
VAPS compared to standard PS have been observed in OHS (Storre, Seuthe et al. 2006; 
Janssens, Metzger et al. 2009). However, the high pressures required to achieve the high 
target tidal volumes, were at the expense of sleep quality and comfort (Janssens, Metzger et 
al. 2009). The only trial in which iVAPS led to a small but significant comparative 
underventilation (mean overnight tcPCO2 7.2 v 6.7kPa) was in stable neuromuscular-skeletal 
patients experienced in NIV use from our group (Jaye, Chatwin et al. 2009). As a result of 
that study, the iVAPS algorithm was modified. In the present study, tcPCO2 is compared as a 
secondary outcome resulting in CO2 elimination similar to that of standard PS ventilation 
(median difference (95% CI) of -0.04(-0.03 to 0.4)kPa in mean overnight tcPCO2). 
Equivalence of overnight mean SpO2 had been shown and so was used as the primary 
outcome to establish sample size.  
 Sleep architecture and efficiency in this study were also comparable with studies in naïve 
patients (Storre, Seuthe et al. 2006), and in experienced NIV users whose sleep efficiency 
ranged from 68-86% (Ambrogio, Lowman et al. 2009; Jaye, Chatwin et al. 2009).  
In this trial, I observed several benefits of the iVAPS mode including automation of initial 
setting selection, a lower mean delivered PS and an increased adherence in the studied 
population. 
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Most common barriers to the implementation of NIV are insufficient staff knowledge, 
confidence and training (Cabrini, Antonelli et al.; Vanpee, Delaunois et al. 2002; 
Maheshwari, Paioli et al. 2006). Automating initial ventilator set-up in this study has 
provided similar outcomes to manual NIV initiation by a skilled healthcare professional 
which may facilitate NIV use in units with less experience, however a degree of clinical 
expertise is still required for followup titration, as indicated by the adjustments made to 
ventilation. 
Early during the course of NIV therapy, the pressure support required for optimal 
therapeutic effect is often poorly tolerated and can lead to impaired adherence. Uniquely, in 
the present study, a lower mean pressure support during iVAPS than during standard PS 
ventilation (8.3 v 10.0cmH20; p=0.001) produced a similar MV and ventilatory control. In 
previous studies, delivered pressures have been significantly higher during VAPS in OHS 
(Storre, Seuthe et al. 2006; Janssens, Metzger et al. 2009) and in CRF (Ambrogio, Lowman et 
al. 2009).  Lower pressures in iVAPS mode during this study may have contributed to the 
patients’ preference for this mode and to increased adherence. 
Patients used the iVAPS mode for an hour longer each night than the standard PS, while the 
percentage of days used were comparable. Overall NIV adherence (5:23 (3:11–6:32) 
hh:mm/night) was similar to that of previous standard PS studies (Criner, Brennan et al. 
1999; Janssens, Derivaz et al. 2003; Chatwin, Nickol et al. 2008) as well as VAPS studies in 
NIV naive patients (Crisafulli, Manni et al. 2009; Murphy, Davidson et al. 2012). Greater 
overall adherence (7.5-8.5 hours) has been observed in VAPS studies of experienced NIV 
users (Oscroft, Ali et al.; Jaye, Chatwin et al. 2009). Murphy et al (Murphy, Davidson et al. 
2012) showed a lower nightly average hours in VAPS compared to standard PS ventilation 
(04:11 v 05:08 hh:mm/night), although this did not reach significance. The current study is 
the first to demonstrate an increased nightly adherence with VAPS ventilation.  
When using VAPS modes, it is imperative to consider the volume that is targeted.  
Manufacturers target different minute volumes with calculations based on RR, Vt, and the 
inclusion or exclusion of deadspace ventilation (VD).  iVAPS targets VA to eliminate the added 
effect of greater wasted VD with increasing RR.  Automated selection of the target volume 
and settings is dependent both on parameters learnt from the patient and on the 
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algorithms. The iVAPS algorithm targets 100% of the learnt daytime VA and should be able 
to cope with nocturnal ventilatory demands, which usually decrease in sleep. In daytime 
hypercapnic patients (as in 2/3 of our patients) an awake spontaneous breathing learn 
period might underestimate the required nocturnal ventilation, however in this study, 
hypercapnia did not predict the need for further titration of iVAPS settings. Further 
validation of the algorithm may be required in patients with acute respiratory failure or 
more severe hypoventilation. Varying pathologies might also behave differently due to 
unique respiratory mechanics, ventilatory patterns and VD (Carlucci, Pisani et al. 2013). 
Comparisons of ventilatory strategies, and iVAPS mechanisms, between disease groups was 
not the aim of this study.   
Another important consideration in volume delivery is leak detection and ventilator 
compensation. In this trial, I did not measure leak externally. The ventilator-reported leak, 
similar in value in both modes, did not impair sleep or ventilation as demonstrated for by 
PSG and O2/CO2 measures. 
5.4.1 Methodological issues and study limitations 
The primary outcome was the mean overnight oxygen saturation (SpO2 %) during a sleep 
study performed on NIV at the end of each one month of ventilator therapy. A non-
inferiority SpO2 margin of a 2.5% with an assumed SD of 3% was made based on clinical 
experience at the tertiary domicillary ventilation department that I work in. It could be 
argued that tcPCO2 is a better indicator of ventilator efficacy, however in a preceding 
version of the iVAPS algorithm, lesser correction of overnight tcPCO2 was observed during 
iVAPS ventilation. Since these previous results, the iVAPS algorithm has been altered to 
target a greater proportion of the awake minute ventilation. However, equivalence of 
overnight mean SpO2, has previously been shown and so was used as the primary outcome 
with which to power this study.  In these patients, whose arterial oxygen saturation values  
sit close to the steep portion of the oxygen dissociation curve, mean oxygen levels are also 
important indicators of hypoventilation. 
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Patients were naïve to NIV, with no bias to any previous ventilator mode or settings. No 
learning effect was observed. Three patients (13%) could not tolerate NIV from the outset, 
in keeping with previous NIV intolerance results (Criner, Brennan et al. 1999; Chatwin, 
Nickol et al. 2008). 
I studied a mixed patient population restricting the ability to comment on the efficacy and 
mechanisms of VAPS in individual pathophysiologies. Including only patients completely 
naive to NIV, meant COPD patients who had previously received acute NIV were ineligible. 
Despite this, increasing OHS numbers in many clinics are well represented. In addition, 
regular nocturnal monitoring in NMD and CWD provides early diagnosis in patients with less 
severe nocturnal hypoventilation. As such the results of this study are biased towards a 
population with mainly restrictive lung pathologies and milder hypoventilation. This might 
explain my relatively conservative PS values. However the heterogeneity is representative of 
real world clinic patients. Although I observed an increased adherence with iVAPS across all 
disease groups, small numbers mean that the generalisability of this conclusion is limited.  
Complete resolution of the diurnal hypercapnia observed at baseline (mean PaCO2 6.4kPa) 
in this trial cannot be confirmed. Only baseline ABGs were taken and no correlation 
between PaCO2 and tcPCO2 measures was performed. tcPCO2, however, has previously 
shown good agreement with PaCO2 and is used successfully in NIV management (Kelly and 
Klim 2011; Storre, Magnet et al. 2011) The correction of CO2 levels in this study were in the 
order of previous studies whose diurnal PaCO2 also showed improvement, and indeed in 
COPD, the degree of improvement in daytime PaCO2 has been correlated with the 
improvement in mean overnight tcPCO2  (Meecham Jones, Paul et al. 1995). 
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5.5 Conclusion 
I found in this group of patients with predominantly restrictive disorders, CRF and naive to 
NIV, that iVAPS is an alternative ventilator mode to standard PS ventilation producing non-
inferior control of nocturnal hypoventilation. iVAPS therapy required a lower PS which may 
decrease deleterious effects of high pressure (barotrauma, leak, gastric distension) and 
increase ventilator adherence. iVAPS may reduce the healthcare team experience required 
for initiating domicillary NIV, thereby increasing the availability of NIV.   
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6 THE IMPACT OF iVAPS VERSUS STANDARD PS NIV ON RECOVERY FROM 
ACUTE HYPERCAPNIC EXACERBATIONS OF CHRONIC RESPIRATORY 
FAILURE 
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6.1 Introduction 
NIV is a well-established evidence-based therapy in patients with acute hypercapnic 
exacerbations of COPD. It has been shown to reduce morbidity, decrease intensive care unit 
(ICU) admissions and reduce mortality by approximately 50% (Plant, Owen et al. 2000). NIV 
also provides a more rapid improvement in arterial blood gas disturbance (Plant, Owen et al. 
2000) and breathlessness (Bott, Keilty et al. 1993), when compared to standard therapy 
alone. Moreover, avoiding endotracheal intubation (ETI) has the advantage of evading 
detrimental side effects associated with intubation (Brochard, Mancebo et al. 1995; Plant, 
Owen et al. 2000). NIV can also be used to treat acute hypercapnic respiratory failure in 
exacerbations of other chronic diseases with similar impact (Celikel, Sungur et al. 1998; 
Carlucci, Richard et al. 2001). Although in other disease processes, patient selection is 
paramount.  
Standard pressure support (PS) ventilation has fixed pressure levels, preset by the clinician 
and adjusted manually. Intelligent volume assured pressure support (iVAPS) ventilation 
automatically titrates to achieve a desired target alveolar ventilation (as described in 
Chapter 2, section 3). During acute exacerbations, the pulmonary mechanics and resultant 
work of breathing are constantly changing due to changes in airway inflammation, 
bronchospasm and sputum plugging (O'Donnell and Parker 2006) (as described in Chapter 1, 
section 1.2).  The automatic and constant titration of iVAPS may yield positive benefits on 
ventilator efficacy and patient comfort, and reduce the clinician experience required for 
optimal individualised therapeutic ventilation. 
Patients admitted acutely and requiring NIV therapy are encouraged to use NIV for as long 
as possible each day until their condition has stabilised.  However, patient compliance is 
affected by the ability to tolerate the level of PS judged appropriate for a desirable clinical 
outcome. The result is that patients may tolerate only sub-optimal settings thereby reducing 
the therapeutic effect. A key objective of autotitration is to ensure that consistent 
ventilation is achieved using the minimum PS support necessary. This may improve 
compliance and thereby hasten recovery from the acute episode, particularly in relation to 
resolution of ABG disturbances. 
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Autotitration may also reduce the amount of expertise required and time spent with 
patients in NIV set up and titration. A previous study has shown that the inclusion of NIV in 
the medical treatment of ARF added significantly to nursing workload. During the first hour 
of an admission with acute exacerbation of COPD, more time was spent with the patients 
receiving NIV, compared to standard therapy and overall NIV added 44 minutes to patient 
care during the first 24 hours of care (Plant, Owen et al. 2000). Increasing experience levels 
has seen greater NIV success even in the more unwell population (Diaz, Alcaraz et al. 2005; 
Crummy, Buchan et al. 2007), however in centres with less experience there is a significant 
training burden that could be reduced by more intelligent ventilators that automatically set 
and titrate ventilation.  
In the acute setting, iVAPS has been used in one feasibility study with short term, non-
randomised application in ICU (Battisti, Tassaux et al. 2007). This study found that iVAPS was 
comparable to standard PS ventilation for the resolution of acidosis, hypercapnia and 
symptom relief in acute HCRF. However, the iVAPS ventilator was used for only a short 
period (45mins) and only after initial patient stabilisation in the ICU. A similar mode AVAPS 
has been successful in facilitating more rapid recovery of consciousness, correction of PCO2 
and respiratory rate in patients with hypercapnic encephalopathy when compared with 
standard PS NIV in ICU (Briones Claudett, Briones Claudett et al. 2013). Recovery of 
consciousness is a key early feature of therapy success in patients at high risk of NIV failure. 
These findings, however, did not translate to reductions in NIV use or length of stay.  
Autotitrating ventilators have not been tested over a longer period in the acute setting 
outside the ICU, withholding one case report (Okuda, Kashio et al. 2012).  
The aim of this study was to prospectively evaluate the feasibility of using autotitrating NIV 
in patients admitted to hospital with acute exacerbations of chronic respiratory failure 
compared to outcomes obtained using standard PS NIV. I tested the hypothesis that 
autotitrating iVAPS non-invasive ventilation would ventilate patients with acute hypercapnic 
exacerbations of chronic ventilatory failure as effectively as standard PS NIV. The primary 
outcome was the correction of pH at 1 hour. I also aimed to evaluate ventilator efficacy at 4 
and 24 hours of NIV therapy and to compare the effects of each mode of ventilation on lung 
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function. The delivered ventilation, ventilator tolerance, compliance and clinician time were 
also compared between modes. 
6.2 Methods 
6.2.1 Patients 
Patients with admissions to the Royal Brompton and Harefield NHS Foundation Trust for 
acute exacerbations of CRF, and inpatients with an acute deterioration of their condition 
were recruited over the period from February 2011 to February 2014. Patients included 
those with known existing respiratory disease, specifically restrictive ventilatory disorders 
such as NMD (eg. MND, old polio) or CWD (eg. idiopathic scoliosis, obesity), and obstructive 
ventilatory disorders (eg. COPD or bronchiectasis). Inclusion and exclusion criteria are 
shown in Table 6-1. Inclusion criteria were being aged ≥ 18 years and admitted with an 
acute exacerbation of respiratory failure confirmed by daytime arterial blood gas (ABG) 
values PaCO2 > 6.0 kPa, pH between 7.25 and 7.35, and respiratory rate > 20 bpm. 
Exclusion criteria were patients with moderate to severe bulbar weakness, severe acute 
exacerbation confirmed by pH < 7.25, need for immediate intubation, hypotensive (systolic 
BP <= 90 mmHg), acute myocardial infarction, acute dysrhythmia, other system failure (e.g. 
acute renal failure, liver failure), or lack of capacity to understand rationale and/or consent 
form for study. 
The study was approved by the NRES South East London REC 3 (REC: 10/H0808/56) and all 
patients gave written informed consent. 
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Table 6-1: Inclusion and exclusion criteria for iVAPS versus standard PS ventilation in 
patients with acute exacerbation of chronic respiratory failure 
Inclusion criteria Exclusion criteria 
 Chronic respiratory disease; 
obstructive or restrictive 
 moderate to severe bulbar 
weakness 
 acute exacerbation of respiratory 
failure confirmed by daytime 
arterial blood gas (ABG) values 
PaCO2 > 6.0 kPa, pH 7.25 - 7.35, 
and RR > 20 bpm  
 severe acute exacerbation (pH < 
7.25, need for immediate 
intubation, hypotensive (systolic 
BP <= 90 mmHg)) 
 Royal Brompton Hospital 
admissions or inpatients with 
acute deterioration 
 acute myocardial infarction, 
acute dysrhythmia 
 ≥18 years   other system failure  
  lack of capacity to understand 
rationale and give informed 
consent  
 
6.2.2 Protocol 
This was a prospective randomised, crossover study. Patients were admitted acutely to a 
RBH respiratory ward from another hospital, from clinic, or from home; each had their ABG 
measured.  RBH respiratory ward inpatients suffering an acute deterioration in their ABG 
were also considered. Following informed consent, patients were randomised to either 
iVAPS (AutoVPAP) or standard PS ((VPAP III ST-A) NIV (ResMed Ltd; Bella Vista, Australia) 
treatment and had supplemental oxygen entrained (if necessary). After 24 hours on the first 
ventilator the patient was swapped to the alternative ventilator for a further 24 hours of 
treatment, after a 1 hour washout period during which they spontaneously ventilated on 
optimal O2 therapy (Figure 6-1). Patients were encouraged to use NIV as much as possible 
and were closely monitored over the first six hours of each period. 
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Figure 6-1: Flow diagram of protocol for study: Intelligent volume assured pressure support 
ventilation (iVAPS) versus standard pressure support NIV (PS) in patients with acute 
exacerbation of chronic respiratory failure 
 
Initiation and titration of NIV: Patients were randomised to either iVAPS or standard PS 
mode of NIV. NIV was initiated and titrated according to a standardised protocol, and were 
given optimal medical therapy determined by the attending clinician.  The time spent in set-
up and settling period was recorded.  
Patients who did not have their own domicillary NIV mask, were fitted with an oronasal 
mask, with specific attention given to the prevention of leaks. Supplemental oxygen was 
entrained (if necessary) to achieve stable SaO2 of > 93% for restrictive patients, and  88 - 
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92% for obstructive patients (O'Driscoll, Howard et al. 2008).   An initial EPAP setting of 
5cmH2O was used and this was titrated to alleviate any obstructive respiratory events or 
flow limitation observed or to decrease inspiratory effort in the instance of intrinsic PEEP (as 
indicated by an increase work of triggering).  Other settings were left as per factory default 
settings or the protocol disease specific variations; rise time: restrictive 300ms and 
obstructive 150ms, inspiratory time/total time: restrictive 40% and obstructive 30%. 
Standard PS: Maximum tolerated PS was set, titrated upwards from 12cmH2O or from the 
patient’s usual settings in those patients previously receiving domicillary NIV. The RR was 
initially set at 12 or patient’s usual settings. 
iVAPS: The initial target alveolar ventilation was calculated via the formulae (Tuggey and 
Elliott 2005):    
 restrictive: (12ml/kg of body weight - anatomical deadspace) * 15  
 obstructive: (10ml/kg of body weight – anatomical deadspace)* 15  
Maximum and minimum PS values were set to maximise PS variability. The maximum 
capability of the iVAPS ventilator was an IPAP of 30cmH2O, which meant that maximum PS 
was also determined by the level of PEEP. The variable back up RR was set at 12bpm in the 
first instance and titrated upwards to match patient requirement.  
Once the optimal maximum tolerated fixed PS (for standard PS) or maximum PS boundary 
(for iVAPS) was achieved, patients continued treatment for 1 hour, after which a repeat 
blood gas was taken on NIV. NIV adjustments were made depending on patient tolerance 
and improvement in blood gases over the first 1 hour and 4 hours of NIV.   
Titration was made according to the ABG result; to decrease PCO2 by 0.5kPa, either a) the PS 
was increased by 2cmH2O (in standard PS mode) or b) the target VA was increased by 5% (in 
iVAPS) with a corresponding increase in the maximum PS to attain the new targeted 
volume. The RR was adjusted if the patient could not tolerate further PS increase, or if 
unintentional leak prevented the delivery of adequate tidal volumes for a given PS. 
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Oxygen saturations were corrected first by the increase of IPAP or by entrained 
supplemental oxygen (if necessary) to achieve stable SaO2 of > 93% for restrictive patients, 
and (88 - 92%) for obstructive patients. Further adjustments to NIV were made as per ‘on-
call’ criteria; if the patient was unable to tolerate NIV, oxygen desaturation to levels below 
93% for restrictive patients, and 88% for obstructive patients or tcPCO2 >2kPa above the 
optimal achieved tcPCO2. Settings were altered over the 24 hour period to achieve 
maximum patient tolerance and alterations were recorded.  
NIV failure: was defined as patients who were unable to tolerate NIV, or if they failed to 
make any sustained improvement within six hours (British Thoracic Society 2002), or they 
further deteriorated requiring alternative ventilation, or endotracheal intubation and 
mechanical ventilation.  
6.2.3 Measurements 
Measurements were made in accordance with the study protocol in Figure 6-1. Earlobe 
capillary ABG’s while awake were used to determine eligibility for the trial, and to guide 
titration of ventilators at baseline and at 1, 4 and 24 hours post NIV initiation (British 
Thoracic Society 1997). Once established on NIV, ABGs were recorded while patient was 
using NIV. At 24 hours, NIV was removed for ≥1 hour to reach a new baseline stable state 
(Janssens, Howarth-Frey et al. 1998).  
Ventilation efficacy: The primary outcome variable was arterial pH (H+) at 1 hour post NIV 
initiation.  Secondary outcome measures were arterial PCO2, PO2, SaO2, RR, HR, and Borg 
score at each time point, mean and min SaO2, mean HR and mean and max tcPCO2, oxygen 
desaturation index (ODI) and time spent with SpO2 < 90% over each treatment period.   
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At baseline and at +1, +4, and +24 hours from initiation of each ventilator mode, respiratory 
rate (RR) was recorded and breathlessness was assessed subjectively using the Borg 
breathlessness scale. SaO2, HR and tcPCO2 were also measured continuously using a tcPCO2 
monitor (TOSCA; Linde Medical Sensors AG, Basel, Switzerland) via a combined earlobe 
sensor (a forehead sensor was used in cases of peripheral shut –down where physiological 
traces were unable to be obtained from the earlobe) and trends of these measures were 
recorded throughout each 24 hour treatment period.  For more details see Chapter 2, 
sections 2.6 and 2.7). 
Respiratory function was measured by forced expiratory volume in 1 sec (FEV1), forced vital 
capacity (FVC), maximal inspiratory and expiratory pressure at mouth (MIP & MEP 
respectively) and sniff nasal inspiratory pressure (SNIP) (see Chapter 2, sections 2.4 and 2.5). 
These were compared at baseline and at the end of each treatment period.  
A Visual Analogue Scale (VAS) was used to measure subjective patient comfort at the end of 
each treatment period as well as ventilator preference at trial completion (see Chapter 2, 
section 5.4). Compliance with treatment (hours of use) and ventilation delivery data were 
determined using downloaded ventilator data. Both the number of titrations/ adjustments 
and the time spent will be recorded at each time period. Time spent at the bedside by the 
researcher dealing with issues pertaining to NIV were logged for each mode of ventilation. 
6.2.4 Analysis and power calculation  
TOSCA analysis was performed by a clinical sleep technician blinded to the ventilator mode.  
Non-physiological data or missing traces were excluded from analysis of the 24 hour indices. 
Statistical analysis: The primary outcome variable, pH at 1 hour from NIV initiation, and 
secondary outcomes were compared using paired t tests for normally distributed data, and 
Wilcoxon Signed Rank test for non-parametric data. Within patient measures were 
compared using one way analysis of variance (ANOVA) for repeated measures for normally 
distributed data, and non-parametric Kruskal-Wallis ANOVA on Ranks test.   
Power calculation: Arterial pH indicates the appropriateness of alveolar ventilation to 
maintain blood gas homeostasis (Plant and Elliott 2003).  An improvement in pH at 1 hour 
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post NIV has been shown to be an indicator of treatment success (Bott, Keilty et al. 1993; 
Brochard, Mancebo et al. 1995) in patients with exacerbations of COPD.  Previous 
investigation of the effects of NIV on pulmonary gas exchange and haemodynamics during 
COPD exacerbations found a baseline mean(SD) pH of 7.31(0.05) of patients enrolled in the 
study. A clinically significant improvement of 0.04 would thus normalise the pH. Therefore, 
18 patients would be required to have a 90% chance of detecting as significant a difference 
between ventilators in pH after one hour of NIV of 0.04, with an assumed SD of 0.05 
(p=0.05) (Diaz, Iglesia et al. 1997). In this study, I aimed to recruit 20 to allow for dropouts or 
incomplete data. 
6.3 Results 
6.3.1 Patient Demographics 
Fourteen patients were studied. All patients with acute hypercapnic acidosis who were 
under the care of the Sleep and Ventilation team were considered. Of 24 eligible patients, 
nine patients required PS levels that exceeded the capacity of the ventilator (IPAP 
>30cmH2O) and one patient was not studied due to researcher absence. All 14 patients 
approached, gave consent (or their families gave consent on their behalf if they were too 
unwell) and were subsequently recruited.  One patient who began the first arm of the study 
was withdrawn when her PS requirements exceeded 30cmH20. 
The demographics of n=13 patients that completed the study are shown in Table 6-2. All 
data were non-parametric and presented as median (IQR) due to the small sample size. 
Patients were of mixed pathologies; obstructive (n=5) and restrictive (n=8). All obstructive 
patients had COPD. The restrictive group included scoliosis (n=1), MND (n=1), bilateral 
diaphragm paralysis (n=1) and primary OHS (n=5; 2 of these patients also had ILD, one had 
McLeod’s syndrome and one also had mild COPD). All patients were hypercapnic and 
acidotic on admission to the study and nearly half were naïve to NIV despite 77% having 
LTOT. 
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Table 6-2:  Demographic data of patients with an acute exacerbation of a chronic 
ventilator disorder and treated with both standard PS and iVAPS NIV (n=13) 
 Median (IQR) or n (%) 
Age (years) 69 (59 to 73) 
Male (n %) 7 (54)  
BMI (kg/m2) 27 (22 to 38) 
  
Pathology: 
obstructive/restrictive (n) 
 
5/8 
pH 7.32 (7.30 to 7.34) 
PO2 (kPa) 8.41 (7.46 to 9.24) 
PCO2 (kPa) 9.09 (8.03 to 10.27) 
SaO2 (%) 90 (85 to 92) 
HR (bpm) 96 (78 to 107) 
RR (bpm) 22 (19 to 25) 
Borg breathlessness score 1 (0 to 2) 
FEV1 (% predicted) 20 (16 to 30) 
FEV1/FVC (%) 50 (18 to 91) 
Exacerbation frequency (/year) 3 (2 to 5) 
Days since last exacerbation (days) 30 (12 to 188) 
NIV naïve (n) 6 (46) 
Previous Acute NIV (n) 5 (39) 
Previous Home NIV (n) 6 (46) 
LTOT (n) 
 
10 (77) 
Medications:  
SABA (n) 10 (77) 
LABA (n) 9 (70) 
Inhaled steroids (n) 10 (77) 
Oral steroids (n) 4 (31) 
Theophylline (n) 5 (39) 
Prophylactic antibiotics (n) 1 (8) 
  
Comorbidities:  
Hypertension (n) 6 (46) 
Pulmonary hypertension (n) 7 (54) 
Diabetes (n) 3 (23) 
OSA (n) 4 (31) 
Cardiac disease (n) 6 (46) 
Values expressed as n (%) or median (IQR). PO2 = arterial partial pressure of oxygen, PCO2 = arterial partial pressure of 
carbon dioxide; SaO2 = arterial oxygen saturation, FVC = forced vital capacity, FEV1 = forced expiratory volume in 1 
second. NIV = non-invasive ventilation, LTOT= long term oxygen therapy, SABA= short-acting bronchodilator, LABA= 
long-acting bronchodilator, OSA= obstructive sleep apnoea 
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6.3.2 Ventilator efficacy  
 iVAPS and standard PS ventilation performed similarly over the 24 hour periods (See Table 
6-3 and Figure 6-2). The primary outcome, the change in pH after 1 hour of each mode of 
ventilation, was not statistically different between iVAPS and standard PS ventilation; 
(median(IQR) +0.03(-0.02 to 0.07) v +0.08(0.02 to 0.11); p=0.08). Interestingly, the median 
improvement in pH did not continue to increase after 1 hour in either ventilator, despite 
continued improvements in PCO2. 
Both modes of ventilation lead to overall improvements in gas exchange. There was no 
statistical difference between the ventilator modes for any ABG improvements obsereved at 
+1, +4 or +24 hours of NIV therapy.  Notably, the PO2 was worse at +1 and +4 hours during 
standard PS ventilation than at baseline, and at +1 hour during iVAPS. However, the SaO2 
did improve over the course of the 24 hours and this was the parameter used in titration.  
Additionally, there were no statistical differences in changes observed in HR, RR or 
breathlessness after 1, 4 or 24 hours of NIV use.   
Peak benefits on physiological outcomes were observed at +4 after initiation on NIV therapy 
in both modes of ventilation, where the ventilator adherance was 79 (50 to 93)% and 99 (30 
to 100)% for iVAPS and standard PS respectively.  At 24 hours, NIV adherence was less, 
potentially limiting the overall physiological improvements; 58 (46 to 74)% v 48 (34 to 71)%. 
However, therapy adherence was similar for both modes of ventilation at all time points and 
therefore did not affect the potential efficacy of either mode. 
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Table 6-3: Changes in respiratory parameters following iVAPS and standard PS NIV therapy 
at +1, +4 and+24 hours after NIV initiation. (n=13)  
  iVAPS (n=7) Standard PS (n=6) p 
Change at 1hr pH 0.03 (-0.02 to 0.07) 0.08 (0.02 to 0.11) 0.08 
 PCO2 (kPa) -0.27 (-1.54 to 0.46) -1.33 (-1.92 to -0.41) 0.08 
 PO2 (kPa) -0.21 (-0.91 to 0.76) -0.72 (-2.04 to 0.77) 0.18 
 SaO2 (%) -1.5 (-3.0 to 5.3) -0.0 (-3.0 to 3.0) 0.82 
 RR (bpm) -5 (-7 to -2) -4 (-6 to -2) 0.78 
 Borg 0 (-0.5 to 0.8) -0.0 (-1.5 to 0.1) 0.11 
 HR (bpm) -5 (-9 to 5) -2 (-10 to 2) 0.25 
 Ventilator use 
(mins) 65 (60 to 79) 63 (56 to 79) 0.80 
     
Change at 4hr pH 0.06 (0.01 to 0.13) 0.08 (0.03 to 0.11) 0.28 
 PCO2 (kPa) -0.87 (-2.62 to -0.17) -1.74 (-2.55 to -0.43) 0.50 
 PO2 (kPa) 1.07 (-1.66 to 1.95) -0.64 (-2.94 to 0.27) 0.23 
 SaO2 (%) 0.0 (-2.0 to 2.0) 1.0 (0.0 to 2.0) 0.73 
 RR (bpm) -2 (-8 to 3 ) -4 (-11 to 0) 0.83 
 Borg n/a n/a n/a  
 HR (bpm) -4 (-9 to 1) -7 (-22 to 8) 0.48 
 Ventilator use 
(mins) 189 (119to 223) 238 (73 to 256) 0.24 
     
Change at 24hr pH 0.04 (-0.04 to 0.09) 0.07 (0.03 to 0.12) 0.22 
 PCO2 (kPa) -0.75 (-2.22 to 0.37) -1.40 (-2.66 to -0.61) 0.25 
 PO2 (kPa) 0.22 (-0.33 to 2.69) 0.26 (-1.52 to 2) 0.48 
 SaO2 (%) 0.0 (-1.5 to 3.5) 2.0 (-2.3 to 6.8) 0.46 
 RR (bpm)  0 (-6 to 2) -5 (-8 to -4) 0.21 
 HR (bpm)  0 (-16 to 6) -1 (-14 to 4) 0.72 
 Borg  0 (-1 to 0) 1 (-1 to 3) 0.24 
 Ventilator use 
(mins) 834 (656 to 1071) 695 (496 to 1020) 0.26 
All values reported median (IRQ). Missing data 1 hour: ABG (n=1), HR (n=1),  RR (n=3), Borg (n=9), hours used (n=5); 4 
hours; ABG (n=5), RR (n=4), Borg (n=12), HR (n=5), hours used (n=6); 24hours:  ABG (n=2), Borg (n=4), HR (n=1), RR (n=2), 
hours used (n=4) PO2 = arterial partial pressure of oxygen, PCO2 = arterial partial pressure of carbon dioxide; SaO2 = 
arterial oxygen saturation, RR = respiratory rate, HR = heart rate. 
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Figure 6-2: Respiratory parameters following iVAPS  (dark) and standard PS (light) NIV 
therapy at +1, +4 and+24 hours after NIV initiation. (n=13)  
Boxplots representing median (middle line), IQR (box), min-max (tails), outliers > 2 box lengths from IQR(circles); PO2 = 
arterial partial pressure of oxygen, PCO2 = arterial partial pressure of carbon dioxide; SaO2 = arterial oxygen saturation
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6.3.3 Effect of baseline measures and order of ventilation on ventilator efficacy 
A baseline comparison was made to assess for order effect (See Table 6-4). 
Comparing the first baseline period (first 24 hours) to the second baseline period (second 24 
hours) irrespective of the subsequent treatment, baseline measures were predictably 
improved for the second 24 hour period; pH was significantly lower in period 1 versus 
period 2 (7.33 v 7.38; p=0.005), PCO2 higher (9.11 v 7.94kPa p=0.06) and PO2 lower (8.33 v 
9.75kPa; p=0.02). Notably patients still reported a similar level of breathlessness on the Borg 
scale.  
However, because subsequent treatment was randomised (prior to the first period of 
ventilation), the impact of improved ventilation parameters was accounted for. Additionally, 
seven patients were randomised to receive iVAPS first, whilst only 6 to standard PS. There 
were no significant differences in baseline measures prior to the initiation of either iVAPS or 
standard PS ventilation. Blood gases were similar at baseline for both ventilation modes (pH 
7.36 v 7.34; p=0.53 and PCO2 8.38 v 8.31kPa; p=0.48).  
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Table 6-4: Baseline comparisons; a) prior to initiation on iVAPS and standard PS NIV and b) prior to the first and second 24 hour treatment 
periods (n=13) 
  A) Baseline prior to ventilator mode   B) Baseline prior to start of each 24 hour period 
 n iVAPS 
Period 1 (n=7) 
Period 2 (n=6) 
Standard PS 
Period 1 (n=7) 
Period 2 (n=6) 
p  Period 1 
iVAPS (n=7) 
Standard PS (n=6)  
Period 2 
iVAPS (n=6) 
Standard PS (n=7)   
p  
FiO2 (L/min) 9 2 (1 to 3) 2 (1 to 2) 0.18  2 (1 to 3) 2 (1 to 2) 0.93 
pH 12 7.36 (7.32 to 7.40) 7.34 (7.31 to 7.38) 0.53  7.33 (7.30 to 7.34) 7.38 (7.37 to 7.43) 0.005 
PCO2 (kPa) 12 8.38 (6.84 to 9.55) 8.31 (7.75 to 9.91) 0.48  9.11 (7.98 to 10.32) 7.94 (5.87 to 8.68) 0.06 
PO2 (kPa) 12 8.44 (7.35 to 9.00) 9.03 (7.86 to 11.11) 0.24  8.33 (7.44 to 9.28) 9.75 (7.95 to 11.27) 0.02 
SpO2 (%) 13 95 (88 to 97) 94 (90 to 97) 0.75  94 (88 to 96) 95 (91 to 97) 0.16 
HR (bpm) 13 89 (78 to 103) 89 (74 to 100) 0.60  96 (78 to 107) 89 (74 to 94) 0.12 
RR (bpm) 13 20 (20 to 23) 22 (19 to 26) 0.44  22 (19 to 25) 21 (20 to 23) 0.78 
Borg 10 1 (0 to 5) 1 (0 to 3) 0.53  1 (0 to 4) 1 (0 to 5) 1.00 
FEV1%pred 6 22 (17 to 28) 21 (18 to 31) 0.60  18 (14 to 39) 21 (17 to 31) 0.89 
FEV1/FVC 7 52 (16 to 90) 65 (20 to 68) 0.46  67 (20 to 91) 66 (28 to 85) 0.75 
SNIP (cmH2O) 7 24 (20 to 40) 30 (18 to 44) 0.45  27 (21 to 39) 29 (18 to 43) 0.27 
All data reported as median (IQR). There were no significant differences between ventilators; Significant differences between 24 hour period *. FiO2 = fraction of inspired oxygen, PCO2 = 
arterial carbon dioxide, PO2 = arterial oxygenation, SpO2 = oxygen saturation, HR = heart rate, RR = respiratory rate, FVC = forced vital capacity, FEV1 = forced expiratory volume in 1 
second, SNIP = sniff inspiratory pressure. 
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Ventilator data: Ventilator settings and delivered ventilation could have impacted the 
changes in ventilation seen. These are presented in Table 6-5. The iVAPS ventilator used a 
similar IPAP (p=0.09) but delivered a significantly lower MV (p= 0.05) by a greater Vt 
(p=0.06) but the same RR (p=0.96). The lower MV observed during iVAPS ventilation, may 
have been due to a ceiling effect of the preset maximum PS. The iVAPS did not achieve its 
target VA which was set at 10.1 (8.75 to 13.8)L/min. The delivered VA was 7 (5.7 to 
9.2)L/min. This was despite the PS boundary being set to the maximum tolerated (a median 
of 19cmH2O), therefore allowing a median maximum IPAP of 24cmH2O which was the 
median IPAP delivered. 
Other parameters may also have limited the volumes delivered by the set pressures during 
iVAPS ventilation. The rise time was similar for both ventilators, however, due to the 
differences in inspiratory time (Ti) parameters that were pre-set in each mode I cannot 
compare these. (ie. During iVAPS, minimum and maximum Ti boundaries are pre-set while in 
standard PS ventilation a fixed Ti is set. There was no downloaded data available on the 
actual Ti received during the iVAPS). 
Inspection of individual patient data showed that the lower MV observed during iVAPS 
ventilation appeared to be influenced by an outlier whose Vt increased from 568 to 1050ml 
and the MV from 6.91 to 23.20L/min when she changed from the iVAPS ventilator to 
standard PS. This was despite a mean IPAP increase of only 2cmH20 from 25 to 27 but a 
concurrent rise in leak 0 to 9L/min (see Appendix 23). Removal of the outlier resulted in no 
statistical differences in the ventilation delivered with either mode of ventilation (see Table 
6-6). 
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Table 6-5: Ventilation settings and delivery following treatment with iVAPS and standard PS 
non-invasive ventilation.  
 iVAPS Standard PS p 
Settings at 24 hours (n=12)    
Target VA (l/min) (n=13) 10.1 (8.75 to 13.8) n/a n/a 
PS min-max (cmH2O) (n=13) 3 (1.5 to 5) –  
19 (16.5 to 20) 
n/a n/a 
IPAP set (cmH2O)  n/a 23.5 (19.3 to 27) n/a 
EPAP (cmH2O) 5.5 (5 to 6) 5.5 (4.3 to 6) 0.56 
RR (bpm) 15 (12 to 16) 15 (13 to 16) 0.67 
O2 entrained (L/min) 1.0 (0 to 2) 1.0 (0 to 2) 0.32 
    
Delivered Ventilation (n=11)    
Mean NIV Usage Time (mins) 834 (656 to 1071) 695 (565 to 1020) 0.37 
IPAP median v IPAP (cmH2O) 24 (16 to 25) 24 (19 to 27) 0.09 
VA (l/min) (n=9) 7 (5.7 to 9.2) n/a n/a 
Median Minute Ventilation (l/min)  8.7  (6.9 to 11.0) 12.3 (7.5 to 17.1) 0.05* 
Median Tidal Volume (ml)  490 (453 to 647) 700 (425 to 1125) 0.06 
Median RR (bpm)  16 (14 to 17) 15 (14 to 16) 0.96 
Median leak (l/min)  6 (0 to 15) 0 (0 to 13) 0.48 
Values expressed as median (IQR). P value <0.05 considered significant, * indicates difference between ventilators was 
statistically significant.  iVPAS= intelligent volume assured pressure support, PS= pressure support, VA= alveolar 
ventilation, EPAP= expiratory positive airway pressure; IPAP= inspiratory airway pressure; RR= respiratory rate, NIV= 
non-invasive ventilation. 
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Table 6-6:  Ventilation delivery following treatment with iVAPS and standard PS non-invasive 
ventilation (outlier removed)  
 iVAPS 
(n=10) 
Standard PS 
(n=10) 
p 
Delivered Ventilation     
IPAP median v IPAP (cmH2O) 24 (15 to 25) 24 (19 to 27) 0.14 
VA (l/min) (n=9) 7 (5.7 to 9.2) n/a n/a 
Median Minute Ventilation (l/min)  9.0  (7.2 to 14) 10.6 (7.5 to 17.1) 0.09 
Median Tidal Volume (ml)  481 (443 to 663) 613 (425 to 1069) 0.11 
Median RR (bpm)  16 (15to 18) 15 (15 to 17) 0.77 
Median leak (l/min)  8 (1 to 18) 0 (0 to 14) 0.29 
Values expressed as median (IQR). P value <0.05 considered significant, * indicates difference between ventilators was 
statistically significant.  iVPAS= intelligent volume assured pressure support, PS= pressure support, VA= alveolar 
ventilation, EPAP= expiratory positive airway pressure; IPAP= inspiratory airway pressure; RR= respiratory rate, NIV= 
non-invasive ventilation. 
 
Respiratory function: Differences in the modes of ventilation delivery have the potential to 
affect differently the respiratory mechanics and respiratory muscle unloading. However, 
there were no significant differences in the changes in spirometry or global inspiratory 
strength as measured by the sniff inspiratory pressure over the 24 hour, for either mode of 
ventilation as shown in Table 6-7. Care must be taken in the interpretation of these results 
due to many patients being too acutely unwell to perform these manoeuvres. 
Table 6-7:  Changes in respiratory function over the 24 hour period of each ventilation 
mode, iVAPS and standard PS  
Change at 24 hours n iVAPS Standard PS p 
FEV1 (% predicted) 6 0 (-1 to 3) -2 (-3 to 0) 0.23 
FVC (% predicted) 6 -1 (-7 to 5) -5 (-17 to -1) 0.20 
 SNIP (cmH2O) 5 -2 (-5 to 6) 2 (0 to 6) 0.35 
Values expressed as median (IQR). Missing data due to patients being too acutely unwell to perform spirometry. FVC = 
forced vital capacity, FEV1 = forced expiratory volume in 1 second, SNIP = sniff inspiratory pressure. 
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Tolerance of and preference for NIV modes: There was no statistically significant difference 
of subjective tolerance between modes of ventilation (Table 6-8). There there was no 
overall preference for either mode of ventilation in retrospect (See Figure 6-3). 
 
Table 6-8: Subjective tolerance data following treatment with iVAPS and standard PS 
ventilation. (n=11)  
 iVAPS Standard PS p 
Comfort of Breath Delivered (mm) 67 (46 to 78) 52 (37 to 64) 0.34 
Ease of Falling Asleep (mm) 71 (52 to 85) 74 (51 to 85) 0.72 
Ease of Use of Vent (n=10) (mm) 68 (50 to 75) 52 (47 to 81) 0.21 
Liked Using Vent (mm) 55 (53 to 68) 48 (39 to 53) 0.11 
Values expressed as median (IQR). VAS= Visual analogue scale from 0 – 100mm used to score each question, 0 being 
negative and 100 being a positive response.   P value <0.05 was considered significant. 
 
 
 
Figure 6-3: VAS demonstrating patient ventilator preference for n=11; individual patient 
data plus median and distribution. 
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6.3.4 NIV titration and clinician time in the first 24 hours of acute NIV therapy 
Both modes of ventilation required similar clinician time and expertise for initiation and 
titration of therapy. There were no significant differences between titration episodes or 
number of individual adjustments made to the ventilators over the 24 hour periods (p=0.55) 
(see Table 6-9). Major adjustments included IPAP, EPAP, RR or O2 supplementation. Minor 
adjustments included breath pressurisation issues and comfort measures.  
The time spent in NIV service provision was also similar for both ventilators (p=0.92).  
Table 6-9: NIV set-up, titration and adjustments: count and time spent with patients on 
iVAPS and standard PS non-invasive ventilation. (n=13) 
NIV adjustments  iVAPS Standard PS p 
Number of adjustments 2 (1 to 2.25) 2 (1.5 to 2.25) 0.55 
 - major 1.5 (1.0 to 3.5) 1.5 (0 to 4) 0.31 
 - minor 0.0 (0.0 to 1.25) 1.0 (0.0 to 3.0) 0.17 
    
Clinician Time (mins)    
Set up 15 (15 to 19) 15 (15 to 30) 0.48 
Major adjustments 15 (15 to 38) 23 (0 to 45) 0.62 
Minor adjustments 3 (0 to 45) 15 (0 to 56) 0.24 
Total NIV time 45 (30 to 113) 45 (30 to 79) 0.92 
    
Total medical time 0 (0) 0 (0) 1.0 
Total emergency time 0 (0 to 15) 0 (0) 0.18 
TOTAL patient time (mins) 45 (30 to 120) 60 (60 to 105) 0.64 
Values expressed as median (IQR). No significant difference was observed between ventilators (p value <0.05) 
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6.4 Discussion 
This prospective study has shown that iVAPS can be used in the treatment of patients with 
acute acidotic respiratory failure. The iVAPS ventilator modality performed as effectively as 
standard PS ventilation (titrated by a skilled clinician) in improving blood gases, and 
although there was a clinically lower MV observed with iVAPS, this was associated with no 
apparent clinical detriment. Clinician time required for iVAPS therapy was similar to that of 
standard PS NIV therapy and there was no difference in patient comfort, tolerance or 
compliance in this group during acute exacerbation.  
Most trials of NIV report improvements in acidosis, gas exchange and RR, usually within the 
first hour (Bott, Keilty et al. 1993; Brochard, Mancebo et al. 1995), certainly by 4-6 (Plant, 
Owen et al. 2000). Indeed the risk of NIV failure is higher in more severe acidosis where 
there is no early improvement (Brochard, Mancebo et al. 1995; Plant, Owen et al. 2000; 
Carlucci, Richard et al. 2001; Ambrosino and Vagheggini 2007).  The improvements in pH 
and PCO2 observed in the current study are in keeping with those observed in previous 
controlled trials of standard PS NIV. Summarising the effects of NIV in larger controlled trials 
reporting on pre and post NIV, the ABG improvements are approximately +0.039(pH), -0.75 
(PCO2), +2.20(PO2) and a reduction in RR by 7.8bpm.  (Brochard, Mancebo et al. 1995; Diaz, 
Iglesia et al. 1997; Celikel, Sungur et al. 1998; Plant, Owen et al. 2000). To date, the only 
other study of VAPS in acute HRF  investigated ABG changes after 45 minutes of ventilation 
to determine the ventilator efficacy compared to standard PS (Battisti, Tassaux et al. 2007). 
Both ventilators achieved similar ABG improvements in patients of mixed diagnoses with 
correction of acidosis and reductions in PCO2 of ~0.2kPa but which remained >6.53kPa. 
A lack of continued improvement of ABGs beyond the first 4 hours in this study may have 
been associated with several issues, including the debate surrounding the ‘normalisation’ of 
blood gases in NIV therapy, as well as chronic adaptations to chemosensitivity in respiratory 
disease and NIV adherence. ‘Normalisation’ of blood gases is a debated concept. Windisch 
has lead a ‘high intensity’ debate advocating the use of high levels of PS (IPAP > 30cmH2O) 
with the aim of returning PCO2 to within normal limits, compared to lower PS levels that 
improve acidosis but where a relative hypercapnia remains (Windisch, Haenel et al. 2009). 
While this point has specifically been made for the patient group requiring chronic home 
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ventilation therapy for RF related to COPD, the principle remains in the acute setting.  In the 
current study, PS was relatively modest, with a median IPAP of 24cmH20 in both modes of 
ventilation and might explain the incomplete PCO2 correction. However, it is in acute RF 
when patients, often naïve to NIV, can be intolerant of the PS levels that are deemed 
therapeutic and are required to cause normalisation of PCO2, particularly in the crucial first 
few hours. Indeed, one published case report of AVAPS in the acute ward setting describes 
the need for lower more tolerable levels of PS for daytime treatment of hypercapnic acute 
exacerbations of COPD, whilst providing greater overnight support to counteract nocturnal 
sleep disordered breathing and hypoventilation (Okuda, Kashio et al. 2012).  The titration 
protocol for iVAPS in this study was to increase target VA by 5% for each 0.5kPa CO2 
reduction desired. In a large AVAPS study in OHS, the target Vt was increased by 10% for the 
same desired CO2 reduction (Murphy, Davidson et al. 2012). However, by targeting VA, 
rather than Vt, the deadspace ventilation is negated as is the effect of RR on the overall MV. 
Thus, a lower percent increase in target ventilation was feasible. 
The primary aims of NIV in acute RF, are to reverse acidosis and to provide adequate 
oxygenation, and also prevention of ultimate respiratory muscle fatigue by correction of the 
rapid, shallow breathing pattern associated with acute exacerbations.  The mechanism of 
acute ABG changes is due to change in VA, not V/Q matching (Diaz, Iglesia et al. 1997).  NIV 
augments VA by increasing Vt, allowing RR and thus WOB to decrease (Tobin, Jubran et al. 
2001). It is thus suggested that iVAPS, with targeted volumes provided by the lowest PS 
required, might be an alternative approach to correction breathing pattern rather than by 
providing constantly high pressures. However in the current study, there was a reduction in 
the 24 hour RR observed only in the standard PS ventilation strategy which may suggest that 
the lower tidal volumes observed during iVAPS ventilation were sub-optimal. This is 
informative, since patients’ VA requirements can often far exceed the ml/kg algorithms that 
clinicians use to guide settings. Target values for VA were set according to formulae based 
on a Vt of 10 to 12 ml/kg and calculated for a standardised 15bpm. Acute patients may 
require higher ventilation targets during periods of exacerbation. Higher target volumes 
particularly may be required despite improving PCO2 and SaO2 levels, which may not 
indicate a lower WOB for the patient (as evidenced in this study by the RR remaining 
elevated). Concurrently, however, in the current study the patients’ perception of 
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breathlessness was minimal with surprisingly low Borg scores at all times, despite a high RR 
and profound hypercapnia and hypoxia. This may be explained by the group of complex 
patients studied with chronic RF, half of whom had previously required NIV, who have 
adapted to chronic breathlessness as part of their normal symptom burden.  A chronically 
reduced chemosensitivity in these patients is also likely to play a significant role in their 
perception of breathelessness, particularly as 77% were also users of LTOT.  
The treatment of acute RF with NIV is more successful with increasing clinician skill and 
experience which also allows for treatment of more unwell patients non-invasively (Carlucci, 
Delmastro et al. 2003; Girou, Brun-Buisson et al. 2003).  It was postulated that autotitration 
may reduce the considerable skill and expertise required to set and titrate the therapeutic 
balance of tolerable PS and breathing pattern. In this study, however, autotitrating iVAPS 
required similar number of adjustments and time spent in initiation and titration of therapy 
as did standard PS NIV.  This can be related to the initial underestimate of VA required 
(based on ml/kg) during acute exacerbation, but may also be related to the maximum PS 
tolerated by the patient. This level may be insufficient to produce the pre-set targeted 
volume. This PS ceiling effect remains a limitation to the iVAPS functionality and its potential 
benefits in reducing manual titration time. Also, the iVAPS mode has a maximum IPAP of 
30cmH2O. In patients who required a maximum IPAP of 30, the level of PS received was 
influenced by their level of PEEP, thereby creating another limitation to achieving targeted 
Vt.  
iVAPS also offers a validated learn function to automatically determine ventilation settings 
(Jaye, Chatwin et al. 2009; Kelly, Jaye et al. 2014). In the current study this function was not 
used. It was deemed that in the acute setting, the ventilator has the potential to learn the 
dysfunctional rapid, shallow breathing pattern of the acutely unwell patient.  However, I 
observed that target VA value was often far greater after titration than the initial setting 
based on ml/kg set.  Perhaps the learn period may be of use, but only to determine the 
required VA and not the patient’s preferred breathing pattern. Unfortunately the learn 
period would consist of wearing a mask with minimal PS to determine current level of VA 
which would be difficult for these patients to tolerate.  I would recommend the use of O2/ 
CO2 monitoring during initial ventilation until PCO2 is corrected. This technique has been 
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used reliably in NIV intiation previously (Storre, Magnet et al. 2011).  A ‘learn period’ may 
then be performed to set targets for the remaining therapy. But again, this requires 
equipment and knowledge. 
6.4.1 Methodological issues and study limitations 
Previous studies comparing different ventilatory modes in the acute setting have used a 
variety of primary outcomes including NIV failure and ET, ABGs before and after each 
intervention (Meecham Jones, Paul et al. 1995), and change in respiratory indices (Kirakli, 
Cerci et al. 2008).  An improvement in pH at one hour is considered a clinical success (Bott, 
Keilty et al. 1993; Brochard, Mancebo et al. 1995) and as such forms part of recommended 
guidelines (BTS 2002). Therefore this is an appropriate primary outcome, which would 
otherwise be part of clinical practice in the assessment of NIV efficacy. 
A 24 hour period of NIV therapy allows both ventilator efficacy and patient tolerance and, 
therefore, compliance to be investigated in response to the new algorithm over the 
important first 24 hours of NIV treatment. A washout period is required to prevent prevent 
carryover effect in a crossover trial (Meecham Jones, Paul et al. 1994; Girault, Leroy et al. 
1997). Baseline measures were taken with the patient spontaneously breathing, on 
supplemental O2 as required. Measures made at 1 and 24 hours after NIV initiation were 
attempted to be made on NIV. A washout period of one hour was attempted, however this 
was not always possible as some patients refused to remove NIV for this length of time.  
Transcutaneous CO2 was used to detect 24 hour trends; the more accurate paCO2 was used 
for spot measures. There is limited or no correlation between transcutaneous and arterial 
PCO2 in conditions that affect the arterialisation of the earlobe, including profound 
peripheral vasoconstriction, which occurs frequently in acute exacerbations of COPD.  
Results of this study must be interpreted with caution as only thirteen patients were studied 
and they were a heterogenous population.  Recruitment was difficult in a tertiary referral 
centre with no emergency department.  This reduced the power of the study to 80%. 
However, patients acted as their own controls during the crossover and as such we could 
gain important data from their ventilator interactions.  During an acute exacerbation, we 
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would expect a rapid improvement in blood gas disturbance and symptoms if treated is 
effective. Thus we would expect the second 24 hours of monitoring to present with 
significant improvements in patients’ respiratory stauses as we observed in this trial.  iVAPS 
benefits might therefore be underestimated due to 7 of the 13 patients having been 
randomised to receive iVAPS first. Newer ventilators now have the facility to provide higher 
levels of pressure support (up to 40cmH2O) would be beneficial, particularly in ‘normalising’ 
blood gases. 
6.5 Conclusion 
This study has shown that iVAPS can be used as an alternative mode of NIV in the treatment 
of patients with acute acidotic respiratory failure. Results must be interpreted cautiously 
due to the small, heterogenous sample of complex NIV patients that were treated in our 
tertiary referral centre.  Many patients had co-existing morbidities, including obesity, heart 
failure and pulmonary hypertension, all of which are compounding factors on the success of 
NIV. These conditions also independently affect the ventilator settings at initiation. Acute 
hypercapnic, acidotic exacerbations of chronic respiratory failure were also complicated in 
this study for a number of reasons including acute cardiac decompensation or pulmonary 
oedema, decompensation of existing ventilatory disorder and even due to non-compliance 
with domicillary NIV.  On the other hand, these are the patients needing NIV treatment. 
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7.1 Introduction 
The final chapter of this thesis includes a summary of its aims and main findings, a 
discussion of the clinical benefits of iVAPS and the lessons learnt in its application. 
Furthermore, future directions for the use of iVAPS are outlined.  Examples of best practice 
observed in this thesis are also discussed.  
7.2 Summary of Aims 
The delivery of NIV has evolved significantly over recent years.  Volume assured pressure 
support (VAPS) is a new autotitrating mode of ventilation combining the benefits of 
pressure and volume- preset ventilators.  The overall aim of this thesis was to investigate 
the use of autotitrating VAPS NIV in patients with chronic HRF during wakefulness and 
sleep, specifically in the detection and treatment of acute exacerbations.  
7.3 Summary of Main Findings 
1) During iVAPS therapy, stable state VA is maintained during exacerbations when 
airway resistance (Raw) is increased (Chapter 3). Additionally, wake levels of VA are 
maintained during sleep, and across sleep stages, when muscle tone and respiratory 
drive are decreased and MV usually decreases (Chapter 4) 
2) The mechanism of maintenance of VA is potentially due to complex patient-
ventilator interactions, and individual variation (Chapters 3 and 4). No obvious 
differences in the ventilator responses in obstructive or restrictive pathologies were 
found, despite a higher variability in Raw in obstructive pathologies (Chapters 3 and 
4) 
3) No individual ventilator-measured parameters could be used to indicate the 
presence of, or predict, an impending exacerbation during domiciliary iVAPS 
ventilation (Chapter 3) 
4) iVAPS is as effective as standard PS NIV in the treatment of acute HRF (Chapter 6) as 
well as in patients with newly diagnosed chronic ventilatory failure and who are 
naïve to NIV (Chapter 5). An increased adherence to nocturnal therapy was observed 
during chronic iVAPS ventilation (Chapter 5). 
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5) The intelligent ‘learn function’, enabling the ventilator to automatically select 
ventilator settings, was useful in chronic respiratory failure patients, naïve to NIV, 
but not in patients in acute respiratory failure (Chapters 3 and 6). However, iVAPS 
ventilation, despite its automated functions, requires some clinical knowledge and 
skill for effective use (Chapter 5 and 6). 
7.4 Clinical benefits of iVAPS 
This thesis shows that iVAPS can be used as an alternative mode of NIV in the treatment of 
chronic HRF across a variety of pathologies (Chapters 3 and 5).  Novel data is also shown on 
the use of iVAPS in treating patients with acute HRF outside of an ITU setting (Chapter 6). 
More specific benefits are outlined below. 
1) Maintenance of VA: 
In Chapters 3 and 4, the iVAPS mode was used in the nocturnal ventilation of patients with 
chronic HVF.  In Chapter 3, stable state ventilation was compared with ventilation during an 
exacerbation while in Chapter 4, wake ventilation was compared with ventilation across 
sleep stages. Both studies confirmed that iVAPS does maintain VA, despite a significant 35% 
decrease in PEF (Chapter 3). Stable VA was also observed during overnight iVAPS ventilation 
in conjunction with preserved sleep stage distribution (Chapter 4). Together these data 
provide clinicians with confidence that MV can be maintained in patients receiving 
domicilary iVAPS ventilation, even in the face of the changes in respiratory function, 
where standard PS may not. The ability of iVAPS to maintain a preset target ventilation, 
based on wake ventilator parameters, may also reduce the number of sleep studies 
necessary for NIV initiation.  Follow-up frequency might also be reduced, mindful that the 
ventilator will autotitrate in the face of disease progression. 
2) Automated selection of ventilation targets and settings: 
In all Chapters (except Chapter 6), ventilation targets were set based on the automatic 
intelligent learn function, which uses an algorithm set to target 100% of patients’ wake 
ventilation. This thesis suggests that this is an  appropriate target; compared to the previous 
target of 90%, when a slight but significant underventilation was observed (Jaye, Chatwin et 
al. 2009). In previous literature, the ‘learn period’ has been performed under a variety of 
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circumstances including on PEEP alone, or on arbitrary PS levels. The use of tcPCO2 
monitoring during the learn period would ensure a more accurate target VA for ventilatory 
control and be an indicator of adequate minimal PS boundary settings (Storre, Magnet et 
al.; Storre, Magnet et al. 2011).  This however requires added expertise and equipment at 
the time of NIV initiation, but it may be beneficial in the longterm by obviating the need 
for overnight sleep studies. 
3) Individualised therapy: 
Autotitrated ventilator responses to changes in airway physiology vary greatly between 
individuals, independent of diagnosis. In some patients there is little or no change in PS, 
whereas in others there are more frequent and/or more marked modifications(Battisti, 
Tassaux et al. 2007), and in some the PS remains stable while the RR changes, since the 
algorithm allows for combined interactions of responses by PS, RR, Ti and triggering 
variables. 
7.5 Clinical lessons learnt 
1) Setting ventilation targets:  
 iVAPS ventilation is effective in maintaining preset ventilation targets. A learning point 
should be made that clinicians ensure normocapnic ventilation (with or without support) 
prior to using the ‘learn period’ for the automated selection of ventilation targets. 
2) Preset PS boundaries:  
Data from patients included in this thesis are informative for clinical practice regarding 
setting selection. Preset PS boundaries deemed safe with respect to patient diagnosis, are 
clinician-determined.  There are no set guidelines for setting such boundaries and clinicians 
and researchers have adopted various methods including; use of the widest possible range 
(OcmH2O to maximum tolerated PS) to setting a tighter range (a few cmH2O above and 
below patients’ previous PS levels required to produce desired MV). A pragmatic approach 
was adopted in this thesis to promote NIV tolerance, however both ‘floor’ and ‘ceiling’ 
effects were observed relating to the PS used to achieve the target VA. Patients recruited for 
studies in Chapter 3 and 4 were not naïve to NIV and were frequently intolerant of the new 
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‘learnt’ targets, particularly the target RR, which was often much higher than the patient’s 
previous ventilator settings. A lower RR, thereby required higher PS levels than would 
otherwise have been required to maintain targeted MV.  
 
 
 
 
 
 
 
 
 
 
 
 
 
3) Ventilator settings during exacerbations:  
In Chapter 6, the ventilator used to deliver iVAPS (AutoVPAP) was limited due to a maximum 
IPAP of only 28cmH2O. Subsequent ventilator models supporting iVAPS (eg the Stellar 150) 
achieve an IPAP >35cmH2O and would therefore be more appropriate for patients often 
necessitating higher pressures for CO2 correction.  Also, the automatic learn function is not 
applicable during acute exacerbations when patients’ breathing patterns are often 
compromised and VA is inadequate. Target VA was therefore set using manual calculations 
based on ml/kg calculations. Initial target VA was prone to underestimation during this 
study, requiring further manual titration. Patients may have increased MV demands during 
an exacerbation that exceed their usual metabolic requirements. Also, obesity in itself can 
lead to increased ventilation demands. I therefore based calculations on actual body weight, 
not ideal body weight.    
Guidance for setting PS boundaries to achieve target VA and patient tolerance: 
 OHS: minimum PS often needs to be high to overcome the decrease in lung 
volumes and increase in WOB with position change from sitting to supine. 
 NMD: minimum PS needs to be high to give the patients the sense of security of 
adequate Vt in the presence of weakness.  
 COPD or asthma: the PS range can usually be set wider to allow for more variable 
lung resistance and compliance. A lower minimum PS may therefore increase 
patient comfort and reduce the side effects (bloating, leak etc). 
 NMD/CWD: PS  boundaries may need to be set with ventilation aims other than 
arterial blood gas maintenance; ie. Lung and chest wall stretching, nocturnal 
muscle resting. 
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iVAPS was used during acute exacerbations, outside of an ITU setting. The automated 
nature of autotitration has the potential to assist in an environment with less monitoring, 
lower staffing ratios and potentially less expertise. However, this thesis has shown that 
considerable skill is required to appropriately titrate both target ventilation and other 
ventilator settings. 
4) Mechanisms of VA maintenance 
The mechanism for the maintenance of VA during the studies of iVAPS remains unclear. 
Expectations were that the RR may rise during exacerbations, or that the PS required to 
attain the target volume may increase to counteract increases in Raw. However, neither of 
these findings were observed despite prior bench testing (Fauroux, Leroux et al. 2010).   
 
 
 
 
 
 
 
 
 
 
 
Potential reasons that mechanisms of VA maintenance were not clear in this thesis 
include the following: 
 amplitude of changes:  may be small and therefore difficult to detect; In patients 
with restrictive pathologies where volumes and flows are small, detecting change 
might be more difficult still.  
 simultaneous changes: of different parameters (eg: PS and RR, or Ti) 
 ‘floor’ and ‘ceiling’ effects: of PS boundaries that prevent further titration to 
achieve VA 
 variability: between patients, independent of diagnosis 
 patient-ventilator asynchrony + ineffective patient efforts unregistered by the 
ventilator: no external measure of patient effort to confirm the synchrony between 
patient effort and ventilator support. 
 algorithm based on flow: high patient flow rates during periods of increased WOB 
(ie. during exacerbation of COPD or the supine position in obese patients), can be 
interpreted by the ventilator as adequate patient inspiratory flow generation, 
thereby preventing increased support despite high patient effort.  
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7.6 Future directions  
1) Exacerbation prediction 
Exacerbations, particularly of COPD, have no clear cut objective predictive measure. 
Additionally, there does not appear to be any predictive change in any ventilator-measured 
parameters during iVAPS therapy. However, individuals have similar responses in repeat 
exacerbations, leading to several future possibilities with respect to exacerbation prediction: 
a) ‘Individualised medicine’: An individual’s response to pertubations to ventilation 
might need to be assessed in the same way as individual response to drug therapy. 
The ability to predict an exacerbation in an individual may therefore be based upon 
data collected from a previous exacerbation. This is important, particularly as the 
greatest predictor for frequent exacerbations is prior exacerbations (Hurst, 
Donaldson et al. 2009). Also, frequent exacerbators have worse QoL and a faster 
decline of lung function.  
Once the normal variation of ventilatory parameters is determined in an individual 
susceptible to exacerbations, then perhaps alerts could be set on the patient’s own 
ventilator should the measured parameters fall outside of their own ‘normal’; not 
dissimilar to the use of PEF in asthma whereby percentage reductions from baseline 
are considered significant. This process has previously been used with some success 
during standard PS ventilation (Borel, Pelletier et al. 2015). Ventilation parameters 
were labelled as ‘abnormal’ if they fell outside the inidivdual patient’s own IQR for 
each parameter; an increase in RR and percentage of triggered breaths was observed 
pre-exacerbation onset.  
b) Clustering: Recently, chronic disease management has utilised a ‘clustering’ 
approach to the classification or ‘phenotyping’ of disease characteristics and 
presentation. Previously, COPD exacerbations had been clustered temporally, 
revealing differences between isolated, initial and recurrent exacerbations (Hurst, 
Donaldson et al. 2009). The same practice could be extended to exacerbations by 
clustering them according to the ventilator response. Key to this practice will be to 
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phenotype exacerbations in more patients, perhaps clustering them according to 
their individual ventilatory characteristics eg: those patients who maintained 
ventilation by increased PS (and thereby Vt) compared to those who increased RR. 
Phenotyping different ventilator responses may better enable clinicians to marry 
up personalised care with new technologies- both with respect to potentially 
identifying exacerbation predictive signals and also to assist in the identification of 
patients in whom iVAPS may be of longterm benefit. 
 
c) Exacerbation identification and analysis: As discussed at length in Chapter 3 section 
4, analysis of exacerbations requires careful consideration of the following: 
exacerbation definition (symptom-, therapy- or healthcare utilisation- defined), 
timeframe and characteristics of prodrome, onset and recovery from exacerbations, 
and also standardisation of measured parameters.  A standardised definition of 
exacerbation in COPD would allow more comprehensive comparison of results 
across studies. Statistical analysis methods based on a moving-time platform make 
the most sense in prospective exacerbation prediction. 
2) iVAPS in exercise and rehabilitation 
Exercise plays an important role of the therapy of patients in CHRF (Spruit, Singh et al. 2013) 
both in the acute (hospital and ITU) and chronic settings. NIV enhances the benefits of 
exercise in these patients by reducing the ventilatory limitations and thereby reducing 
dyspnoea and allowing exercise at a greater intensity and duration (Corner and Garrod 
2009; Dyer, Flude et al. 2011). However, exercise presents another ‘physiological challenge’ 
to patients with CHRF.  Similarities between exercise and acute exacerbations exist; 
increased VO2 with increased ventilatory demand, changes in respiratory pattern (increased 
RR, decreased Vt, increased inspiratory flow rate), DHI in obstructive patients, and muscle 
fatigue in restrictive patients.   
Often, clinicians will increase patients’ ventilatory support in ITU to allow greater peripheral 
muscle exercise. However, the amount of ‘added support’ is often arbitrary. An NIV mode 
that could respond to patient’s increasing requirements may be more tolerable.  Several 
modes of ventilation have previously investigated this notion eg: PAV (proportional assist 
    
 220 
ventilation) by assessment of lung mechanics and work of breathing and NAVA (neutrally 
adjusted ventilator assist) by continuous diaphragm EMG monitoring. I would not 
recommend iVAPS in this situation. The algorithm for VA maintenance is based on flow, not 
on any measure of neural drive or diaphragm work. iVAPS targets a preset VA and therefore 
would not increase its MV in accordance with increasing oxygen consumption demands 
during exercise. Secondly, even if iVAPS could increase its target MV in accordance with 
increased metabolic demand, there is still the issue of a flow-based algorithm ie. PS may 
not be increased if VA and inspiratory flow rates are deemed ‘adequate’, despite high 
patient WOB. 
7.7 Examples of best practice  
Key challenges for health care in the UK include disease prevention, inequalities in care and 
a gap between funding and efficiency. The UK department of health (DoH) framework for 
action towards personalised health care focuses on the use data and technology to 
transform outcomes for patients by improved quality and reduced cost of health services 
(National Information Board 2014). Digital technology is set to transform the way that 
healthcare is provided, specifically by the development of digital platforms for improved 
access to and sharing of health records.  Initiaitives such as remote patient monitoring eg. 
Telemonitoring and indeed ventilator data monitoring are in keeping with tackling these 
issues. Real-time digital information on patients’ health enables professionals to be better 
informed, and thus deal more efficiently and effectively with illness and disability.  
Furthermore, collaborations between the NHS, technology companies and patients may 
unlock the innovative potential of data and technology to create products for smarter, 
faster and better healthcare.   
1) Personalised health care:  
Personalising health care has been central to the DoH’s goals, specifically for patients with 
long term conditions. Development of new ventilators and modes of ventilation are focused 
of improving patient comfort, and thereby compliance, with the overall aim of increasing 
efficacy of NIV therapy. The iVAPS algorithm was developed specifically to address comfort 
and patient-ventilator synchrony whilst maintaining ventilation in the face of changing 
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respiratory physiology. The autotitrating algorithm allows both an automated setting 
selection based on an individual’s own respiratory pattern as well as continual realtime 
adjustment to ventilatory parameters to achieve a constant VA. A common theme 
throughout this thesis, is the individual variation of patient’s ventilatory requirements, both 
during stable state and during exacerbation. It stands to reason therefore that ventilator 
responses are also individual, independent of diagnosis. The iVAPS features, therefore, 
have been shown to provide a personalised, targeted therapy.   
2) Disease prevention:  
A proactive approach with more focus on prevention of disease and complications or 
exacerbation, is key to producing efficiency savings including reductions in hospital 
admissions and healthcare utilisation. Patients on NIV have very little reserve and early 
identification of exacerbations and timely treatment is in the interest of patients, caregivers 
and the healthcare systems as patients may be treated at home and therefore prevent 
hospital admissions. Identifying ventilatory parameters that predict exacerbations could aid 
this process. Both RR and the percentage of patient-triggered breaths have been observed 
to increase prior to an exacerbation during other therapies; LTOT and standard PS therapy 
(Yanez, Guerrero et al. 2012; Borel, Pelletier et al. 2015). 
Remote monitoring of ventilator-measured parameters could allow clinicians early means 
of exacerbation identification, should future research be successful in determining a signal 
parameter. Such ‘in-home’ monitoring has already been successful in telemonitoring in a 
wide range of chronic diseases (Pare, Jaana et al. 2007). Remote monitoring is also widely 
used in Europe for those on patients on CPAP therapy and has been seen to increase 
compliance and reduce care time by healthcare providers. Individualised care, closer to 
home aims to reduce inequalities and improve access to services.   
3) Working with industry:  
Clinical trials play an essential role in the validation of new medical devices and 
technologies. The studies in Chapters 5 and 6 have benchmarked iVAPS against current best 
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practise, standard PS ventilation in the treatment of patients with both chronic and acute 
HVF. All new modes of ventilation should be tested in such a manner.  
Working with industry, in this case ResMed Ltd (Australia) has enabled the robust clinical 
validation and safe implementation of new ventilator technologies within the NHS 
framework (‘combinatorial innovation’) with the intention of improving care for patients 
requiring NIV therapy. The studies were conceived, designed and performed independent 
of the manufacturer, Resmed Ltd (Australia) to avoid conflict of interest which is of 
paramount importance scientifically. However the benefit of working with industry is 
discussed below:   
The ventilators (Stellar 150, AutoVPAP and VPAP III STA) and humidification units were all 
loaned by ResMed Ltd (Australia). Consumables including masks, tubing, filters were 
provided from the NHS budget as these patients were already on NIV therapy or would 
otherwise be initiating NIV with continued care provided by the NHS. Financial investment 
by Resmed also included 20 laptops for data transfer and storage (18 netbooks at £150) and 
an unrestricted research grant (£178, 000), and technical expertise (data management 
systems). At the end of the trial, those patients who preferred iVAPS to their previous 
ventilation were allowed to keep the ventilators as a goodwill gesture from ResMed Ltd 
(Australia) (18 ventilators at £3,500 each). Partnership with Resmed, therefore provided 
estimated cost savings for the trial of in excess of £250,000. 
The collaboration has also had an impact on the refinement of the iVAPS algorithm. Initially 
set to target 90% of a patients’s wake ventilation. Our group demonstrated a relative 
nocturnal hypoventilation. Resmed Ltd (Australia) responded by increasing the target to 
100% and the data within this thesis provide evidence that this is sufficient to maintain 
ventilatory control overnight. 
4) Patient involvement:  
Patient involvement was essential throughout this thesis, both in the validation of the new 
ventilator mode, and also in informing of its benefits and limitations. Information was also 
gathered on the usefulness of the intelligent ‘learn function’ and also showed which 
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patients most benefitted most from the iVAPS autotitration.eg. patients who had large MV 
and would otherwise require large pressures, patients with large fluctuations in their Raw. 
Patients in whom limitations of the ventilator mode were more obvious included breathless 
patients (flow rate) or OHS patients during position change to supine. In chapters 5 and 6, 
patients used visual analogue scales to quantify their experience with the new mode of 
ventilation, and in particular they were asked to compare it to the best practice – pressure 
support. 
In Chapter 3 patients kept daily diaries of their symptoms and their PEF. No detriment to 
anxiety, depression or HRQoL was observed as a result of the increased focus on day-to-day 
chronic disease variation. In some patients, such actions empowered them to be more 
proactive in their approach to managing their condition. 
7.8 Overall Summary  
Autotitrating iVAPS is an effective mode of ventilation in the treatment of hypercapnic 
respiratory failure, both chronic and acute. Alveolar ventilation is maintained during iVAPS 
therapy, even during periods of changing ventilatory requirements associated with sleep 
and exacerbations. The mechanism of maintenance of VA remains unclear. What is 
important is to understand the characteristics of exacerbations and individual ventilatory 
responses, and also whether an autotitrating mode of NIV improves outcomes of 
exacerbations, including survival. 
7.9 Epilogue 
In chronic COPD, the latest evidence has revealed that NIV, when targeted to reduce carbon 
dioxide, does increase survival (Kohnlein, Windisch et al. 2014). Furthermore, we await the 
results of a trial focussing on patients who have recently received acute NIV for acute COPD 
exacerbations (HOTHMV trial). A combined effect of the results of these trials may be that a 
far greater number of COPD patients are referred for chronic NIV. With the phenotyping of 
individual patients’ ventilator responses to exacerbations, we will be better placed to apply 
new technologies, including new modes of ventilation, such as iVAPS.  
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Appendix 2:  Patient consent form (Chapter 3) 
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Appendix 4: Patient consent form (Chapter 5) 
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Appendix 6:  Patient consent form (Chapter 6) 
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Appendix 7: VPAP and AutoVPAP data capture detail 
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Appendix 8:  Data Management: Exacerbation Logger for Stellar 150 ventilator 
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Appendix 9: Daily Symptom Diary 
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Appendix 10: Exacerbation Detection Protocol 
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Appendix 11: Visual Analogue Scale (VAS) for subjective ventilator tolerance 
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Appendix 12: Symptom burden, HRQoL, co-morbidities and medications in n=30 patients 
who completed the study 
 Total Completed 
(n=30) 
Restrictive 
 (n=10) 
Obstructive 
 (n=20) 
p 
Baseline Stable 
Symptoms  
    
Breathlessness 23 (77) 5 (50) 18 (90) 0.03 
Sputum Colour 4 (13) 0 (0) 4 (20) 0.27 
Sputum Volume 13 (43) 3 (30) 10 (50) 0.44 
Cold symptoms  12 (40) 2 (20) 10 (50) 0.24 
Wheeze 9 (30) 1 (10) 8 (40) 0.20 
Sore Throat 1 (3) 1 (10) 0 (0) 0.33 
Cough 15 (50) 3 (30) 12 (60) 0.25 
Fever 3 (10) 0 (0) 3 (15) 0.53 
Night Time Symptoms/ 
Disrupted Sleep 
18 (60) 5 (50) 13 (65) 0.46 
Reduced Physical Activity 28 (93) 9 (90) 19 (95) 1.00 
     
Baseline HRQOL:     
SGRQ Symptom Score 49.5 (23.6 to 75.1) 43.2 (23 to 56.7) 54 (19.5 to 77.9) 0.25 
SGRQ Activity 77 (56.4 to 92.5) 69.6 (34.2 to 86.1) 82.5 (62.1 to 92.5) 0.25 
SGRQ Impacts 41.2 (24.2) 40.6 (17.8) 41.6 (27.3) 0.91 
SGRQ TOTAL 53.7 (23.4) 45.6 (19.4) 57.8 (24.6) 0.15 
HAD Anxiety 7.1 (4.2) 4.9 (3.3) 8 (4.3) 0.06 
HAD Depression 6 (4 to 8) 4 (1 to 8.5) 6 (4.3 to 7.8) 0.30 
     
Comorbidities     
Obesity 15 (50) 4 (40) 11 (55) 0.70 
Heart Disease 8 (27) 2 (20) 6 (30) 0.68 
Hypertension 11 (37) 3 (30) 8 (40) 0.70 
Diabetes 6 (20) 0 (0) 6 (30) 0.07 
OSA 7 (23) 0 (0) 7 (35) 0.06 
Smoking History:     
Ex 17 (57) 2 (20) 15 (75) <0.01 
Never 11 (37) 8 (73) 3 (15)  
current 2 (7) 0 (0) 2 (10)  
Pack years 36.9 (30.3) 48.5 (67.2) 35.6 (27) 0.83 
     
Prescribed Medications     
SABA 23 (77) 5 (50) 18 (90) 0.03 
LABA 21 (70) 3 (30) 18 (90) <0.01 
Inhaled Steroid 19 (63) 3 (30) 16 (80) 0.02 
Oral Steroid 6 (20) 1 (10) 5 (25) 0.63 
Theophylline 4 (13) 0 (0) 4 (20) 0.27 
Prophylactic Antibiotics 5 (17) 2 (20) 3 (15) 1.00 
LTOT (n) 13 (43) 2 (20) 11 (55) 0.12 
 Data are presented as n (%) mean (SD) or median (IQR). Differences between pathologies were compared by unpaired t-
tests or Mann-Whitney. Categorical data are presented  as n (%) and compared by Chi2 or Fischer’s exact test. P<0.05 
was considered significant. OSA = obstructive sleep apnoea, SABA= short acting bronchodilator, LABA= long acting 
bronchodilator, LTOT= long term oxygen therapy, HRQoL= health-related quality of life, SGRQ= St George Respiratory 
Questionnaire, HAD = Hospital Anxiety and Depression score 
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Appendix 13: Time course of ventilator-measured parameters at exacerbation with outlier excluded (n=14) 
  
   
 
Time course of symptom count, peak expiratory flow (PEF) and ventilator parameters, alveolar ventilation (VA), pressure support (PS), respiratory rate (RR), and tidal volume (Vt) from 
seven days prior  (-7) to exacerbation onset (day 0, vertical line) and seven days into exacerbation (+7) of chronic respiratory failure. Values are expressed as mean and 95% CI (in SD 
multiples away from each patient’s stable mean) for each variable. Dashed lines represent ± 1.96 standard deviations away from a mean, where 95% of all stable measures would be 
expected to fall.  
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Appendix 14: Longitudinal measures of lung function and health related quality of life over 
the 4 month study period; measures made at baseline, 1 month and 4 months.  
 Baseline 1 month 4 months p 
BMI (kg/m2) 30 (23 to 41) n/a 30 (22 to 40) 0.09 
FEV1 (% pred) 30 (18 to 51) 38 (19 to 57) 38 (21 to 47) 0.48 
FVC (%pred) 49 (19) 49 (17) 53 (18) 0.32 
FEV1/FVC 65 (24) 64 (21) 63 (24) 0.56 
PEF (L/min) 174 (120 to 237) 195 (129 to 
255) 
178 (104 to 
254) 
0.91 
SaO2 (on air) (%) 96 (93.5 to 97.5) 97 (95 to 97.3) 97 (95 to 98) 0.83 
tcPCO2 (on air)  (kPa) 6.12 (0.91) 6.19 (1.0) 5.96 (0.76) 0.29 
HR (on air)  (bpm) 87 (15) 88 (17) 89 (17) 0.65 
     
HRQoL:     
SGRQ Symptoms 59 (22)* 52 (24) 51 (23)*  0.04 
SGRQ Activity 80 (16) 82 (14) 80 (18) 0.54 
SGRQ Impacts 48 (22) 48 (23) 48 (21) 0.98 
SGRQ Total 59 (18) 59 (18) 57 (18) 0.08 
HAD Anxiety 7 (5) 7 (4) 8 (4) 0.43 
HAD Depression 6 (4) 6 (4) 7 (4) 0.69 
Repeated measures ANOVA was used to compare longitudinal physiological and quality of life measures. Post hoc paired 
t-tests with bonferonni correction were used to further investigate significant differences between time points. *p=0.04 
BMI = body mass index, FEV1 = forced expiratory volume in 1 second, FVC= forced vital capacity,  SaO2 = arterial oxygen 
saturation, tcPCO2 = transcutaneous carbon dioxide, HR = heart rate, SGRQ = St George Respiratory Questionnaire, HAD 
= Hopsital Anxiety and Depression Questionnaire.  
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Appendix 15:  Robust regression of measured variables, clustering for patients and accounting for the day of exacerbation: all exacerbators 
(n=21). 
  Exacerbation  
Coeff(95%CI) 
p Exacerbation Day  
(Day -14 to exacerbation 
end) 
Coeff(95%CI) 
p 
          
Peak Flow (L/min) -10 (-22 to 3) 0.12 0.3 (-0.7 to 1.3) 0.50 
Nightly Use (mins) 
-7 (-38 to 24) 
0.63 
0 (-1 to 1) 
0.64 
Alveolar Ventilation (L/min) 1.0 (0.4 to 1.7) <0.01 0 (-0.1 to 0) 0.40 
Pressure Support (cmH2O) 0.7 (-0.5 to 1.8) 0.23 0 (-0.1 to 0)  0.04 
Respiratory Rate (bpm) 
-0.4 (-0.7 to 0) 
0.03 
0 (0) 
0.71 
Tidal Volume (ml) 79 (24 to 133) <0.01 -2 (-7 to 2) 0.29 
Leak (L/min) -0.2 (-2.2 to 1.9) 0.88 0 (-0.1 to 0.1) 1.00 
I:E 0 (-0.1 to 0) 0.58 0 (0) 0.63 
Inspiratory time (s) 0 (0) 0.53 0 (0) 0.32 
Regression coefficients  for all exacerbators (n=21). To investigate any change in parameters associated with the time course of exacerbations, data was compared by regression with 
robust variance (ordinary least squares regression with clustered Huber variances (subjects) and factor(time in days)). Day of onset was labelled day 0, and days -14 to +(x) were thus 
defined, where x is the length of exacerbation. Days -14 to -8 were considered as stable state (no prior exac 1/52); and days -7 to -1 were the prodromal period. 
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Appendix 16: Daily measured PEF, symptoms and ventilator data: stable state  v symptom-defined exacerbation  
 Stable (7 days) Exacerbation (x days) p 
Daily Patient Diary:    
Peak Flow (L/min) 195 (84) 188 (75) 0.03 
Daily activity (hrs) 2.2 (1.4 to 2.9) 1.6 (0.9 to 2.9) 0.04 
Total daily symptoms (n) 0.1 (0 to 0.9) 1.7 (1.5 to 2.2) <0.01 
Total daily treatments (n) 0 (0 to 0.2) 0.9 (0.6 to 1.4) <0.01 
    
Ventilator-measured Data:    
Nightly Ventilator Use (mins) 502 (393 to 594) 494 (427 to 577) 0.51 
Alveolar Ventilation (L/min) 8.3 (5.9 to 11.7) 8.8 (7.5 to 12.2) 0.52 
Minute Ventilation (L/min) 10.4 (8 to 13.4) 10.8 (9 to 14.4) 0.45 
Pressure Support (cmH2O) 13.3 (11.4 to 16.4) 13.3 (10.3 to 16) 0.47 
IPAP (cmH2O) 19.2 (16.9 to 22.1) 19.3 (15.8 to 22.4) 0.48 
Tidal Volume (ml) 637 (477 to 889) 649 (553 to 874) 0.70 
Respiratory Rate (bpm) 16 (14.9 to 18.3) 16 (15 to 18.2) 0.49 
Inspiratory Time (sec) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 0.36 
I:E 0.5 (0.5 to 0.7) 0.5 (0.5 to 0.6) 1.00 
Leak (L/min) 3.9 (0.9 to 12.1) 2.9 (1.1 to 14.1) 0.59 
% patient triggered breaths 0.06 (0.04 to 0.10) 0.06 (0.03 to 0.09) 0.63 
Ineffective efforts 353 (62 to 578) 341 (197 to 561) 0.63 
Individual means of both 7 days stable state and of all days of symptom-defined exacerbations were compared.  Either group mean (SD) or median (IQR) are presented with appropriate 
paired t-test or Wilcoxon signed rank comparisons between stable state and exacerbation. IPAP = inspiratory positive airway pressure, I:E = inspiratory to expiratory rati
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Appendix 17: Physiological measures (EEG % delta, heart rate, oxygen saturation (SaO2) and 
transcutaneous carbon dioxide (tcPCO2)) for all patients across wake-sleep states; wake, stage 2, slow 
wave sleep  (SWS) and REM sleep. *p <0.05 after Bonferroni correction for multiple analyses 
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Appendix 18: Ventilator-measured parameters for all patients across wake-sleep states; wake, stage 2, 
slow wave sleep  (SWS) and REM sleep. *p <0.05 after Bonferroni correction for multiple analyses 
Continued on next page 
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Appendix 19:  Mixed models analysis – Treatment and order effects; patients as random variables 
Variable  Period (1v2) 
Coeff (SE) 
p  Treatment (PS 
v iVAPS) 
Coeff (SE) 
p 
FEV1 (L) 0.01 (0.06) 0.83  0.12 (0.06) 0.07 
FEV1% pred 0.4 (1.8) 0.81  3.1 (1.8) 0.10 
FVC (L) -0.02 (0.11) 0.86  -0.04 (0.11) 0.68 
FVC % pred 0.3 (2.2) 0.91  -0.3 (2.2) 0.89 
FEV1/FVC 8.0 (9.0) 0.37  13.4 (9.0) 0.14 
SNIP (cmH2O) 0.6 (2.7) 0.82  -2.8 (2.7) 0.31 
MIP (cmH2O) 6.5 (4.0) 0.10  -0.8 (4.0) 0.85 
MEP (cmH2O) 10.1 (1.8) 0.00*  4.5 (1.8) 0.01* 
Sleep efficiency -1.7 (4.2) 0.69  4.9 (4.2) 0.24 
Stage 1 NREM sleep (%) 1.3 (2.0) 0.51  -1.5 (2.0) 0.47 
Stage 2 NREM sleep (%) -1.4 (2.5) 0.57  2.6 (2.5) 0.29 
SWS% -1.1 (1.6) 0.51  -2.0 (1.6) 0.21 
REM% -6.0 (3.5) 0.08  5.6 (3.5) 0.10 
Mean SpO2(%) 0.55 (0.95) 0.57  -0.55 (0.95) 0.57 
Min SpO2 (%) 0.30 (1.74) 0.86  0.30 (1.74) 0.86 
SpO2 Desaturation Index (<4%) 
(events/hour) 
-1.0 (1.4) 0.47  0.9 (1.4) 0.52 
Arousals  5.4 (11.6) 0.64  4.4 (11.6) 0.71 
Apnoea index (events/hour) -0.3 (2.5) 0.91  -1.5 (2.5) 0.55 
tcPCO2 mean (kPa) 0.03 (0.17) 0.86  0.05 (0.17) 0.76 
tcPCO2 max (kPa) 0.01 (0.22) 0.05  0.04 (0.22) 0.84 
Mean vent useage (hr) -0.08 (0.29) 0.79  1.1 (0.29) 0.000* 
% days used in study -1.3 (4.7) 0.79  -3.5 (4.7) 0.46 
Mean PS delivered (cmH2O) 0.4 (0.9) 0.66  -2.2 (0.9) 0.02* 
Median MV delivered (L/min) 0.48 (0.94) 0.61  -2.6 (0.94) 0.006* 
Median Vt delivered (ml) -40 (36) 0.27  -36 (36) 0.33 
Median leak (L/min) 0.2 (3.1) 0.41  2.6 (3.1) 0.41 
Median RR (bpm) 0.4 (0.9) 0.64  0.8 (0.9) 0.36 
Q1: Comfort of breath delivered -0.5 (5) 0.91  4.5 (5) 0.37 
Q2: Ease of falling asleep -3 (6) 0.62  1 (6) 0.86 
Q3: Ease of use of ventilator -2 (3) 0.59  -2 (3) 0.50 
Q4: Liked using ventilator 5 (7) 0.45  15 (7) 0.04* 
A positive coefficient means that in the case of the period, there was an increase in the variable in period. P value <0.05 was MIP = 
maximal inspiratory pressure at mouth ; MEP= maximal expiratory pressure at mouth; SNIP = sniff nasal inspiratory pressure; REM = 
rapid eye movement;  NREM = non-REM; SWS = slow wave sleep; SpO2 = oxygen saturations; tcPCO2 = transcutaneous carbon dioxide; 
PS = pressure support; MV = minute ventilation; Vt = tidal volume, RR = respiratory rate. 
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Appendix 20: Individual ventilation settings and adherence levels during treatment with iVAPS and standard PS non-invasive ventilation. (n=18 
completers and n=5 non-completers). 
 iVAPS  
 
Standard PS 
Patient ID 
EPAP 
(cmH2O) 
Min PS 
(cmH2O) 
Max PS 
(cmH2O) 
Target VA 
(L/min) 
RR 
(bpm) 
Mean 
Hrs/day  
(hh:mm) 
IPAP 
(cmH2O) 
EPAP 
(cmH2O) 
PS (IPAP – 
EPAP) 
(cmH2O) 
RR 
(bpm) 
Mean 
Hrs/day  
(hh:mm) 
            
4 7 3 17 7.46 13.4 07:26 17 7 10 14 n/a 
5 6 3 16 3.32 22 05:09 12 4 8 12 06:18 
6 8 3 15 4.13 14 07:30 10 6 4 13 04:13 
7 7 5 18 5.39 16.5 07:50 17 7 10 12 07:39 
8 12 5 20 7.00 18 05:40 22 12 10 12 03:05 
9 9 5 18 5.12 16.5 05:21 23 9 14 10 06:16 
11 7 5 20 4.58 13.5 07:54 15 6 9 12 07:41 
13 5 5 18 4.13 12 06:35 15 5 10 12 05:47 
14 4 3 18 3.32 15 04:59 15 6 9 14 04:20 
16 8 5 17 5.03 9.5 06:17 26 8 18 15 05:48 
17 9 5 13 4.67 16.5 02:30 19 10 9 12 00:55 
18 9 5 16 5.57 16 08:32 19 9 10 12 08:22 
20 6 6 18 3.23 21 03:21 14 6 8 12 02:27 
21 15 5 10 8.74 21 02:43 21 14 13 12 01:19 
22 7.5 5 15 4.44 18.5 05:46 18 7.6 10.4 13 03:17 
23 6 5 20 6.05 29 04:22 17 5 12 12 02:19 
24 14.5 5 10 7.82 21 06:29 26 14.6 11.4 12 05:25 
26 8 5 18 3.77 15 04:48 16 8 8 12 02:27 
Median 
(IQR) 
7.8 (6.0-
9.0) 
5.0 (5.0-
5.0) 
17.5 
(15.0-
18.0) 
4.9  
(4.1-6.1) 
16.5 
(14.0-
21.0)* 
 
5:40 (4:42 
- 6:49) † 
17.0 
(15.0-
21.0) 
7.3 (6.0-
9.0) 
10.0 (9.0-
11.4) 
12.0 
(12.0-
13.0)* 
 
4:20 (2:27 - 
6:17) † 
            
10 5 3 16 2.69 23  - - - - - 
12 - - - - -  20 6 14 10 ... 
15 8 5 16 6.92 18 01:59 18 8 10 14 - 
19 3 5 16 2.87 20.5  - - - - - 
25 - - - - -  12 5 7 12 ... 
EPAP: expiratory positive airway pressure; IPAP: inspiratory airway pressure; RR: respiratory rate; PS: pressure support. 1 cmH2O = 0.098 kPa. Statistical significance difference between 
ventilators * p=0.001, †p=0.004 
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Table: Patients in whom initiation of NIV was unsuccessful (n=3) 
Patient 
ID 
Ag
e Sex Diagnosis 
Initiating 
Ventilator 
Day 
pCO2 
Over-
night 
mean 
tcPCO2 Reason for withdrawal 
10 18 M DMD iVAPS 6.02 6.26 Daytime normocapnic and intolerant of pressure;  
decided against NIV 
19 46 F Scoliosis due to 
transverse myelitis 
iVAPS 5.23 6.14 Suffers from migraines and intolerant of pressure 
25 48 M Myotonic 
dystrophy 
Standard 
PS 
5.70 6.63 Bulbar involvement; problems with swallow; 
claustrophobic 
DMD = Duchenne Muscular Dystrophy; iVAPS = intelligent volume assured pressure support; PS = pressure support; pCO2 = arterial carbon dioxide tcPCO2 = transcutaneous carbon dioxi
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Appendix 21: Correlates with ventilator adherence (hh:mm/day)  
 All ventilators (n=36)  iVAPS 
(n=19) 
 Standard PS 
(n=17) 
  
 r p  r p  r p  Zobs 
Age (yrs) 0.14 0.38  0.48 0.63  0.66 0.51  -0.48 
BMI( kg/m2) 0.00 0.92  0.13 0.90  0.08 0.94  0.13 
Baseline PCO2 (kPa) 0.35 0.04*  -0.46 0.05*  -0.27 0.29  -2.58
† 
HCO3
- (mmol) 0.45 0.006*  -0.47 0.04*  -0.47 0.06  -0.37 
FEV1 (L) 0.36 0.02*  0.50 0.03*  0.32 0.21  2.33
† 
FEV1% pred 0.39 0.01*  0.52 0.03*  0.38 0.14  1.95 
FVC (L) 0.36 0.04*  0.49 0.04*  0.28 0.28  2.65
† 
FVC% pred 0.41 0.01*  0.52 0.03*  0.38 0.14  1.95 
           
Questions 1-4           
1: comfort of breath 0.37 0.03*  0.52 0.03*  0.26 0.32  3.07
† 
2: ease of falling asleep 0.37 0.03*  0.50 0.04*  0.31 0.23  2.24
† 
3: ease of using vent 0.41 0.02**  0.39 0.13  0.54 0.02*  -1.90 
4: liked using ventilator 0.40 0.02*  0.30 0.24  0.43 0.08  -1.52 
           
Mean o/n tcPCO2 (kPa) -0.51 0.003*  -0.28 0.24  -0.65 0.00*  4.77
† 
Max o/n tcPCO2 (kPa) -0.37 0.02*  -0.18 0.46  -0.56 0.02*  4.46
† 
Mean o/n SpO2 (%) 0.33 0.06  0.24 0.32  0.31 0.23  -0.56 
Arousal index  - 0.13 0.04*  -0.48 0.06  -0.30 0.27  -1.94 
           
% of days used 0.48 0.005*  0.46 0.05*  0.69 0.00*  -3.24
† 
Analysis made on an intention to treat basis. (Fisher r to Z transformation: z= 0.5[ln(1+r) – ln(1-r)] (Zobs = Z1-Z2/√ [(1/N1-3) + (1/ N2-3)]). 
†
Statistical significance of the difference between 
correlation coefficients (Z observed >± 1.96)  BMI = body mass index; PCO2 = arterial carbon dioxide; HCO3
-
 = arterial bicarbonate;  FVC = forced vital capacity, FEV1 = forced expiratory 
volume in 1 second; SpO2 = oxygen saturations; tcPCO2 = transcutaneous carbon dioxide; o/n = overnight. 
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Appendix 22: Ventilator adherence (hh:mm/ night) separtated by disease group.  Sixteen 
of eighteen patients significantly used their iVAPS ventilators for over an hour longer each 
night compared to standard PS ventilators (p=0.004). Of the 2 patients who used the 
iVAPS ventilator for less time each night, one had scoliosis and one had OHS. 
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Appendix 23:  Individual patient data (n=11)  representing the median delivered ventilation 
over 24 hour periods from each of the Standard PS and iVAPS modes of NIV for ventilator 
paramters; inspiratory positive airway pressure (IPAP), minute ventilation (MV), tidal 
volume (Vt) and respiratory rate (RR) and leak. 
 
 
 
 
 
 
 
